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Preamble
It is important that the medical profession plays a signiﬁcant
role in critically evaluating the use of diagnostic procedures
and therapies as they are introduced and tested in the
detection, management, or prevention of disease states.
Rigorous and expert analysis of the available data docu-
menting absolute and relative beneﬁts and risks of those
procedures and therapies can produce helpful guidelines
that improve the effectiveness of care, optimize patient
outcomes, and favorably affect the overall cost of care by
focusing resources on the most effective strategies.
The American College of Cardiology Foundation (ACCF)
and the American Heart Association (AHA) have jointly
engaged in the production of such guidelines in the area of
cardiovascular disease since 1980. The ACC/AHA Task Force
on Practice Guidelines, whose charge is to develop,
update, or revise practice guidelines for important cardio-
vascular diseases and procedures, directs this effort. The
Task Force is pleased to have this guideline developed in
conjunction with the European Society of Cardiology (ESC).
Writing committees are charged with the task of performing
an assessment of the evidence and acting as an independent
group of authors to develop or update written recommen-
dations for clinical practice.
Experts in the subject under consideration have been
selected from all 3 organizations to examine subject-speciﬁc
data and write guidelines. The process includes additional
representatives from other medical practitioner and speci-
alty groups when appropriate. Writing committees are
speciﬁcally charged to perform a formal literature review,
weigh the strength of evidence for or against a particular
treatment or procedure, and include estimates of expected
health outcomes where data exist. Patient-speciﬁc modi-
ﬁers, comorbidities, and issues of patient preference that
might inﬂuence the choice of particular tests or therapies
are considered as well as frequency of follow-up and cost
effectiveness. When available, information from studies on
cost will be considered; however, review of data on efﬁcacy
and clinical outcomes will constitute the primary basis for
preparing recommendations in these guidelines.
The ACC/AHA Task Force on Practice Guidelines and the
ESC Committee for Practice Guidelines make every effort
to avoid any actual, potential, or perceived conﬂict of inter-
est that might arise as a result of an industry relationship or
personal interest of the writing committee. Speciﬁcally, all
members of the Writing Committee, as well as peer
reviewers of the document, were asked to provide disclos-
ure statements of all such relationships that might be
perceived as real or potential conﬂicts of interest. Writing
Committee members are also strongly encouraged to
declare a previous relationship with industry that might be
perceived as relevant to guideline development. If a
Writing Committee member develops a new relationship
with industry during his or her tenure, he or she is required
to notify guideline staff in writing. The continued
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participation of the Writing Committee member will be
reviewed. These statements are reviewed by the parent
Task Force, reported orally to all members of the Writing
Committee at each meeting, and updated and reviewed by
the Writing Committee as changes occur. Please refer to the
methodology manuals for further description of the policies
used in guideline development, including relationships with
industry, which are available on the ACC, AHA and ESC
World Wide Web sites (http://www.acc.org/clinical/manual/
manual_ introltr.htm, http://circ.ahajournals.org/manual,
and http://www.escardio.org/knowledge/guidelines/Rules,
respectively). Please see Appendix 1 for author relationships
with industry and Appendix 2 for peer reviewer relationships
with industry that are pertinent to these guidelines.
These practice guidelines are intended to assist health
care providers in clinical decision making by describing a
range of generally acceptable approaches for the diagnosis
and management of speciﬁc diseases or conditions. These
guidelines attempt to deﬁne practices that meet the
needs of most patients in most circumstances. These guide-
line recommendations reﬂect a consensus of expert opinion
after a thorough review of the available, current scientiﬁc
evidence and are intended to improve patient care. If
these guidelines are used as the basis for regulatory/payer
decisions, the ultimate goal is quality of care and serving
the patient’s best interests. The ultimate judgment regard-
ing care of a particular patient must be made by the health
care provider and the patient in light of all of the circum-
stances presented by that patient. There are circumstances
in which deviations from these guidelines are appropriate.
The guidelines will be reviewed annually by the ACC/AHA
Task Force on Practice Guidelines and the ESC Committee
for Practice Guidelines and will be considered current
unless they are updated, revised, or sunsetted and with-
drawn from distribution. The executive summary and rec-
ommendations are published in the September 5, 2006
issue of the Journal of the American College of
Cardiology, September 5, 2006 issue of Circulation, and
September 17, 2006 issue of the European Heart Journal.
The full-text guideline is e-published in the same issues of
the Journal of the American College of Cardiology and
Circulation and published in the September 2006 issue of
Europace, as well as posted on the ACC (www.acc.org),
AHA (www.americanheart.org), and ESC (www.escardio.
org) World Wide Web sites. Copies of the full text and the
executive summary are available from all 3 organizations.
Sidney C. Smith, Jr., MD, FACC, FAHA, FESC, Chair, ACC/
AHA Task Force on Practice Guidelines.
Silvia G. Priori, MD, PhD, FESC, Chair, ESC Committee for
Practice Guidelines.
1. Introduction
Several excellent guidelines already exist on treating patients
who have ventricular arrhythmias (Table 1). The purpose of
this document is to update and combine the previously
published recommendations into one source approved by
the major cardiology organizations in the United States and
Europe. We have consciously attempted to create a stream-
lined document, not a textbook, that would be useful
speciﬁcally to locate recommendations on the evaluation
and treatment of patients who have or may be at risk
for ventricular arrhythmias. Thus, sections on epidemiology,
mechanisms and substrates, and clinical presentations are
brief, because there are no recommendations for those
sections. For the other sections, the wording has been kept
to a minimum, and clinical presentations have been conﬁned
to those aspects relevant to forming recommendations.
1.1. Organization of committee and evidence
review
Writing Committee members were selected with attention
to cardiovascular subspecialties, broad geographical
representation, and involvement in academic medicine
and clinical practice. The Writing Committee on the
Management of Patients With Ventricular Arrhythmias
and Prevention of Sudden Cardiac Death also included
members of the ACC/AHA Task Force on Practice
Guidelines, ESC Committee on Practice Guidelines, ACC
Board of Trustees, ACC Board of Governors, ESC Board, the
European Heart Rhythm Association (EHRA), and the Heart
Rhythm Society (HRS).
The committee was co-chaired by A. John Camm, MD,
FACC, FAHA, FESC, and Douglas P. Zipes, MD, MACC, FAHA,
FESC. This document was reviewed by 2 ofﬁcial reviewers
nominated by the ACC, 2 ofﬁcial reviewers nominated by
the AHA, 2 ofﬁcial reviewers nominated by the ESC, 1 ofﬁcial
reviewer from the ACC/AHA Task Force on Practice
Guidelines, reviewers from the EHRA and HRS, and 18
content reviewers, including members from ACCF Clinical
Electrophysiology Committee, AHA Council on Clinical
Cardiology, Electrocardiography, and Arrhythmias, and AHA
Advanced Cardiac Life Support Subcommittee.
The committee conducted comprehensive searching of the
scientiﬁc and medical literature on ventricular arrhythmias
and sudden cardiac death (SCD). Literature searching was
limited to publications on humans and in English from 1990
to 2006. The search parameters were extended for selected
topics when a historical reference was needed or if limited
studies existed in English. In addition to broad-based search-
ing on ventricular arrhythmias and SCD, speciﬁc targeted
searches were performed on ventricular arrhythmias and
SCD and the following subtopics: mechanisms, substrates,
clinical presentations, ECG, exercise testing, echocardio-
graphy, imaging, electrophysiological (EP) testing, drug
therapy (antiarrhythmic and nonantiarrhythmic), implantable
and external cardioverter devices, ablation, surgery, acute
speciﬁc arrhythmias (e.g., acute coronary syndrome [ACS],
heart failure [HF], stable sustained monomorphic ventricular
tachycardia [VT], torsades de pointes), speciﬁc pathology
(e.g., congenital heart disease, myocarditis, endocrine
disorders, renal failure), cardiomyopathies, genetic arrhy-
thmias, structurally normal hearts, athletes, elderly,
gender, pediatric, and drug-induced arrhythmias. The
complete list of keywords is beyond the scope of this
section. The committee reviewed all compiled reports from
computerized searches and conducted additional manual
searching. Literature citations were generally restricted to
published manuscripts appearing in journals in the Index
Medicus. Because of the scope and importance of certain
ongoing clinical trials and other emerging information,
published abstracts were cited in the text when they were
the only published information available.
The ﬁnal recommendations for indications for a diagnostic
procedure, a particular therapy, or an intervention for
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management of patients with ventricular arrhythmias and
prevention of SCD summarize both clinical evidence and
expert opinion. Once recommendations were written, a
Classiﬁcation of Recommendation and Level of Evidence
grade was assigned to each recommendation.
Classiﬁcation of Recommendations and Level of Evidence
are expressed in the ACC/AHA/ESC format as follows:
Classiﬁcation of Recommendations
. Class I: Conditions for which there is evidence and/or
general agreement that a given procedure or treatment
is beneﬁcial, useful, and effective.
. Class II: Conditions for which there is conﬂicting evidence
and/or divergence of opinion about the usefulness/efﬁ-
cacy of a procedure or treatment.
* Class IIa: Weight of evidence/opinion is in favor of use-
fulness/efﬁcacy.
* Class IIb: Usefulness/efﬁcacy is less well established by
evidence/opinion.
. Class III: Conditions for which there is evidence and/or
general agreement that a procedure/treatment is not
useful/effective and in some cases may be harmful.
Level of Evidence
. Level of Evidence A: Data derived from multiple random-
ized clinical trials or meta-analyses.
. Level of Evidence B: Data derived from a single random-
ized trial or nonrandomized studies.
. Level of Evidence C: Only consensus opinion of experts,
case studies, or standard-of-care.
The schema for classiﬁcation of recommendations and
level of evidence is summarized in Table 2, which also illus-
trates how the grading system provides an estimate of the
size of treatment effect and an estimate of the certainty
of the treatment effect.
Recommendations with respect to therapy have con-
sidered the following:
(1) The therapy to be offered (implantable cardioverter-
deﬁbrillator [ICD], antiarrhythmic drugs, surgery, and
miscellaneous other treatments).
(2) The point at which therapy is offered (primary
prevention for those who are at risk but have not yet
had a life-threatening ventricular arrhythmia or
sudden cardiac ‘death’ episode, or secondary for those
Table 1 Clinical practice guidelines and policy statements that overlap with ACC/AHA/ESC guidelines for the management of patients
with ventricular arrhythmias and the prevention of SCD
Document Sponsor Citation
Guidelines
SCD ESC Eur Heart J 2001;22:1374–450
Syncope ESC Eur Heart J 2004;25:2054–72
Exercise testing ACC/AHA Circulation 2002;106:1883–92
Cardiac pacemakers and antiarrhythmia devices ACC/AHA/NASPE Circulation 2002;106:2145–61
Echocardiography ACC/AHA J Am Coll Cardiol 2003;42:954–70
Supraventricular arrhythmias ACC/AHA/ESC Eur Heart J 2003;24:1857–97
J Am Coll Cardiol 2003;42:1493–531
SCD Update ESC Eur Heart J 2003;24:3–5
Congenital heart disease ESC Eur Heart J 2003;24:1035–84
European guidelines on CVD prevention ESC Eur J Cardiovasc Prev Rehab
2003;10(Suppl 1):S1–78
Infective endocarditis ESC Eur Heart J 2004;25:267–76
Pericardial disease ESC Eur Heart J 2004;25:587–610
Pulmonary arterial hypertension ESC Eur Heart J 2004;25:2243–78
AED use in Europe ESC/ERC Eur Heart J 2004;25:437–45
ST-elevation myocardial infarction ACC/AHA J Am Coll Cardiol 2004;44:e1–211
Chronic heart failure ACC/AHA J Am Coll Cardiol 2005;46:e1–82
Chronic heart failure ESC Eur Heart J 2005;26:1115–40
CPR and ECC AHA/ILCOR Circulation 2005;112:IV-1–203
Resuscitation ERC Resuscitation 2005;67(Suppl):539–86
Valvular heart disease ACC/AHA J Am Coll Cardiol 2006;48:e1–e148
Statements
Invasive electrophysiology studies, catheter ablation,
and cardioversion
ACC/AHA J Am Coll Cardiol 2000;36:1725–36
Hypertrophic cardiomyopathy ACC/ESC Eur Heart J 2003;24:1965–91
J Am Coll Cardiol 2003;42:1687–713
Cardiovascular disease during pregnancy ESC Eur Heart J 2003;24:761–81
Physical activity and recreational sports
AHA for young patients with genetic CVD
Circulation 2004;109:2807–16
36th Bethesda Conference: Eligibility recommendations for
competitive athletes with cardiovascular abnormalities
ACC J Am Coll Cardiol 2005;45:1318–75
The guidelines from the ACC, AHA, and ESC are available at www.acc.org, www.americanheart.org, and www.escardio.org, respectively.
ACC, American College of Cardiology; AHA, American Heart Association; CVD, cardiovascular disease; CPR, cardiopulmonary resuscitation; ECC, emergency
cardiovascular care; ERC, European Resuscitation Council; ESC, European Society of Cardiology; ILCOR, International Liaison Committee on Resuscitation;
NASPE, Heart Rhythm Society (formerly North American Society for Pacing and Electrophysiology); SCD, sudden cardiac death.
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Table 2 Applying classiﬁcation of recommendations and level of evidence†
aData available from clinical trials or registries about the usefulness/efﬁcacy in different subpopulations, such as gender, age, history of diabetes, history of prior MI, history of heart failure, and prior aspirin use.
bA recommendation with a Level of Evidence of B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Even
though randomized trials are not available, there may be a very clear consensus that a particular therapy is useful or effective.
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patients who have already experienced such arrhyth-
mias or events).
(3) The purpose of therapy (life preservation or symptom
reduction/improved quality of life).
(4) The etiology of the arrhythmia substrate (coronary heart
disease [CHD], cardiomyopathy, or other conditions).
(5) The functional status of the patient (New York Heart
Association [NYHA] functional class).
(6) The state of left ventricular (LV) function (LV ejection
fraction [LVEF]).
(7) The speciﬁc arrhythmia concerned (e.g., sustained
monomorphic VT, polymorphic VT, and ventricular ﬁbril-
lation [VF]).
Not all therapeutic combinations are clinically relevant,
and many have no evidence base and probably will not
have one in the future because of the lack of clinical rel-
evance or the relative rarity of the particular grouping. In
many instances, the probable value of therapy may be
reasonably inferred by the response of similar patients to
speciﬁc therapies.
1.2. Prophylactic implantable
cardioverter-deﬁbrillator recommendations
across published guidelines
The ACC/AHA/NASPE 2002 Guidelines Update for
Implantation of Cardiac Pacemakers and Antiarrhythmia
Devices,1 the ACC/AHA 2004 Guidelines for the
Management of Patients With ST-Elevation Myocardial
Infarction,2 the ESC 2001 and 2003 Guidelines on
Prevention of Sudden Cardiac Death,3,4 the ESC 2005
Guidelines for the Diagnosis and Treatment of Chronic
Heart Failure,5a and the ACC/AHA 2005 Guideline Update
for the Diagnosis and Management of Chronic Heart Failure
in the Adult6 include a large number of recommendations
on ICD therapy that merit attention.
Recommendations for prophylactic ICD implantation
based on ejection fractions (EFs) have been inconsistent
because clinical investigators have chosen different EFs for
enrollment in trials of therapy, average values of the EF in
such trials have been substantially lower than the cutoff
value for enrollment, and subgroup analyses of clinical
trial populations based on EF have not been consistent in
their implications. Substantial differences between guide-
lines have resulted. However, no trial has randomized
patients with an intermediate range of EFs. For instance,
there is no trial that has speciﬁcally studied patients with
an LVEF between 31% and 35%, yet recommendations have
been set for such patients on the basis of data derived
from trials that studied groups with EFs less than or equal
to 30%, others that enrolled patients with an EF less than
or equal to 35%, and one trial that enrolled patients
with an EF less than or equal to 40%. Recognizing these
inconsistencies, this Guideline Writing Committee decided
to construct recommendations to apply to patients with
an EF less than or equal to a range of values. The highest
appropriate class of recommendation was then based on
all trials that recruited patients with EFs within this
range. In this way, potential conﬂicts between guidelines
were reduced and errors due to drawing false conclusions
relating to unstudied patient groups were minimized
(Table 3).
It is important to note that experts can review the same
data and arrive at different interpretations. Attempting
to homogenize heterogeneous trials invariably leads to
varying interpretations of the trial data. Furthermore,
differences between the United States and Europe may
modulate how recommendations are implemented.
Guidelines are composed of recommendations on the basis
of the best available medical science; however, implemen-
tation of these recommendations will be affected by
the ﬁnancial, cultural, and societal differences between
individual countries.
1.3. Classiﬁcation of ventricular arrhythmias and
sudden cardiac death
This classiﬁcation table is provided for direction and intro-
duction to the guidelines (Table 4).
2. Epidemiology
The epidemiology of ventricular arrhythmias spans a range
of risk descriptors and clinical applications, ranging from
premature ventricular complexes (PVCs) and nonsustained
ventricular tachycardia (NSVT) in normal subjects to SCD
due to ventricular tachyarrhythmias in patients with and
without structural heart disease.9 Epidemiological patterns
have implications that help improve proﬁling risk based on
individual subject characteristics and for efﬁcient designs
of clinical trials.10 Techniques include identiﬁcation of clini-
cal and lifestyle risk factors for disease development,
measurement of risk among subgroups of patients with
established disease, and the newly emerging ﬁeld of
genetic epidemiology.9,11
2.1. Ventricular arrhythmias
2.1.1. Premature ventricular complexes and
nonsustained ventricular tachycardia
Single and repetitive forms of PVCs have been studied for
their role in risk prediction in several contrasting clinical cir-
cumstances, including implications in apparently normal
subjects compared with those with identiﬁed disease
states, in steady-state pathophysiology versus transient
events, and in inactive subjects versus those under physical
stress. The epidemiological implications vary for each of
these contingencies.
2.1.1.1. Premature ventricular complexes in the absence
of heart disease. Among presumably normal individuals,
estimates of the prevalence of PVCs and NSVT vary accord-
ing to the sampling technique used and the source of data.
PVCs were recorded on standard 12-lead electrocardiograms
(ECGs) in 0.8% of subjects in a healthy military population,
with a range of 0.5% among those under the age of 20 y to
2.2% of those over 50 y of age.12 In a study of middle-aged
men, both with and without known heart disease, a 6-h
monitor sampling technique identiﬁed a 62% incidence of
asymptomatic ventricular arrhythmias, more than one half
of which were infrequent single PVCs.13 The incidence,
frequency, and complexity of ventricular arrhythmias were
greater in the presence of known or suspected heart
disease, and mortality risk implications were absent in
those without heart disease.13,14 In contrast to PVCs and
monomorphic patterns of NSVT, polymorphic ventricular
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Table 3 Inconsistencies between ACC/AHA/ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of SCD and other published ACC/AHA and ESC
guidelines with respect to ICD therapy for primary prevention to reduce total mortality by a reduction in SCD
Group addressed in recommendation Guideline and class of recommendation with level of evidencea for each group
2005 ACC/AHA HF 2005 ESC HF 2004 ACC/AHA
STEMI
2002 ACC/AHA/NASPE
PM and ICD
Comment from the ACC/AHA/ESC VA and
SCD guidelines
LVD d/t MI, LVEF 30% or less, NYHA II, III Class I; LOE: B Class I; LOE: A Class IIa; LOE: B Class IIa; LOE: B VA and SCD has combined all trials that
enrolled patients with LVD d/t MI into
one recommendation, Class I; LOE: A
LVD d/t MI, LVEF 30% to 35%, NYHA II, III Class IIa; LOE: B Class I; LOE: A N/A N/A
LVD d/t MI, LVEF 30% to 40%, NSVT, positive
EP study
N/A N/A Class I; LOE: B Class IIb; LOE: B
LVD d/t MI, LVEF 30% or less, NYHA I Class IIa; LOE: B N/A N/A N/A VA and SCD has expanded the range of LVEF
to 30% to 35% or less for patients with LVD
d/t MI and NYHA functional class I into one
recommendation, Class IIa; LOE: B
LVD d/t MI, LVEF 31% to 35% or less, NYHA I N/A N/A N/A N/A
NICM, LVEF 30% or less, NYHA II, III Class I; LOE: B Class I; LOE: A N/A N/A VA and SCD has combined all trials of
NICM, NYHA II, III into one recommendation,
Class I; LOE: B
NICM, LVEF 30% to 35%, NYHA II, III Class IIa; LOE: B Class I; LOE: A N/A N/A
NICM, LVEF 30% or less, NYHA I Class IIb; LOE: C N/A N/A N/A VA and SCD has expanded the range of LVEF
to 30% to 35% or less for patients with NICM
and NYHA functional class I into one
recommendation, Class IIb; LOE: B.
NICM, LVEF 31% to 35% or less, NYHA I N/A N/A N/A N/A
ACC/AHA HF, ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult;6 ACC/AHA/NASPE PM and ICD, ACC/AHA/NASPE 2002 Guidelines Update for Implantation of
Cardiac Pacemakers and Antiarrhythmia Devices;1 ACC/AHA STEMI, ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction;2 EP, electrophysiological; ESC HF, ESC 2005
Guidelines for the Diagnosis and Treatment of Chronic Heart Failure;5 LOE, level of evidence; LVD d/t MI, left ventricular dysfunction due to prior myocardial infarction; LVEF, left ventricular ejection fraction; N/A,
populations not addressed; NICM, nonischemic cardiomyopathy; NSVT, nonsustained ventricular tachycardia; NYHA, New York Heart Association functional class; SCD, sudden cardiac death; VA, ventricular arrhythmias.
aFor an explanation of Class Recommendation and Level of Evidence, see Table 2. For further discussion, please see the Introduction.
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Table 4 Classiﬁcation of ventricular arrhythmias
Classiﬁcation by clinical presentation Reference
Hemodynamically stable Asymptomatic The absence of symptoms that could result
from an arrhythmia
7
Minimal symptoms,
e.g., palpitations
Patient reports palpitations felt in either the
chest, throat, or neck as described by the
following:
* Heartbeat sensations that feel like
pounding or racing
* An unpleasant awareness of heartbeat
* Feeling skipped beats or a pause
7
Hemodynamically unstable Presyncope Patient reports presyncope as described by
the following:
* Dizziness
* Lightheadedness
* Feeling faint
* ‘Graying out’
7
Syncope Sudden loss of consciousness with loss of
postural tone, not related to anesthesia,
with spontaneous recovery as reported by
the patient or observer. Patient may
experience syncope when supine
7
Sudden cardiac death Death from an unexpected circulatory
arrest, usually due to a cardiac arrhythmia
occurring within an hour of the onset of
symptoms
7a
Sudden cardiac arrest Death from an unexpected circulatory
arrest, usually due to a cardiac arrhythmia
occurring within an hour of the onset of
symptoms, in whom medical intervention
(e.g., deﬁbrillation) reverses the event
7
Classiﬁcation by electrocardiography
Nonsustained VT Three or more beats in duration, terminating
spontaneously in less than 30 s.
7
VT is a cardiac arrhythmia of three or
more consecutive complexes in duration
emanating from the ventricles at a rate of
greater than 100 bpm (cycle length less
than 600 ms)
Monomorphic Nonsustained VTwith a single QRS
morphology
7
Polymorphic Nonsustained VTwith a changing QRS
morphology at cycle length between
600 and 180 ms
7
Sustained VT VT greater than 30 s in duration and/or
requiring termination due to
hemodynamic compromise in less
than 30 s
7
Monomorphic Sustained VTwith a stable single
QRS morphology
7
Polymorphic Sustained VTwith a changing or multiform
QRS morphology at cycle length between
600 and 180 ms
7
Bundle-branch re-entrant
tachycardia
VT due to re-entry involving the His-Purkinje
system, usually with LBBB morphology;
this usually occurs in the setting of
cardiomyopathy
7
Bidirectional VT VTwith a beat-to-beat alternans in the QRS
frontal plane axis, often associated with
digitalis toxicity
7
Continued
ACC/AHA/ESC Guidelines 755
Downloaded from https://academic.oup.com/europace/article-abstract/8/9/746/534498
by guest
on 02 April 2018
tachyarrhythmias in the absence of structural heart disease
are indicators of risk.15 Many nonsustained polymorphic VT
events occurring in individuals free of grossly evident struc-
tural abnormalities of the heart are due to abnormalities at
a molecular level or a consequence of electrolyte disturb-
ances or adverse drug effects.
In the Tecumseh, Michigan, communitywide cardiovascu-
lar epidemiology study, PVCs in subjects with structurally
normal hearts carried no adverse prognostic signiﬁcance
under the age of 30 y, but in those older than 30 y, PVCs
and short runs of NSVT began to inﬂuence risk.16 More
recent studies provide conﬂicting implications regarding
risk in asymptomatic subjects. In one study,17 asymptomatic
ventricular arrhythmias in the absence of identiﬁable heart
disease predicted a small increase in risk, while another
study18 suggested no increased risk.
In contrast to the apparently non-life-threatening
implication of PVCs at rest, PVCs elicited during exercise
testing, even in apparently normal individuals, appear to
imply risk over time. In one study,19 PVCs and NSVT
induced during exercise correlated with increased risk of
total mortality, while in another study,20 both exercise-
and recovery-phase PVCs correlated with risk, with the
greater burden associated with recovery-phase arrhythmias.
A selection bias, based on indications for stress testing, may
have inﬂuenced these observations.21
2.1.1.2. Premature ventricular complexes in the presence
of established heart disease. PVCs and runs of NSVT in sub-
jects with structural heart disease contribute to an
increased mortality risk, the magnitude of which varies
with the nature and extent of the underlying disease.
Among survivors of myocardial infarction (MI), frequent
and repetitive forms of ventricular ectopic activity,
accompanied by a reduced EF, predict an increased risk of
SCD during long-term follow-up.21–23 Most studies cite a fre-
quency cutoff of 10 PVCs per hour and the occurrence of
repetitive forms of ventricular ectopy as thresholds for
increased risk. Several investigators have emphasized that
the most powerful predictors among the various forms of
PVCs are runs of NSVT.21,22 Although the speciﬁcity of this
relationship is now questioned. The power of risk prediction
conferred by the presence of PVCs and NSVT appears to be
directly related to the extent of structural disease as esti-
mated by EF and to cardiovascular limitations as estimated
by functional capacity.24
Ventricular arrhythmias during ambulatory recording in
patients with HF do not speciﬁcally predict risk for SCD.25
Table 4 Continued
Classiﬁcation by clinical presentation Reference
Torsades de pointes Characterized by VT associated with a long
QT or QTc, and electrocardiographically
characterized by twisting of the peaks of
the QRS complexes around the isoelectric
line during the arrhythmia:
* ‘Typical,’ initiated following
‘short-long-short’ coupling intervals
* Short coupled variant initiated by
normal-short coupling
7
Ventricular ﬂutter A regular (cycle length variability 30 ms or
less) ventricular arrhythmia approximately
300 bpm (cycle length—200 ms) with a
monomorphic appearance; no isoelectric
interval between successive QRS
complexes
7
Ventricular ﬁbrillation Rapid, usually more than 300 bpm/200 ms
(cycle length 180 ms or less), grossly
irregular ventricular rhythm with marked
variability in QRS cycle length,morphology,
and amplitude
7
Classiﬁcation by disease entity
Chronic coronary heart disease
Heart failure
Congenital heart disease
Neurological disorders
Structurally normal hearts
Sudden infant death syndrome
Cardiomyopathies
Dilated cardiomyopathy
Hypertrophic cardiomyopathy
Arrhythmogenic right ventricular
cardiomyopathy
LBBB, left bundle-branch block; VT, ventricular tachycardia.
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Risk is already high because of the underlying disease.
Suppression of ambient ventricular arrhythmias is no
longer considered a therapeutic target for prevention of
death in the post-MI or nonischemic cardiomyopathy
subgroups.
2.1.2. Ventricular tachycardia and ventricular
ﬁbrillation during acute coronary syndromes
Observations of both post-MI patients26 and survivors of
cardiac arrest that occurred during the acute phase of trans-
mural MI27 suggest that life-threatening ventricular tachyar-
rhythmias occurring during the ﬁrst 24 to 48 h of MI do not
imply continuing risk over time. A study done on follow-up
after in-hospital VF does suggest an adverse prognosis over
the ensuing 6 mo,28 but the patients were not selected for
acute-phase arrhythmias. Later in-hospital VF has previously
been reported to confer long-term risk.29 In contrast,
patients presenting with non-ST-elevation myocardial
infarction (NSTEMI) are at increased long-term risk of
SCD,30 possibly related in part to a persistent propensity
for ventricular tachyarrhythmias.31 Such patients have gen-
erally been excluded from clinical trials for interventions
targeting long-term arrhythmic death risk because of low
absolute risk, but it remains unclear whether the magnitude
of risk is modulated by the extent of myocardial damage
that occurs during the acute event. The long-term risk impli-
cations of sustained VT and VF during the acute phase of MI
may also be applied to frequent PVCs and runs of NSVT.32 It is
important to stress that the clinician’s ability to recognize
individuals with reversible or transient causes of ventricular
tachyarrhythmias is limited.33
2.2. Sudden cardiac death
2.2.1. Incidence of sudden cardiac death
The geographical incidence of SCD varies as a function of
CHD prevalence in different regions.3 Estimates for the
United States34–38 range from less than 200,000 to more
than 450,000 SCDs annually, with the most widely used esti-
mates in the range of 300,000 to 350,000 SCDs annually.39
The variation is based, in part, on the inclusion criteria
used in individual studies. Overall, event rates in Europe
are similar to those in the United States,3 with signiﬁcant
geographic variations reported.
The temporal deﬁnition of SCD strongly inﬂuences epide-
miological data.40 The proportion of all natural deaths due
to SCD is 13% when a deﬁnition of 1 h from onset of symp-
toms is used. In contrast, the communitywide study in
Maastricht, the Netherlands, reported that 18.5% of all
deaths were SCD, using a 24-h deﬁnition.41 The application
of a 24-h deﬁnition of SCD increases the fraction of all
natural deaths falling into the ‘sudden’ category but
reduces the proportion of all sudden natural deaths that
are due to cardiac causes.40
Approximately 50% of all CHD deaths are sudden and unex-
pected, occurring shortly (instantaneous to 1 h) after the
onset of a change in clinical status, with some geographical
variation in the fraction of coronary deaths that are
sudden.42 The decreasing age-adjusted CHD mortality does
not imply a decrease in absolute numbers of cardiac or
sudden deaths43,44 because of the growth and aging of the
U.S. and European populations and the increasing preva-
lence of chronic heart disease.45
2.2.2. Population subgroups and risk prediction
Three factors affect the ability to identify subjects and
population subgroups at risk and consideration of strategies
for prevention of SCD:
. Absolute numbers and event rates (incidence) among
population subgroups (Figure 1)
. Clinical subgroups in which SCDs occur
. Time dependence of risk.39
The overall incidence of SCD in the United States is 1 to 2
per 1000 population (0.1% to 0.2%) annually, with some vari-
ations in estimates based on differences in various sources of
data. This large population base includes those in whom SCD
occurs as a ﬁrst cardiac event, as well as those for whom
SCDs can be predicted with greater accuracy because they
are included in higher risk subgroups (Figure 1). Higher
levels of risk resolution can be achieved by identiﬁcation
of more speciﬁc subgroups. However, the corresponding
absolute number of deaths becomes progressively smaller
as the subgroups become more focused, limiting the poten-
tial impact of interventions to a much smaller fraction of the
total population.10 At least 50% of all SCDs due to CHD occur
as a ﬁrst clinical event or among subgroups of patients
thought to be at relatively low risk for SCD.43
2.2.3. Time-dependent risk
The risk of SCD after a clinical event is not linear as a func-
tion of time.39,46 Survival curves after major cardiovascular
events, which identify risk for both sudden and total cardiac
death, demonstrate that the most rapid rate of attrition
usually occurs during the ﬁrst 6 to 18 mo after the index
event. Curves with these characteristics have been gener-
ated from data on survivors of out-of-hospital cardiac
Figure 1 Absolute numbers of events and event rates of SCD in the
general population and in speciﬁc subpopulations over 1 y. General
population refers to unselected population age greater than or
equal to 35 y, and high-risk subgroups to those with multiple risk
factors for a ﬁrst coronary event. Clinical trials that include speciﬁc
subpopulations of patients are shown in the right side of the ﬁgure.
AVID, Antiarrhythmics Versus Implantable Deﬁbrillators; CASH,
Cardiac Arrest Study Hamburg; CIDS, Canadian Implantable
Deﬁbrillator Study; EF, ejection fraction; HF, heart failure; MADIT,
Multicenter Automatic Deﬁbrillator Implantation Trial; MI, myocar-
dial infarction; MUSTT, Multicenter UnSustained Tachycardia Trial;
SCD-HeFT, Sudden Cardiac Death in Heart Failure Trial. Modiﬁed
with permission from Myerburg RJ, Kessler KM, Castellanos A. SCD.
Structure, function, and time-dependence of risk. Circulation
1992;85:I2–10.
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arrest, new onset of HF, and unstable angina and on high-risk
subgroups of patients with recent MI. In contrast to inherent
(baseline) risk patterns over time, however, beneﬁt patterns
from controlled trials may show divergence of curves early
(e.g., post-MI beta-blocker therapy, clopidogrel in ACSs) or
later (e.g., angiotensin-converting enzyme [ACE] inhibitors
and statins). Mortality is highest in the ﬁrst month after
acute MI (AMI) in patients with EF of less than 30%.47
2.2.4. Age, heredity, gender, and race
The incidence of SCD increases as a function of advancing
age,48 in parallel with the age-related increase in the inci-
dence of total CHD deaths, but may undergo a relative
decrease in the eighth decade and beyond because of com-
peting causes of death. The incidence is 100-fold less in ado-
lescents and adults younger than 30 y (1 in 100 000 per year)
than it is in adults older than 35 y.49–51 The proportion of
coronary deaths and of all cardiac causes of death that are
sudden is highest in the younger age groups.
Hereditary factors that contribute to CHD risk have been
thought to operate nonspeciﬁcally for the SCD syndrome.
However, several studies have identiﬁed mutations and rel-
evant polymorphisms along multiple steps of the cascade
from atherogenesis to plaque destabilization, thrombosis,
and arrhythmogenesis, each of which is associated with a
risk of a coronary event.52–55 Integration of these individual
markers may provide more powerful individual risk predic-
tion in the future.56 In addition, 2 population studies
suggest that SCD, as an expression of CHD, clusters in
speciﬁc families.57,58 There is a large preponderance of
SCD in males compared with females during the young
adult and early middle-age years because of the protection
females enjoy from coronary atherosclerosis before meno-
pause.59–61 As coronary event risk increases in postmenopau-
sal women, SCD risk increases proportionately. Even though
the overall risk is much lower in younger women, the estab-
lished coronary risk factors are still predictive of
events.59,61–63
Studies comparing racial differences in risk of SCD among
whites and African Americans with CHD in the United States
have yielded conﬂicting and inconclusive data. However,
some studies have demonstrated excess risk of cardiac
arrest and SCD among African Americans compared with
whites.61,64 SCD rates among Hispanic populations were
lower.61
2.2.5. Risk proﬁles and sudden cardiac death
Biological and behavioral risk proﬁling for coronary artery
disease, using the conventional risk factors for coronary
atherogenesis,65 is useful for identifying levels of population
risk but has limited value for distinguishing individual
patients at risk for SCD. Multivariate analyses of selected
risk factors for atherogenesis have determined that approxi-
mately one half of all SCDs occur among the 10% of the popu-
lation in the highest risk decile. Thus, the cumulative risk
associated with conventional risk factors for coronary ather-
osclerosis exceeds the simple arithmetic sum of the individ-
ual risks.65 The comparison of risk factors in the victims of
SCD with those in people who developed any manifestations
of coronary artery disease does not provide useful patterns.
In addition, certain angiographic and hemodynamic patterns
discriminate SCD risk from non-SCD risk only under limited
conditions.66
Markers of risk that move beyond the direct lipid depo-
sition concept of atherogenesis into more complex patho-
biology are now being identiﬁed, largely focusing on
mechanisms responsible for destabilization of lipid-laden
plaques. Inﬂammatory markers, such as C-reactive protein
and other indicators of inﬂammation and destabilization,67
have entered into risk formulations, offering potentially
useful additions to conventional risk markers.68,69 In
addition, familial clustering of SCD as a speciﬁc manifes-
tation of the disease57,58 may lead to identiﬁcation of
speciﬁc genetic abnormalities that predispose to SCD.52–54,70
Hypertension is an established risk factor for CHD and also
emerges as a risk factor for SCD.71 Both the ECG pattern of
left ventricular hypertrophy (LVH) and echocardiographic
evidence or LVH are associated with a higher proportion of
sudden and unexpected cardiac death. Intraventricular con-
duction abnormalities such as left bundle-branch block
(LBBB) are also suggestive of a disproportionate number of
SCD.72,73
There are also meaningful associations between cigarette
smoking, obesity, diabetes, and lifestyle and SCD. The
Framingham Study demonstrates that cigarette smokers
have a 2- to 3-fold increase in SCD risk; this is one of the
few risk factors in which the proportion of CHD deaths that
are sudden increases in association with the risk factor.72 In
addition, in a study of 310 survivors of out-of-hospital
cardiac arrest, the recurrent cardiac arrest rate was 27% at
3 y of follow-up among those who continued to smoke after
their index event, compared with 19% in those who
stopped.74 Obesity is a second factor that appears to inﬂu-
ence the proportion of coronary deaths that occur suddenly.72
Associations between levels of physical activity and SCD
have been studied, with varying results.75 A high resting
heart rate with little change during exercise and recovery is
a risk factor for SCD. Epidemiological observations have
suggested a relationship between sedentary activity and
increased CHD death risk. The Framingham Study, however,
showed an insigniﬁcant relationship between low levels of
physical activity and incidence of SCD but a high proportion
of sudden to total cardiac deaths at higher levels of physical
activity.72 An association between acute physical exertion
and SCD demonstrated a 17-fold relative increase for the
risk of SCD during vigorous exercise for the entire populations
(active and inactive). For the habitually inactive, the relative
risk was 74.76 Habitual vigorous exercise attenuates risk.76,77
Therefore, these data indicate that, while the risk of cardiac
arrest is higher during vigorous exercise (especially among
individuals who are usually sedentary), habitual exercise
attenuates the risk of cardiac arrest, both during exercise
and at rest.78
The magnitude of recent life changes in the realms of
health, work, home, and family and personal and social
factors have been related to MI and SCD.79–82 There is an
association between signiﬁcant elevations of life-change
scores during the 6 mo before a coronary event, and the
association is particularly striking in victims of SCD. After
controlling for other major prognostic factors, the risk of
SCD and total mortality is increased by social and economic
stresses,83 and alteration of modiﬁable lifestyle factors has
been proposed as a strategy for reducing risk of SCD in patients
with CHD.84 Acute psychosocial stressors have been associated
with risk of cardiovascular events, including SCD.85,86 The risk
appears to cluster around the time of the stress and appear to
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occur among victims at preexisting risk, with the stressor
simply advancing the time of an impending event.85 The possi-
bility of physical stress-induced coronary plaque disruption has
also been suggested.87
3. Mechanisms and substrates
3.1. Substrate for ventricular arrhythmias
The substrate for SCD varies depending on the underlying
structural heart disease, if any, and ranges from no
obvious evidence of structural damage to advanced cardio-
myopathic states. Most studies suggest that three quarters
of the patients dying of SCD have CHD. Extensive coronary
atherosclerosis is generally found, with a high proportion
of hearts having 3- or 4-vessel coronary disease involve-
ment. Anatomical ﬁndings at autopsy include acute
changes in coronary plaque morphology, such as thrombus,
plaque disruption, or both, in more than 50% of cases of
sudden coronary death. Hearts that have myocardial scars
and no acute infarction show active coronary lesions in
approximately 50% of cases.88 Erosion of proteoglycan- and
smooth muscle cell-rich plaques lacking a superﬁcial lipid
core, or plaque rupture, is a frequent pathological
ﬁnding.89 Plaque rupture appears to be more common in
older women.90 However, these anatomical abnormalities
are not represented by speciﬁc clinical risk factors different
from those that identify patients with CHD in general.
Naturally, the substrate will be different depending on the
nature of the heart disease. As noted in Section 2, other dis-
eases predisposing to SCD include both hypertrophic cardio-
myopathy (HCM) and dilated cardiomyopathy (DCM), right
ventricular (RV) cardiomyopathy, congenital abnormalities
(especially coronary artery anomalies), coronary artery
spasm, and other less common problems.44,46,91 Obesity,
hypertension, lipid abnormalities, and diabetes are import-
ant risk factors.92–95 The heritable abnormalities of RV car-
diomyopathy and HCM are the major substrates found in
the sudden deaths of pre-coronary artery age groups.96–98
The cumulative risk of SCD has been estimated at 15% to
20% of adults with aortic stenosis, with the risk being
higher in symptomatic patients and equal to or less than
5% in asymptomatic patients.99 Mitral valve prolapse is
usually non-life threatening, and its link with SCD has
never been conclusively demonstrated.3 Reported SCD
rates in patients with Wolff-Parkinson-White (WPW)
syndrome have been 0.15%, due in most to the development
of atrial ﬁbrillation (AF) with a rapid ventricular response
that degenerates to VF.100,101
Genetic inﬂuences modulate the risk of SCD in the setting
of coronary (and likely other) heart disease.3,55,102 The Paris
Prospective Study I, analyzing more than 7000 men followed
for an average of 23 y, found that a parental history of SCD
increased the relative risk of SCD for offspring to 1.8,
without elevating the risk for MI. When both parents had
SCD, the relative risk for SCD in offspring was 9.4.58 A retro-
spective study performed on cardiac arrest survivors in King
County, Washington, also reported family history to be a
signiﬁcant, independent risk for SCD, with an odds ratio
of 1.57.57 Genetic inﬂuences may act through multiple,
though not necessarily exclusive, mechanisms: by modulat-
ing the ﬁxed substrate, atherothrombosis, electrogenesis
impulse propagation, neural control and regulation.
In 5% to 10% of cases, SCD occurs in the absence of CHD or
cardiomyopathy. There exists a group of inherited abnormal-
ities such as the long QT syndrome (LQTS), short QT syn-
drome (SQTS), Brugada syndrome, and catecholaminergic
VT, which can precipitate SCD without overt structural
changes in the heart.103–105 Abnormalities in potassium
and sodium channels, in ankyrin B, and in the ryanodine
receptor of the sarcoplasmic reticulum which is responsible
for release of the calcium required for cardiac muscle con-
traction, can disrupt the normal electrical processes of the
heart to cause life-threatening ventricular arrhythmias. It
is important to stress that some individuals can have inher-
ited abnormalities that are not manifest until triggered by
an external event. For example, autonomic modulation
associated with certain types of activity, as well as drugs
that affect cardiac repolarization, can convert a subclinical
genetic abnormality to SCD. It is highly likely that additional
genetic causes of SCD will be found in the future.56
Among the genetic factors, the most common are DNA var-
iants called ‘polymorphisms’ that may be present in a large
proportion of the population and create susceptibility for
SCD. Single nucleotide polymorphisms (SNPs) are DNA var-
iants that can be associated with a functional consequence.
For example, a polymorphism identiﬁed in the alpha 2b
adrenergic receptor is associated with an increased risk of
MI and SCD.106 Studies such as these require validation
before they enter clinical practice. Nevertheless, because
millions of SNPs are present in the DNA of each individual,
a speciﬁc combination of polymorphisms in different
genes, interacting with a speciﬁc trigger or substrate, may
be required to create a risk for SCD.56
3.2. Mechanisms of sudden cardiac death
The rhythm most often recorded at the time of sudden
cardiac arrest is VF. Previous studies suggest that 75% to
80% occur via this mechanism and 15% to 20% are attributed
to bradyarrhythmias, including advanced atrioventricular
(AV) block and asystole.107 Bayes de Luna et al.108 noted
that in 157 ambulatory patients who had SCD while under-
going Holter recording, 62.4% had VF, 16.5% had bradyar-
rhythmias, 12.7% had torsades de pointes, and 8.3% had
primary VT. The true incidence of bradyarrhythmias is not
clear because a rhythm beginning as VF may appear to be
asystole when the ﬁrst ECG is recorded. However, a study
reported by Cobb et al.37 suggests that VF accounts for a
smaller proportion of events than previously thought.
Advanced AV block or signiﬁcant bradycardia can cause VF.
It is difﬁcult to identify accurately the EP mechanism(s)
responsible for SCD. The reason for this is that the mechan-
isms may be multifactoral and are quite likely to be differ-
ent depending on the speciﬁc cardiac abnormality and a
rhythm can start via one mechanism and be perpetuated
via another. It is also important to remember that while
many studies have investigated EP mechanisms responsible
for the onset of VT and VF and their continuation, no class
I or III antiarrhythmic agent109 has clearly been demon-
strated to reduce total and SCD mortality in patients at
risk for SCD. (7a,109) In fact, it is the drugs without direct
EP actions on cardiac muscle or specialized conducting
tissue that have been shown effective for prevention of
SCD. These drugs include beta blockers, ACE inhibitors,
angiotensin receptor-blocking agents, lipid-lowering agents,
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spironolactone, and ﬁbrinolytic and antithrombotic agents;
some data also suggest a protective effect of n-3 fatty
acids,110 although this remains to be conﬁrmed111 (see
Section 6.4).
Because SCD is for the most part the result of a ventricular
tachyarrhythmia, these drugs must be acting on the funda-
mental biochemical, ischemic, ﬁbrotic, or other processes
that underlie the onset or maintenance of the life-
threatening ventricular arrhythmias. Thought of in this
fashion, VF can be considered a ﬁnal common pathway for
the expression of an electrically unstable heart. The
fundamental mechanisms of cardiac arrest include electro-
mechanical dissociation, asystole and heart block, and VF,
with VF being the most common. It is the ‘upstream’
events triggering the electrical instability upon which
these drugs probably act. While we unquestionably need
to pursue investigations into the electrophysiology of these
ventricular tachyarrhythmias, more study needs to be
applied to the drugs affecting upstream events, because
these events appear to yield the greatest dividends, at
least for the present, and must be the reason why the
asymptomatic, apparently stable, individual suddenly devel-
ops SCD at a particular time on a particular day. It must be
that a dynamic factor or factors, possibly transient, interact
with a ﬁxed substrate to precipitate the arrhythmia. The
possibilities ﬁll a long list and include such things as physical
activity, transient ischemia, pH and electrolyte changes,
inﬂammation, hypoxia, stretch, ion channel abnormalities,
neuroendocrine actions, drugs, and so forth, all of which
are capable of modulating conduction in ways we mostly
do not understand. More permanent changes could also
occur, such as plaque rupture, as mentioned earlier.112
4. Clinical presentations of patients with
ventricular arrhythmias and sudden cardiac
death
Ventricular arrhythmias can occur in individuals with or
without a cardiac disorder. There is a great deal of overlap
between clinical presentations (Table 5) and the severity
and type of heart disease. For example, stable and well-
tolerated VT can occur in the individual with previous MI
and impaired ventricular function. The prognosis and man-
agement are individualized according to symptom burden
and severity of underlying heart disease, in addition to the
clinical presentation.
4.1. Asymptomatic
Ventricular arrhythmias may be detected as an incidental
ﬁnding during ECG monitoring or physical examination.
They may also be uncovered during an attempt to further
deﬁne prognosis in an individual with known heart disease.
In general, treatment is indicated to prevent potential mor-
bidity (e.g., ‘tachycardia-induced cardiomyopathy’), reduce
symptom burden, or reduce the risk of SCD. There is no
reason to treat asymptomatic ventricular arrhythmias in
the absence of such potential beneﬁt. The major determi-
nants of risk of SCD are related more to the type and sever-
ity of associated cardiac disease and less to the frequency or
classiﬁcation of ventricular arrhythmia.44,113 Certain
arrhythmias such as rapid polymorphic VT may be compel-
ling to treat even in the asymptomatic individual without
evident heart disease. Nonetheless, such arrhythmias are
rarely asymptomatic and are probably related to ionic
channel abnormalities yet to be elucidated.114,115 NSVT in
the patient with previous MI and impaired LV function indi-
cates increased risk of SCD and the need for further evalu-
ation or treatment.116 The contribution of asymptomatic
ventricular arrhythmias to the patient’s management is
not well established for other cardiac diseases such as
DCM117 or HCM.118
4.2. Symptoms potentially related to ventricular
arrhythmias
Palpitations or a perception of cardiac rhythm irregularity
may be caused by the whole spectrum of arrhythmias and
are also frequently reported in patients in the absence of
any arrhythmia.119 Less frequently, patients with VT may
present with symptoms of paroxysmal dyspnea or chest
pain in the absence of a sensation of rapid heart beating.
In such instances, the dyspnea or chest pain may be
related to the hemodynamic consequences of tachycardia.
‘Presyncope’ is a vague term that is poorly deﬁned but prob-
ably is interpreted by most as a feeling of impending
syncope.120 It is not speciﬁc as a symptom. VT may be a
cause of undiagnosed syncope, especially in patients with
structural heart disease.121 Patients with poor ventricular
function and inducible VTor VF have a high incidence of sub-
sequent appropriate therapies when implanted with an
ICD.122–128 Similar patients with poor ventricular function
may be at risk of SCD.129 Patients with sudden onset of
very rapid VT such as torsades de pointes with the repolari-
zation syndromes will typically present with syncope or
seizure rather than an awareness of rapid heart beating or
palpitations.130
4.2.1. Hemodynamically stable ventricular tachycardia
Patients with slower, stable VT may be asymptomatic but
more frequently present with a sensation of rapid heart
beating possibly accompanied by dyspnea or chest discom-
fort. The stability or tolerance of VT is related to the rate
of tachycardia, presence of retrograde conduction, ventri-
cular function, and the integrity of peripheral compensatory
mechanisms. A presentation with stable, relatively well-
tolerated VT does not suggest the absence of heart disease
Table 5 Clinical presentations of patients with ventricular
arrhythmias and sudden cardiac death
† Asymptomatic individuals with or without electrocardiographic
abnormalities
† Persons with symptoms potentially attributable to ventricular
arrhythmias
W Palpitations
W Dyspnea
W Chest pain
W Syncope and presyncope
† Ventricular tachycardia that is hemodynamically stable
† Ventricular tachycardia that is not hemodynamically stable
† Cardiac arrest
W Asystolic (sinus arrest, atrioventricular block)
W Ventricular tachycardia
W Ventricular ﬁbrillation
W Pulseless electrical activity
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and can be observed in patients with very poor LV function.
Even patients with poor ventricular function may not be
aware of palpitations during VT. Presentation with stable
VT does not in itself indicate a benign prognosis in patients
with signiﬁcant heart disease.131 Incessant VT, although
hemodynamically stable, can be a cause of hemodynamic
deterioration leading to HF.132 In patients with an ICD, the
VT rate can fall below the lower rate of VT detection,
causing underdetection of VT that can prevent arrhythmia
termination. Immediate reinitiation of the VT following
proper ICD therapy can also result in hemodynamic deterio-
ration and an early battery depletion.132,133
4.2.2. Hemodynamically unstable ventricular
tachycardia
The term ‘hemodynamically unstable’ has not been rigidly
deﬁned but is widely used. It connotes a tachycardia associ-
ated with hypotension and poor tissue perfusion that is con-
sidered to have the imminent potential to lead to cardiac
arrest or shock if left untreated. Hemodynamically unstable
VT is usually, but not exclusively, observed in patients with
poor ventricular function. Patients with normal ventricular
function can have unstable VT or VF if the tachycardia is
rapid enough, as in the LQTS and other abnormal repolariza-
tion syndromes.103 Some patients with a normal heart and
idiopathic monomorphic VT or even supraventricular tachy-
cardia (SVT) can become hypotensive during the arrhythmia
because of a vasovagal reaction.
4.3. Sudden cardiac arrest
Rapid sustained VT or VF results in presentation with mark-
edly impaired tissue perfusion and loss of consciousness as
a result of inadequate cardiac output, leading to SCD if
not expediently reversed. Sudden cardiac arrest may be
the presenting symptom with any cardiac disease or even
in individuals with no apparent heart disease.44 The initiat-
ing mechanism of sudden cardiac arrest may or may not be
related to arrhythmia.
5. General evaluation of patients with
documented or suspected ventricular
arrhythmias
5.1. History and physical examination
Palpitations, presyncope, and syncope are the 3most import-
ant symptoms requiring further characterization in patients
suspected of having ventricular arrhythmias. Palpitations
are usually of a sudden onset/offset pattern and may be
associated with presyncope and/or syncope. Sudden episodes
of collapse with loss of consciousness without any premo-
nition that usually last for a few seconds must raise the
suspicion of conduction defects or ventricular arrhythmias.
Other symptoms related to underlying structural heart
disease may also be present, especially chest discomfort,
dyspnea, and fatigue. A thorough drug history including
dosages used must be included in the evaluation of patients
suspected of having ventricular arrhythmias. Two important
studies57,58 have conﬁrmed that a positive family history of
SCD is a strong independent predictor of susceptibility to
ventricular arrhythmias and SCD, as noted earlier. Physical
examination is often unrevealing in patients suspected of
having ventricular arrhythmias unless the arrhythmia occurs
while the patient is being examined or has other ﬁndings
indicative of structural heart disease.
5.2. Noninvasive evaluation
5.2.1. Resting electrocardiogram
Recommendations
Class I
Resting 12-lead ECG is indicated in all patients who
are evaluated for ventricular arrhythmias. (Level of
Evidence: A)
A standard resting 12-lead ECG allows not only identiﬁ-
cation of various congenital abnormalities associated with
ventricular arrhythmias and SCD (e.g., LQTS, SQTS,
Brugada syndrome, ARVC) but also identiﬁcation of various
other ECG parameters, such as those due to electrolyte dis-
turbances, or evidence suggesting underlying structural
disease, such as bundle-branch block, AV block, ventricular
hypertrophy, and Q waves indicative of ischemic heart
disease or inﬁltrative cardiomyopathy. QRS duration and
repolarization abnormalities are both independent predic-
tors of SCD. A prolonged QRS duration greater than 120 to
130 ms has been shown in a number of studies to be associ-
ated with increased mortality in patients with a reduced
LVEF (equal to or less than 30%). Prospective studies have
also reported an association between ST-segment depression
or T-wave abnormalities and increased risk of cardiovascular
death and SCD in particular. These studies have demon-
strated a risk ratio for cardiovascular death of 2.16 (95%
conﬁdence interval [CI] 1.30 to 3.58) to 2.4 (95% CI 1.70
to 3.53) in the presence of an ‘ischemic’ ECG134 and 4.4
(95% CI 2.6 to 7.4) for SCD in the presence of an abnormal
T-wave axis.135,136 A prolonged QTc interval is also an inde-
pendent predictor of SCD. QTc greater than 420 ms has
been shown to have a higher risk of cardiovascular death
relative to a shorter QTc. And a QTc greater than 440 ms sig-
niﬁcantly predicted cardiovascular death with adjusted
relative risk of 2.1.137 Although a prolonged QTc interval
predicts SCD, it is worth noting that some data suggest
that the correlation between QTc and survival may be
‘J-shaped.’ In other words, relatively short QTc intervals
have also been associated with increased risk. For instance,
it has been reported that patients with a mean QTc shorter
than 400 ms during 24-h ECG have a more than 2-fold risk of
dying suddenly than do patients with a mean QTc between
400 and 440 ms after a 2-y follow-up.138 A QTc less than
300 ms is often used to deﬁne the SQTS, which is an indepen-
dent predictor of SCD.139,140
5.2.2. Exercise testing
Recommendations
Class I
(1) Exercise testing is recommended in adult patients with
ventricular arrhythmias who have an intermediate or
greater probability of having CHD by age, gender, and
symptoms to provoke ischemic changes or ventricular
arrhythmias. (Level of Evidence: B) See Table 4 in the
ACC/AHA 2002 Guideline Update for Exercise
Testing141 for further explanation of CHD probability.
(2) Exercise testing, regardless of age, is useful in patients
with known or suspected exercise-induced ventricular
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arrhythmias, including catecholaminergic VT, to provoke
the arrhythmia, achieve a diagnosis, and determine the
patient’s response to tachycardia. (Level of Evidence: B)
Class IIa
Exercise testing can be useful in evaluating response to
medical or ablation therapy in patients with known
exercise-induced ventricular arrhythmias. (Level of
Evidence: B)
Class IIb
(1) Exercise testing may be useful in patients with ventricu-
lar arrhythmias and a low probability of CHD by age,
gender, and symptoms. (Level of Evidence: C) See
Table 4 in the ACC/AHA 2002 Guideline Update for
Exercise Testing 141 for further explanation of CHD
probability.
(2) Exercise testing may be useful in the investigation of iso-
lated premature ventricular complexes (PVCs) in
middle-aged or older patients without other evidence
of CHD. (Level of Evidence: C)
Class III
See Table 1 in the ACC/AHA 2002 Guideline Update
for Exercise Testing141 for contraindications. (Level of
Evidence: B)
Exercise-ECG is commonly used in the evaluation of
patients with ventricular arrhythmias. Its most common
application is for detection of silent ischemia in patients
suspected of having underlying CHD.141 In patients with
known or silent CHD or cardiomyopathies, the presence of
frequent PVCs during or after exercise has been associated
with greater risk for serious cardiovascular events but not
speciﬁcally SCD.19,20,24 Exercise-induced PVCs in apparently
normal individuals should not be used to dictate therapy
unless associated with documented ischemia or sustained
VT. With the exception of beta blockers, at the present
time the use of antiarrhythmic drugs to abolish
exercise-induced PVCs has not been proved to be effective
in reducing SCD.
Exercise testing in adrenergic-dependent rhythm disturb-
ances, including monomorphic VT and polymorphic VT, may
be useful in evaluating symptomatic subjects and evaluating
response to therapy. Ambulatory ECG or event monitoring
may fail to capture the arrhythmia, particularly if the
patient is relatively sedentary. Moreover, exercise testing
may provide prognostic information in these patients,
given that the presence of exercise-induced ventricular
ectopy increases mortality at 12 mo by 3-fold relative to
patients with ectopy at rest only.142 Patients with
exercise-induced paired ventricular complexes or VT have
a lower survival rate than those with exercise-induced
simple ventricular ectopy.143
Although the safety of supervised exercise testing is well
established, less data are available in patients at risk for
serious ventricular arrhythmias. In one series, exercise
testing in patients with life-threatening ventricular arrhyth-
mias was associated with a 2.3% incidence of arrhythmias
requiring cardioversion, intravenous drugs, or resuscita-
tion.144 Such an exercise study may still be warranted
because it is better to expose arrhythmias and risk under
controlled circumstances. Exercise testing should be
performed where resuscitation equipment and trained per-
sonnel are immediately available.
5.2.3. Ambulatory electrocardiography
Recommendations
Class I
(1) Ambulatory ECG is indicated when there is a need to
clarify the diagnosis by detecting arrhythmias,
QT-interval changes, T-wave alternans (TWA), or ST
changes, to evaluate risk, or to judge therapy. (Level
of Evidence: A)
(2) Event monitors are indicated when symptoms are spora-
dic to establish whether or not they are caused by tran-
sient arrhythmias. (Level of Evidence: B)
(3) Implantable recorders are useful in patients with spora-
dic symptoms suspected to be related to arrhythmias
such as syncope when a symptom-rhythm correlation
cannot be established by conventional diagnostic tech-
niques. (Level of Evidence: B)
The use of continuous or intermittent ambulatory record-
ing techniques can be very helpful in diagnosing a suspected
arrhythmia, establishing its frequency, and relating symp-
toms to the presence of the arrhythmia. Silent myocardial
ischemic episodes may also be detected. A 24- to 48-h con-
tinuous Holter recording is appropriate whenever the
arrhythmia is known or suspected to occur at least once a
day. For sporadic episodes producing palpitations, dizziness,
or syncope, conventional event monitors are more appropri-
ate because they can record over extended periods of
time.145
New implantable recorders are capable of monitoring the
rhythm and can record on patient activation or automati-
cally for prespeciﬁed criteria. Although these devices
require surgical implantation, they have been shown to be
extremely useful in diagnosing serious tachyarrhythmias
and bradyarrhythmias in patients with life-threatening
symptoms such as syncope.120,146
5.2.4. Electrocardiographic techniques and
measurements
Recommendations
Class IIa
It is reasonable to use TWA to improve the diagnosis and
risk stratiﬁcation of patients with ventricular arrhyth-
mias or who are at risk for developing life-threatening
ventricular arrhythmias. (Level of Evidence: A)
Class IIb
ECGtechniques suchas signal-averagedECG(SAECG),heart
rate variability (HRV), baroﬂex sensitivity, and heart rate
turbulence may be useful to improve the diagnosis and
risk stratiﬁcation of patients with ventricular arrhythmias
or who are at risk of developing life-threatening ventri-
cular arrhythmias. (Level of Evidence: B)
ICD trials, especially Multicenter Automatic Deﬁbrillator
Implantation Trial (MADIT) II, have highlighted the need to
develop novel tools in order to identify patients at highest
risk of ventricular arrhythmias and SCD. Numerous modal-
ities exist at present for assessing this risk but only 2 are cur-
rently approved by the U.S. Food and Drug Administration
762 ACC/AHA/ESC Guidelines
Downloaded from https://academic.oup.com/europace/article-abstract/8/9/746/534498
by guest
on 02 April 2018
(FDA): SAECG and TWA. However, HRV and baroﬂex sensi-
tivity also show considerable promise. SAECG improves the
signal-to-noise ratio of a surface ECG, permitting the identi-
ﬁcation of low-amplitude (microvolt level) signals at the end
of the QRS complex referred to as ‘late potentials.’ Late
potentials indicate regions of abnormal myocardium demon-
strating slow conduction, a substrate abnormality that may
allow for reentrant ventricular arrhythmias, and they are
believed to serve as a marker for the presence of an EP sub-
strate for reentrant ventricular tachyarrhythmias. The pre-
sence of an abnormal SAECG was shown to increase the
risk of arrhythmic events by 6- to 8-fold in a post-MI
setting.147 However, the restoration of patency to the
infarct-related coronary artery with ﬁbrinolysis or angio-
plasty and the widespread use of surgical revascularization
have modiﬁed the arrhythmogenic substrate, leading to a
noticeable reduction in the predictive power of this tool.
SAECG in isolation, therefore, is no longer useful for the
identiﬁcation of post-MI patients at risk of ventricular
arrhythmias. However, a high negative predictive value of
89% to 99% rendered the SAECG a useful tool with which to
exclude a wide-complex tachycardia as a cause of unex-
plained syncope.148,149
TWA, which is a ﬂuctuation in the amplitude or mor-
phology of the T wave that alternates every other beat
assessed during exercise testing or atrial pacing, has been
shown to be an effective tool for identifying high-risk
patients post-MI150 and in the presence of ischemic or non-
ischemic cardiomyopathy. This association appears to be
independent of EF and equally strong in patients with
ischemic and nonischemic cardiomyopathy. TWA appears to
have a very high negative predictive accuracy.151–153 TWA
may also be used to identify risk of arrhythmic mortality in
patients with LV dysfunction due to prior MI.154 In a small
study of patients with MADIT II characteristics (post-MI
with EF less than or equal to 30%), a microvolt TWA test
was found to be better than QRS duration at identifying a
high-risk group and also a low-risk group unlikely to
beneﬁt from ICD therapy.155
HRV, which is a beat-to-beat variation in cardiac cycle
length resulting from autonomic inﬂuence on the sinus
node of patients in sinus rhythm, has been shown to inde-
pendently predict the risk of SCD and total mortality in
patients post-MI156 both with and without impaired LV func-
tion.157–159 Observational studies also suggest its usefulness
in the presence of nonischemic cardiomyopathy, but this has
to be conﬁrmed with large clinical trials. There are many
different forms of heart rate analysis, some of which, such
as heart rate turbulence, may be more productive than
others. Reduced baroﬂex sensitivity, a quantitative assess-
ment of the ability of the autonomic nervous system to
react to acute stimulation involving primarily vagal reﬂexes,
compared with a continuous assessment of basal sympatho-
vagal information provided by HRV, has also proved success-
ful in assessing the risk of SCD both alone (increased
inducibility of arrhythmic events including VT during EP
testing)160,161 and when used in combination with HRV
(increased risk of cardiac mortality post-MI)157 and TWA
(increased risk of arrhythmic events if both parameters
are abnormal in a cohort of patients with ICDs).162
Additional prospective studies are needed to further
clarify the role of these ECG parameters in assessing risk
in differing clinical settings.
5.2.5. Left ventricular function and imaging
Recommendations
Class I
(1) Echocardiography is recommended in patients with
ventricular arrhythmias who are suspected of having
structural heart disease. (Level of Evidence: B)
(2) Echocardiography is recommended for the subset of
patients at high risk for the development of serious ven-
tricular arrhythmias or SCD, such as those with dilated,
hypertrophic, or RV cardiomyopathies, AMI survivors, or
relatives of patients with inherited disorders associated
with SCD. (Level of Evidence: B)
(3) Exercise testing with an imaging modality (echocardio-
graphy or nuclear perfusion [single-photon emission
computed tomography (SPECT)]) is recommended to
detect silent ischemia in patients with ventricular
arrhythmias who have an intermediate probability of
having CHD by age, symptoms, and gender and in whom
ECG assessment is less reliable because of digoxin use,
LVH, greater than 1-mm ST-segment depression at rest,
WPW syndrome, or LBBB. (Level of Evidence: B)
(4) Pharmacological stress testing with an imaging modality
(echocardiography or myocardial perfusion SPECT) is
recommended to detect silent ischemia in patients
with ventricular arrhythmias who have an intermediate
probability of having CHD by age, symptoms, and
gender and are physically unable to perform a symptom-
limited exercise test. (Level of Evidence: B)
Class IIa
(1) MRI, cardiac computed tomography (CT), or radio-
nuclide angiography can be useful in patients with ven-
tricular arrhythmias when echocardiography does not
provide accurate assessment of LV and RV function
and/or evaluation of structural changes. (Level of
Evidence: B)
(2) Coronary angiography can be useful in establishing or
excluding the presence of signiﬁcant obstructive CHD
in patients with life-threatening ventricular arrhythmias
or in survivors of SCD, who have an intermediate or
greater probability of having CHD by age, symptoms,
and gender. (Level of Evidence: C)
(3) LF imaging can be useful in patients undergoing biventri-
cular pacing. (Level of Evidence: C)
5.2.5.1. Echocardiograph. Echocardiography is the imaging
technique that is most commonly used because it is inexpen-
sive in comparison with other techniques such as MRI and
cardiac CT, it is readily available, and it provides accurate
diagnosis of myocardial, valvular, and congenital heart
disorders associated with ventricular arrhythmias and
SCD163,164 (Table 6). In addition, LV systolic function and
regional wall motion can be evaluated and, in a majority
of patients, EF can be determined.165 Echocardiography is
therefore indicated in patients with ventricular arrhythmias
suspected of having structural heart disease and in the
subset of patients at high risk for the development of
serious ventricular arrhythmias or SCD, such as those with
dilated, hypertrophic or RV cardiomyopathies, AMI survivors,
or relatives of patients with inherited disorders associated
with SCD. The combination of echocardiography with
exercise or pharmacological stress (commonly known as
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‘stress echo’) is applicable to a selected group of patients
who are suspected of having ventricular arrhythmias trig-
gered by ischemia and who are unable to exercise or have
resting ECG abnormalities that limit the accuracy of ECG
for ischemia detection.164 Anomalous origin of coronary
arteries can be detected by echocardiography or other
imaging techniques.
5.2.5.2. Cardiac magnetic resonance imaging. Advances in
cardiac MRI have made possible the use of this imaging
technique to evaluate both the structure and function of
the beating heart. The excellent image resolution obtained
with current techniques allows for the accurate quantiﬁ-
cation of chamber volumes, LV mass, and ventricular
function.166–168 This is of particular value to patients with
suspected arrhythmogenic RV cardiomyopathy (ARVC), in
whom MRI provides excellent assessment of RV size, func-
tion, and regional wall motion and, importantly, may allow
the detection of fatty inﬁltration within the RV myocar-
dium.169,170 RV angiography may also be useful. Cardiac
MRI increasingly is being applied and validated for the
detection of ischemia (adenosine stress perfusion and
dobutamine stress wall motion studies) and the detection
and quantiﬁcation of infarction/ﬁbrosis, a substrate for VT.
The cost and availability of cardiac MRI are becoming
more competitive. Cardiac MRI can provide a comprehensive
cardiac evaluation in a single study. It is important to stress
that, as with all imaging modalities, accurate interpretation
affects its usefulness.171
5.2.5.3. Cardiac computed tomography. As with MRI, the
ﬁeld of CT has advanced greatly with the development of
fast scanners with better resolution that allow tomographic
imaging of the heart and coronary arteries. These systems
allow precise quantiﬁcation of LV volumes, EF, and LV mass
with results comparable to MRI but in addition provide
segmental images of the coronary arteries from which the
extent of calciﬁcation can be quantiﬁed.172–176 The majority
of cardiac disorders associated with serious ventricular
arrhythmias or SCD are assessed well with echocardiography.
Cardiac CT can be used in selected patients in whom
evaluation of cardiac structures is not feasible with echo-
cardiography and MRI is not available. There is currently
no incremental clinical beneﬁt derived from imaging the
coronary arteries by cardiac CT in patients with ventricular
arrhythmias.
5.2.5.4. Radionuclide techniques. Myocardial perfusion
SPECTusing exercise or pharmacological agents is applicable
for a selected group of patients who are suspected of having
ventricular arrhythmias triggered by ischemia and who
are unable to exercise or have resting ECG abnormalities
that limit the accuracy of ECG for ischemia detection. Myo-
cardial perfusion SPECTcan also be used to assess viability in
patients with LV dysfunction due to prior MI.177 Accurate
quantiﬁcation of LVEF is possible with gated radionuclide
angiography (multiple gated acquisition scan) and thus this
technique may be helpful in patients for whom this
measurement is not available with echocardiography.
5.2.5.5. Coronary angiography. In patients with life-
threatening ventricular arrhythmias or in survivors of SCD,
coronary angiography plays an important diagnostic role in
establishing or excluding the presence of signiﬁcant
obstructive coronary artery disease. It is common for these
patients to undergo this procedure as part of their diagnos-
tic evaluation, particularly if they have an intermediate or
greater probability for CHD. Detailed recommendations
regarding imaging and exercise testing can be found in the
respective guidelines.141,164,177
5.3. Electrophysiological testing
EP testing with intracardiac recording and electrical stimu-
lation at baseline and with drugs has been used for arrhyth-
mia assessment and risk stratiﬁcation for SCD. EP testing for
the evaluation of VT was introduced in 1972 by Wellens
et al.178 The sensitivity, speciﬁcity, and predictive values
of EP testing have been extensively assessed by various
authors, usually in small patient groups. EP testing is
used to document the inducibility of VT, guide ablation,
evaluate drug effects, assess the risks of recurrent VT or
SCD, evaluate loss of consciousness in selected patients
with arrhythmias suspected as a cause, and assess the
indications for ICD therapy.121,179–183 The yield of EP
testing varies fundamentally with the kind and severity of
the underlying heart disease, the presence or absence of
spontaneous VT, concomitant drug therapy, the stimulation
protocol, and the site of stimulation. Highest induction
rates and reproducibility are observed in patients after
MI.184–186
To evaluate patients with ventricular arrhythmias, most
centers use 8 ventricular stimuli at drive cycle lengths
between 600 and 400 ms at the RV apex, at twice diastolic
threshold and the pulse duration of 0.5 to 2 ms, delivering
1 to 3 ventricular extrastimuli at baseline. This test may
be repeated during isoproterenol infusion.187–189 The pre-
maturity of extrastimuli is increased until refractoriness or
induction of sustained ventricular tachyarrhythmia is
achieved. Long-short cycle sequences may be tested.
Because premature ventricular stimulation with a very
short coupling interval is more likely to induce VF as
opposed to monomorphic VT, it may be reasonable to limit
the prematurity of the extrastimuli to a minimum of
180 ms when studying patients for whom only inducible
sustained monomorphic VT would be considered a positive
endpoint.190 EP testing may be repeated at the RV outﬂow
tract (RVOT) or LV.189 In some patients with rate-dependent
induction of VT, rapid atrial or ventricular stimulation may
induce VT.191
Table 6 Conditions associated with ventricular arrhythmias
that can be diagnosed with echocardiography
Disease entity Diagnostic
accuracy
Dilated cardiomyopathy High
Ischemic cardiomyopathy High
Hypertension with moderate to severe LVH High
Hypertrophic cardiomyopathy High
Valvular heart disease High
ARVC Moderate
Brugada syndrome Poor
ARVC, arrhythmogenic right ventricular cardiomyopathy; LVH, left ven-
tricular hypertrophy.
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5.3.1. Electrophysiological testing in patients with
coronary heart diseases
Recommendations
Class I
(1) EP testing is recommended for diagnostic evaluation of
patients with remote MI with symptoms suggestive of
ventricular tachyarrhythmias, including palpitations,
presyncope, and syncope. (Level of Evidence: B)
(2) EP testing is recommended in patients with CHD to guide
and assess the efﬁcacy of VTablation. (Level of Evidence: B)
(3) EP testing is useful in patients with CHD for the diagnos-
tic evaluation of wide-QRS-complex tachycardias of
unclear mechanism. (Level of Evidence: C)
Class IIa
EP testing is reasonable for risk stratiﬁcation in patients
with remote MI, NSVT, and LVEF equal to or less than
40%. (Level of Evidence: B)
Drug testing for assessing antiarrhythmic drug efﬁcacy has
largely been abandoned. EP testing was required in the
MADIT, Multicenter UnSustained Tachycardia Trial (MUSTT),
and Beta-Blocker Strategy plus Implantable Cardioverter
Deﬁbrillator (BEST-ICD) trials and others, but not in the
MADIT II, Sudden Cardiac Death in Heart Failure (SCD-
HeFT), or Antiarrhythmics Versus Implantable Deﬁbrillators
(AVID) trials. Inducibility of VT in patients with NSVT on
Holter monitoring identiﬁed a population at high risk for
VT/VF and ICD use in the MADIT trial.192
In a MUSTT trial substudy, the ECG characteristics of NSVT
(rate, duration, frequency, occurrence in-hospital vs.
out-of-hospital) did not correlate with inducibility.193–195
Survival was worse for in-hospital compared with
out-of-hospital NSVT,193 suggesting that different risk strati-
ﬁcation criteria may be necessary in asymptomatic ambulat-
ory patients. In a MADIT II substudy, inducibility was 36%.
Lower heart rate, lower EF, and a longer interval between
MI and an EP study correlates with higher inducibility.196
In patients with CHD, asymptomatic NSVT, and an EF less
than 40%, inducibility of sustained VT ranges between 20%
and 40%.116 Inducibility conferred a worse prognosis. Induci-
bility identiﬁes patients at high risk of subsequent VT and
that the absence of inducibility indicated a low risk with
MADIT-like patients.197 However, these patients had a high
rate of percutaneous revascularization. In CHD patients with
a low EF (less than 30%), noninducibility does not portend a
good prognosis.198 Persistent inducibility while receiving anti-
arrhythmic drugs predicts a worse prognosis.199 Patients in
whom amiodarone suppressed VT inducibility or slowed VT
to a mean cycle length of greater than 400 ms had 30%
higher mortality compared with patients who did not
respond to amiodarone and had an ICD placed instead.200
EP-guided antiarrhythmic drug effectiveness in patients with
NSVTwho had induced sustained VT conferred no beneﬁt.195
The prognostic value of inducible ventricular ﬂutter and
VF is still controversial. Limited data on the prognostic
value of inducible ventricular ﬂutter suggest that it may
be an important endpoint.201,202
5.3.2. Electrophysiological testing in patients with
dilated cardiomyopathy
In DCM, EP testing plays a minor role in the evaluation and
management of VT. This is related to low inducibility,
reproducibility of EP study, and the predictive value of
induced VT203,204 (see Section 9.1).
5.3.3. Electrophysiological testing in repolarization
anomalies due to genetic arrhythmia syndromes
5.3.3.1. Long QT syndrome. EP testing has not proved useful
in LQTS103,205 (see Section 11.1.1 for further discussion).
5.3.3.2. Brugada syndrome. The role of EP testing for risk
stratiﬁcation in Brugada syndrome is debated,104,206–208
and it will probably remain undeﬁned until prospective
data are obtained in patients studied with a uniform proto-
col in a large population with adequate follow-up (see
Section 11.1.3 for further discussion).
5.3.3.3. Hypertrophic cardiomyopathy. The value of EP
testing in HCM has been controversial (see Section 9.2 for
further discussion).
5.3.3.4. Arrhythmogenic right ventricular cardiomyopathy.
The arrhythmic manifestations of ARVC are variable.96 The
prognostic role of EP testing in patients presenting with iso-
lated PVCs or NSVT is not known. The response to EP testing
may be inﬂuenced by the severity of the disease. Progression
of disease has to be considered (see Section 9.3 for further
discussion).
5.3.4. Electrophysiological testing in patients with
outﬂow tract ventricular tachycardia
EP testing for the evaluation of outﬂow tract VT is basically
similar to that for other VT entities. It is motivated by
the need to establish precise diagnosis to guide curative
catheter ablation209,210 (see Section 12.1 for further
discussion).
5.3.5. Electrophysiological testing in patients with
syncope
Recommendations
Class I
EP testing is recommended in patients with syncope of
unknown cause with impaired LV function or structural
heart disease. (Level of Evidence: B)
Class IIa
EP testing can be useful in patients with syncope when
bradyarrhythmias or tachyarrhythmias are suspected
and in whom noninvasive diagnostic studies are not con-
clusive. (Level of Evidence: B)
Syncope is a transient symptom that may be caused
by an underlying rhythm disorder with or without an
associated cardiac disease. EP testing is used to document
or exclude the arrhythmic cause of syncope.120,211 It is
most useful in patients with CHD and LV dysfunction.
EP testing is usually not the ﬁrst evaluation step but
rather is complementary to a full syncope work-up. Lack
of correlation between symptoms and a documented
arrhythmia elicited during EP testing may lead to over-
interpretation or underinterpretation of the predictive
value of the results. Transient drug effects that can
provoke syncope may remain undetected. Other causes
such as a neurological etiology need to be considered in
some patients.
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5.3.5.1. Electrophysiological testing when bradyarrhythmia
is suspected. Syncope can be due to bradyarrhythmias from
sinus node dysfunction or AV block. Antiarrhythmic drugs,
beta-blocking agents, cardiac glycosides, and calcium
channel blockers can induce symptomatic bradycardia. EP
testing can be used to document or provoke bradyarrhyth-
mias or AV block when other investigations have failed to
provide conclusive information. The diagnostic yield varies
greatly with the selected patient populations.212 EP
testing is more useful in the presence of structural heart
disease.213 The diagnostic yield in the absence of structural
heart disease or abnormal ECG is low. False-positive results
of EP testing can be present in up to 24% of the patients. In
syncopal patients with chronic BBB and reduced EF (less
than 45%), EP-induced VT is present in up to 42%.184,214,215
In patients with syncope and BBB, false-negative EP
studies are common.216,217 EP testing in patients with
sporadic bradycardia and syncope has limited sensitivity,
even when adding electropharmacological stress such as
intravenous procainamide or atropine.218 EP testing can
provoke nonspeciﬁc tachyarrhythmic responses in patients
with preserved LV function who do not have structural
heart disease.219
5.3.5.2. Electrophysiological testing when supraventricular
tachyarrhythmia is suspected. The role of EP testing is to
document the type of tachyarrhythmia and to guide manage-
ment of patients. In a mixed population, the diagnostic yield
of EP testing was 5%.220 In supraventricular tachyarrhyth-
mias, syncope is rarely the only symptom and palpitations
are usually present as well. Vasodepressive reaction in a
few patients with induced SVT, mainly AV node reentry,221
may be the cause of syncope. Syncope did not correlate
with the rate or cycle length of preexcited R-R intervals in
WPW syndrome during AF.221
5.3.5.3. Electrophysiological testing when ventricular
tachycardia is suspected. Syncope in patients with structural
heart disease and, in particular, signiﬁcant LV dysfunction is
ominous. NSVT on Holter monitoring, syncope, and struc-
tural heart disease are highly sensitive for predicting the
presence of inducible VT.184 Syncope associated with heart
disease and reduced EF has high recurrence and death
rates,222,223 even when EP testing results are negative. EP
testing is useful in patients with LV dysfunction due to
prior MI (EF less than 40%) but not sensitive in patients
with nonischemic cardiomyopathy.184 Induction of poly-
morphic VT or VF, especially with aggressive stimulation
techniques, is not speciﬁc. In CHD, the diagnostic yield
may reach 50%.222 In HCM, EP testing is not diagnostic in
the majority of patients.224 Induction of nonspeciﬁc VTs in
23% of patients with slightly reduced EF has been
observed.225
6. Therapies for ventricular arrhythmias
6.1. General management
The selection of appropriate therapy for the management
of ventricular arrhythmias (PVCs, NSVT, sustained mono-
morphic and polymorphic VT, and ventricular ﬂutter/VF)
necessitates an understanding of the etiology and mechan-
ism of the arrhythmia, an appreciation of the associated
medical conditions that may contribute to and/or
exacerbate the arrhythmia, the risk posed by the arrhy-
thmia, and risk-to-beneﬁt aspects of the selected
therapy.31,99,226–235 Management of the manifest arrhythmia
may involve discontinuation of offending proarrhythmic
drugs, speciﬁc antiarrhythmic therapy with drugs, implanta-
ble devices, ablation, and surgery.
6.2. Drug therapy
With the exception of beta blockers, the currently available
antiarrhythmic drugs have not been shown in randomized
clinical trials to be effective in the primary management
of patients with life-threatening ventricular arrhythmias or
in the prevention of SCD. As a general rule, antiarrhythmic
agents may be effective as adjunctive therapy in the man-
agement of arrhythmia-prone patients under special circum-
stances. Because of potential adverse side effects of the
available antiarrhythmic drugs, these agents must be used
with caution. This section provides general comments
about drug and interventional therapy for life-threatening
arrhythmias. The recommendations and level of evidence
for speciﬁc therapy of ventricular arrhythmias that occur
in various cardiac disease states are provided in other sec-
tions of these guidelines, with the exception of recommen-
dations on ablation, which are located in Section 6.6.
Many marketed cardiac and noncardiac drugs prolong ven-
tricular repolarization and have the potential to precipitate
life-threatening ventricular tachyarrhythmias202,236–239 (see
Section 13.6). Some patients are more susceptible than
others to the QT-prolonging effects of these drugs even at
an ordinary dosage, possibly due to a genetic propensity or
female gender. More commonly, the proarrhythmic effect
of the agent is related to elevated drug blood levels as a
result of excessive dosage, renal disease, or drug inter-
actions. Once it is appreciated that a patient’s ventricular
arrhythmia may be due to QT prolongation from one or
more prescribed medications, the possible offending thera-
pies should be discontinued and appropriate follow-up moni-
toring of ventricular repolarization and cardiac rhythm
should be carried out.
6.3. Antiarrhythmic drugs
6.3.1. Value of antiarrhythmic drugs
Uses of antiarrhythmic drugs in the acute setting are
described in Section 7.
The available antiarrhythmic drugs can be classiﬁed by
the Vaughan Williams 4-level schema (type I: fast sodium
channel blockers, type II: beta blockers, type III: repolariza-
tion potassium current blockers, type IV: calcium channel
antagonists)240 or by the more mechanistic and clinically rel-
evant Sicilian Gambit.241 The Vaughan Williams schema is
somewhat outdated because antiarrhythmic drugs have
complex actions that do not easily ﬁt into 1 of the 4 speci-
ﬁed classes of drug effects. This classiﬁcation is of limited
usefulness when choosing an antiarrhythmic drug to
manage a speciﬁc arrhythmia. The Sicilian Gambit, intro-
duced in 1991, was an attempt to provide a classiﬁcation
of antiarrhythmic drugs based on their mechanism of
action and on arrhythmogenic mechanisms.
6.3.1.1. Beta blockers. These drugs are effective in suppres-
sing ventricular ectopic beats and arrhythmias as well as in
reducing SCD in a spectrum of cardiac disorders in patients
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with and without HF. Beta blockers are safe and effective
antiarrhythmic agents that can be considered the mainstay
of antiarrhythmic drug therapy.242,243 The mechanism of anti-
arrhythmic efﬁcacy of this class of drugs involves competitive
adrenergic-receptor blockade of sympathetically mediated
triggering mechanisms, slowing of the sinus rate, and possibly
inhibition of excess calcium release by the ryanodine
receptor.244
6.3.1.2. Amiodarone and sotalol. Amiodarone has a spec-
trum of actions that includes block of potassium repolariza-
tion currents that can inhibit or terminate ventricular
arrhythmias by increasing the wavelength for reentry. The
overall long-term survival beneﬁt from amiodarone is con-
troversial, with most studies showing no clear advantage
over placebo. A few studies and one meta-analysis of
several large studies have shown reduction in SCD using
amiodarone for LV dysfunction due to prior MI and
nonischemic DCM,245–247 but the SCD-HeFT trial showed no
survival beneﬁt from amiodarone compared with placebo.
7a,248. Chronic administration of amiodarone is associated
with complex drug interactions and a host of adverse side
effects involving the lung, liver, thyroid, and skin. As a
general rule, the longer the therapy and the higher dose
of amiodarone, the greater is the likelihood that adverse
side effects will require discontinuance of the drug.
Sotalol, like amiodarone, is effective in suppressing
ventricular arrhythmias, but it has greater proarrhythmic
effects and has not been shown to provide a clear increase
in survival; worsening ventricular arrhythmias occur in 2%
to 4% of treated patients.249
6.3.1.3. Efﬁcacy of antiarrhythmic drugs. Overall, the
available antiarrhythmic drugs other than beta blockers
should not be used as primary therapy in the management
of ventricular arrhythmias and the prevention of SCD. The
efﬁcacy of non-beta-blocker antiarrhythmic drugs is equiv-
ocal at best, and each drug has signiﬁcant potential for
adverse events including proarrhythmia.
6.3.2. Special considerations where antiarrhythmic
drugs may be indicated
Amiodarone therapy may be considered in special situ-
ations;109 secondary subset analyses indicate possible survi-
val beneﬁt when amiodarone is combined with beta
blockers.250,251 However, the SCD-HeFT study showed no
beneﬁt in patients with NYHA functional class II HF and poten-
tial harm in patients with NYHA functional class III HF and EF
equal to or less than 35%.8 Azimilide was shown to decrease
the risk of appropriate and inappropriate shocks in patients
with ICDs.252 Both sotalol and amiodarone have also been
shown to reduce the frequency of ICD shock therapy.253,254
6.3.2.1. Patients with ventricular tachyarrhythmias who do
notmeet criteria for an implantable cardioverter-deﬁbrillator.
Beta blockers are the ﬁrst-line therapy, but if this therapy at full
therapeutic dose is not effective, then amiodarone or sotalol
can be tried with monitoring for adverse effects during
administration.
6.3.2.2. Patients with implantable cardioverter-
deﬁbrillators who have recurrent ventricular tachycardia/
ventricular ﬁbrillation with frequent appropriate implanta-
ble cardioverter-deﬁbrillator ﬁring. This scenario, in its
extreme, has been called deﬁbrillator (tachycardia) storm,
and it requires the addition of antiarrhythmic drugs and/or
catheter ablation for control of the recurrent VT and
associated ICD shocks. Sotalol is effective in suppressing
atrial and ventricular arrhythmias;253 the combination of
beta blockers and amiodarone is an alternative approach.
Because many such patients have low EF and poor renal
function, amiodarone and beta blockers rather than sotalol
can be the ﬁrst-line therapy for deﬁbrillator storm. Sotalol
should be avoided in patients with severely depressed LV
function or signiﬁcant HF. Animal studies255,256 and a case
report showed the beneﬁts of neural modulation via spinal
cord approaches.257 Intravenous amiodarone has been
useful.
6.3.2.3. Patients with implantable cardioverter-
deﬁbrillators who have paroxysmal or chronic atrial ﬁbrilla-
tion with rapid rates and inappropriate implantable
cardioverter-deﬁbrillator ﬁring. Control of the rapid ventri-
cular response to atrial tachyarrhythmias is essential, and
combination therapy with a beta blocker and/or a calcium
channel blocker is useful. Amiodarone has been used off-
label for rate control if other therapies are contraindicated,
not tolerated, or ineffective. Ablation of the AV node may be
required when pharmacological therapy is not effective.
6.4. Nonantiarrhythmic drugs
Use of nonantiarrhythmic drugs in the acute setting is
further discussed in Section 7.
6.4.1. Electrolytes
Administration of potassium and magnesium, either as intra-
venously in the acute setting or orally for chronic augmenta-
tion in the blood levels of these electrolytes, can favorably
inﬂuence the EP substrate involved in ventricular arrhyth-
mias. These drugs are especially useful in the presence of
hypokalemia and hypomagnesemia and should be considered
as adjunctive therapies in the absence of low-level electro-
lytes. Adverse remodeling occurs in the ventricle following
MI or in association with nonischemic cardiomyopathy;
these structural changes with secondary ion channel altera-
tions can exacerbate the potential for ventricular arrhyth-
mias. Several drugs, such as ACE inhibitors, angiotensin II
receptor antagonists, and aldosterone blockade with spiro-
nolactone or eplerenone, improve the myocardial substrate
through reverse remodeling, and these therapies have been
associated with a reduction in SCD as well as non-SCD.110,258
It is important to remember that electrolyte disturbances
are common in patients with HF, particularly those using
high doses of loop diuretics.
6.4.2. Antithrombins/antiplatelets
In a retrospective analysis of more than 6700 patients parti-
cipating in the Studies Of Left Ventricular Dysfunction
(SOLVD) prevention and treatment trials, antithrombin
therapy was associated with reduction in SCD.259
Antiplatelet therapy that included aspirin and anticoagulant
therapy contributed to this reduction in SCD, possibly as a
result of reducing the frequency of coronary thrombotic
occlusions in this high-risk group of patients.
6.4.3. n-3 Fatty acids and lipids
Increasing experimental and clinical evidence suggests that
n-3 fatty acids are antiarrhythmic260 and may prevent SCD in
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humans.261 However, data are conﬂicting. In a randomized
trial in patients with a recent episode of sustained ventricu-
lar arrhythmia and an ICD, ﬁsh oil supplementation did not
reduce the risk of VT/VF and perhaps was proarrhythmic
in some patients.262 However, a second similar study found
a trend toward prolongation of the ﬁrst VT/VF event or
death from any cause (p ¼ 0.057) and signiﬁcant risk
reduction when all probable VT/VF events were
included.262,263
Findings indicate that statins reduce the occurrence of
life-threatening ventricular arrhythmias in high-risk
cardiac patients with electrical instability.264 Both of these
therapies suggest that the mechanism of the antiarrhythmic
effects may be related to EP stabilization of the bilipid
myocyte membrane involved in maintaining electrolyte
gradients.
6.5. Implantable and external cardioverter devices
6.5.1. Implantable cardioverter-deﬁbrillator
Several prospective multicenter clinical trials have docu-
mented improved survival with ICD therapy in high-risk
patients with LV dysfunction due to prior MI and nonischemic
cardiomyopathy8,192,265–270 (Figure 2). ICD therapy, com-
pared with conventional or traditional antiarrhythmic drug
therapy, has been associated with mortality reductions
from 23% to 55% depending on the risk group participating
in the trial, with the improvement in survival due almost
exclusively to a reduction in SCD. The trials may be sub-
categorized into 2 types: primary prevention (prophylactic)
trials in which the subjects have not experienced a life-
threatening ventricular arrhythmia or a symptomatic equiv-
alent and secondary prevention trials involving subjects who
have had an abortive cardiac arrest, a life-threatening VT, or
unexplained syncope with work-up suggesting a high prob-
ability that a ventricular tachyarrhythmia was the cause of
the syncope.
Important ICD advancements continue to occur in the
transvenous implantation procedure, generator size
reduction, system longevity, arrhythmia detection, and
multiprogrammable features. However, it is important to
remember that device failure, although rare, can occur.
Current ICDs include options for single-chamber, dual-
chamber, and biventricular cardiac resynchronization
pacing for nonshock termination of ventricular arrhythmia
in addition to multilevel shock discharge for VT or VF.
Problems associated with ICD therapy include inappropriate
shock discharge mostly for AF with rapid ventricular
response, deﬁbrillator storm with appropriate recurrent
ICD discharge for recurrent ventricular tachyarrhythmias or
inappropriate discharge for a multiplicity of reasons, infec-
tions related to device implantation, and exacerbation of
HF when a high percentage of the heartbeats are paced
from the RV apex, especially when ventricular function is
Figure 2 Major implantable cardioverter-deﬁbrillator (ICD) trials. Hazard ratios (vertical line) and 95% conﬁdence intervals (horizontal lines)
for death from any cause in the ICD group compared with the non-ICD group. CABG, coronary artery bypass graft surgery; EP, electrophysio-
logical study; LVD, left ventricular dysfunction; LVEF, left ventricular ejection fraction; MI, myocardial infarction; N, number of patients;
NICM, nonischemic cardiomyopathy; NSVT, nonsustained ventricular tachycardia; PVCs, premature ventricular complexes; SAECG,
signal-averaged electrocardiogram. Includes only ICD and amiodarone patients from CASH. For expansion of trial names, see Appendix 3.
768 ACC/AHA/ESC Guidelines
Downloaded from https://academic.oup.com/europace/article-abstract/8/9/746/534498
by guest
on 02 April 2018
already compromised. It is probably advisable to limit RV
pacing to a minimum for any given patient. Possible sol-
utions include the selection of an appropriately low
minimum rate and an appropriately long AV interval.
Avoidance of overly aggressive rate acceleration in rate-
modulated modes and, in some recent pacemaker models,
the use of an automatic pacing mode selecting algorithms
that strongly favor atrial over ventricular pacing.271 The
HF is likely to occur in the setting of advanced LV dysfunc-
tion with the ICD unit programmed to dual-chamber (DDD)
pacing at heart rates that dominate the rhythm, thus contri-
buting to paced ventricular desynchronization.
The ACC/AHA/NASPE 2002 Guidelines Update for
Implantation of Cardiac Pacemakers and Antiarrhythmia
Devices, the ACC/AHA 2004 Guidelines for Management of
Patients With ST-Elevation Myocardial Infarction, the ESC
2001 and 2003 Guidelines on Prevention of SCD, the ESC
Guidelines for the Diagnosis and Treatment of Chronic Heart
Failure, and the ACC/AHA 2005 Guideline Update for the
Diagnosis and Management of Chronic Heart Failure in the
Adult include a large number of recommendations on ICD
therapy which merit attention.1–6 Details and background
references are provided in the full-text guidelines, which are
on the ACC, AHA, HRS (formerly known as NASPE), and ESC
Websites. The ﬁndings from the SCD-HeFT trial provide
additional evidence that the ICD is effective in high-risk
cardiac patients with ischemic and nonischemic cardiomyopa-
thy.8 Differences in the recommendations in these guidelines
from those previously published reﬂect primarily data from
new studies. Detailed discussion on the considerations for
therapy recommendations is found in the Introduction.
However, there are inconsistencies among guidelines regard-
ing the EF cutoff used in the recommendations.
6.5.2. Automated external deﬁbrillator
The automated external deﬁbrillator (AED) saves lives when
external deﬁbrillation can be rendered within minutes of
onset of VF. The AED represents an efﬁcient method of deli-
vering deﬁbrillation to persons experiencing out-of-hospital
cardiac arrest, and its use by both traditional and nontradi-
tional ﬁrst responders appears to be safe and effec-
tive.272,273 Appropriate device location to reduce time
delay after onset of cardiac arrest is critical. Federal,
state, and community efforts have been effective in
placing AEDs in schools, sporting events, high-density resi-
dential sites, and airports as well as on airplanes and in
police and ﬁre department vehicles.274–277 Approximately
80% of cardiac arrests occur in the home, and placement
of AEDs in the home appears to be reasonable and appropri-
ate for patients at high risk for life-threatening arrhythmias.
Federal regulatory authorities in the United States have
approved the AED for home use in families with high-risk
inherited arrhythmias such as the LQTS and HCM. The FDA
has now approved over-the-counter sales of AEDs.
6.5.3. Wearable automatic deﬁbrillator
The wearable automatic deﬁbrillator is a vestlike device
worn under the clothing that continuously monitors heart
rhythm and automatically delivers an electric shock when
VF is detected. This device is worn continuously on a
24-h-a-day basis, except when the wearer is bathing or
showering. The wearable automatic deﬁbrillator has been
approved in the United States by the FDA for cardiac
patients with a transient high risk for VF such as those await-
ing cardiac transplantation, those at very high risk after a
recent MI or an invasive cardiac procedure, or those requir-
ing temporary removal of an infected implanted deﬁbrillator
for antibiotic therapy.
6.6. Ablation
Recommendations
Class I
(1) Ablation is indicated in patients who are otherwise at
low risk for SCD and have sustained predominantly
monomorphic VT that is drug resistant, who are drug
intolerant, or who do not wish long-term drug therapy.
(Level of Evidence: C)
(2) Ablation is indicated in patients with bundle-branch
reentrant VT. (Level of Evidence: C)
(3) Ablation is indicated as adjunctive therapy in patients
with an ICD who are receiving multiple shocks as a
result of sustained VT that is not manageable by repro-
gramming or changing drug therapy or who do not wish
long-term drug therapy (206,278). (Level of Evidence: C)
(4) Ablation is indicated in patients with WPW syndrome
resuscitated from sudden cardiac arrest due to AF and
rapid conduction over the accessory pathway causing
VF (279). (Level of Evidence: B)
Class IIa
(1) Ablation can be useful therapy in patients who are
otherwise at low risk for SCD and have symptomatic non-
sustained monomorphic VT that is drug resistant, who
are drug intolerant or who do not wish long-term drug
therapy. (Level of Evidence: C)
(2) Ablation can be useful therapy in patients who are
otherwise at low risk for SCD and have frequent sympto-
matic predominantly monomorphic PVCs that are drug
resistant or who are drug intolerant or who do not
wish long-term drug therapy. (Level of Evidence: C)
(3) Ablation can be useful in symptomatic patients with
WPW syndrome who have accessory pathways with
refractory periods less than 240 ms in duration (279).
(Level of Evidence: B)
Class IIb
(1) Ablation of Purkinje ﬁber potentials may be considered
in patients with ventricular arrhythmia storm consist-
ently provoked by PVCs of similar morphology (280).
(Level of Evidence: C)
(2) Ablation of asymptomatic PVCs may be considered when
the PVCs are very frequent to avoid or treat
tachycardia-induced cardiomyopathy (281). (Level of
Evidence: C)
Class III
Ablation of asymptomatic relatively infrequent PVCs is
not indicated. (Level of Evidence: C)
6.6.1. Catheter ablation—background
The speciﬁc application of radiofrequency (RF) ablation to
VT has evolved as the technology has developed. RF ablation
can be applied in the treatment of VT in patients with LV
dysfunction due to prior MI, cardiomyopathy, bundle-branch
reentry, and various forms of idiopathic VT.282–294
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6.6.2. No apparent structural heart disease
Speciﬁc mapping and ablation techniques that are used
differ depending on the type of VT. While patients with no
overt structural heart disease account for a small percen-
tage of patients with VT, they are of particular interest for
ablation therapy as this technique may be curative.295,296
These typically present as a single VT arising from the RV
with an LBBB inferior axis morphology or from the LV with
a right bundle-branch block (RBBB) morphology and, in
general, are associated with a good prognosis.289,297–300
6.6.3. Bundle-branch reentrant VT
Bundle-branch reentrant VT is often associated with cardio-
myopathy.279 RF catheter ablation of the bundle branches is
curative of the arrhythmia but not of the underlying struc-
tural abnormality.301 Because of the severity of underlying
heart disease and the high prevalence of conduction
abnormalities, adjunct device therapy should be strongly
considered in these patients.301
6.6.4. Structural heart disease
VT is a common complication of structural heart disease and
carries signiﬁcant risk for mortality in CHD patients with low
EF. In those with extensive structural abnormalities,
especially those with prior MI, multiple morphologies of VT
are often present. As a result, ablation of a single VT mor-
phology can provide palliation but not eliminate the need
for device or antiarrhythmic therapy. In these patients, VT
can originate in, or involve, extensive areas of the myocar-
dium and standard RF delivery carries a relatively low
success rate.302–304 Given the inhomogeneous scarring
present in ischemic VT, mapping techniques have evolved
that take into account the complex nature of the circuits,
including bystander regions of abnormal conduction. The
newer 3-dimensional mapping systems permit anatomical
reconstructions and correlation of EP characteristics with
anatomy.190,305–308 These systems have led to an approach
whereby circuits can be mapped during sinus rhythm and
can facilitate ablation in the ischemic patient who often
does not tolerate VTwell.303,309–312 Use of these techniques
may result in better long-term success rates.313
6.6.5. Additional ablation tools
Depending on the arrhythmic substrate, VT circuits can be
close to the endocardium or exist deeper within the myocar-
dium. The focal lesion of traditional RF delivery systems may
not create lesions deep enough to penetrate intramyocar-
dial circuits. As a result, saline-irrigated cooled-tip cath-
eters have been developed and used in VT ablation.
Cooling the tip of the catheter permits deeper tissue
heating. Preliminary results are promising, but further
data are needed.314 Another novel technique involves trans-
thoracic pericardial access for mapping and ablation. This
technique was developed to address VTs that are extremely
deep within the myocardium or actually epicardial. It
involves inserting a sheath into the pericardial space and
performing mapping from the epicardium.206,315,316 Few
centers have taken on this approach. This technique must
be performed with surgical support available if needed,
and caution must be taken to avoid the epicardial coronary
arteries.317,318 Another novel technique, not used recently,
is transcoronary chemical ablation of incessant VT and
VF.319,320 A more recent technique involves spinal cord
modulation to suppress ventricular arrhythmias.255–257
Additional studies have suggested that catheter ablation
of VF in structurally normal hearts may be feasible by
targeting dominant triggers from the distal Purkinje
system. These techniques are still considered highly
experimental.280,317,318,321
6.7. Surgery and revascularization procedures
Surgical therapy for the management of ventricular arrhyth-
mias may involve ablation or surgical resection of an
arrhythmogenic focus, cardiac sympathectomy, or aneurysm
resection. Surgical or percutaneous coronary revasculariza-
tion with improved coronary blood ﬂow and reduction in
myocardial ischemia has favorable antiarrhythmic effects.
(See the ACC/AHA 2004 Guideline Update for Coronary
Artery Bypass Graft Surgery.322)
6.7.1. Antiarrhythmic surgery
In patients with recurrent VT refractory to drugs, implanted
deﬁbrillators, and RF catheter ablation, direct surgical abla-
tion or resection of the arrhythmogenic focus is an approach
that continues to be used in experienced centers. Surgery
requires accurate preoperative and intraoperative mapping
to determine the site or sites of the tachycardia. Some
centers use a scar-based approach to resecting arrhythmo-
genic sites. The short- and long-term success rates of
map-guided surgical therapy for recurrent-refractory VT
are based mostly on the older literature, and few reports
are available to evaluate risk-to-beneﬁt considerations in
the current era in patients refractory to catheter ablation
and implanted deﬁbrillators.323
Left cervicothoracic sympathetic ganglionectomy was
introduced in 1971 for the treatment of adrenergically trig-
gered life-threatening ventricular arrhythmias associated
with the LQTS.324 This procedure, performed through a
limited supraclavicular approach, involves resection of the
lower half of the left stellate ganglion and removal of at
least the second and third thoracic sympathetic ganglia on
the left side.325 This surgical therapy is associated with
reduction in the frequency of arrhythmogenic syncope in
this syndrome and may be useful as adjunctive therapy in
high-risk LQTS patients who have recurrent syncope and/
or aborted cardiac arrest despite combined ICD and beta-
blocker therapy or in LQTS patients who cannot tolerate
beta blockers.326
Large myocardial aneurysms secondary to MI are associ-
ated with hemodynamic compromise and are frequently
accompanied by major ventricular arrhythmias. In selected
patients, aneurysm resection can improve cardiac function
and, along with map-guided EP mapping and resection of
arrhythmogenic ventricular myocardium, may reduce or
eliminate the accompanying ventricular arrhythmias.327
6.7.2. Revascularization for arrhythmia management
In patients with ventricular arrhythmias, assessment for the
presence of obstructive coronary disease and active ische-
mia is essential. Coronary revascularization involving
either percutaneous balloon/stent angioplasty or bypass
surgery is effective anti-ischemic therapy. A review of cor-
onary revascularization studies reveals improved survival
and reduction in SCD during long-term follow-up.328,329 If
obstructive CHD is complicated by ventricular arrhythmias,
770 ACC/AHA/ESC Guidelines
Downloaded from https://academic.oup.com/europace/article-abstract/8/9/746/534498
by guest
on 02 April 2018
especially in patients with left main and proximal left
anterior descending coronary artery disease, there is a
reasonable likelihood that revascularization will reduce
the frequency and complexity of the arrhythmias and, in
some patients, will eliminate such arrhythmias. No con-
trolled trials have evaluated the effects of myocardial revas-
cularization on VT or VF. However, observational studies
suggest that:
. Sustained monomorphic VT in patients with prior MI is
unlikely to be affected by revascularization.330
. Myocardial revascularization is unlikely to prevent recur-
rent cardiac arrest in patients with markedly abnormal
LV function, even if the original arrhythmia appeared to
result from transient ischemia.331
Further discussion can be found in Section 8.7.
Because ventricular arrhythmias are not always reduced
by revascularization332,333 and may in fact be exacerbated
by unrecognized procedure-related MI, careful postproce-
dure monitoring for arrhythmia suppression is indicated.
Suppression of ischemia-mediated ventricular arrhythmias
and improvement in survival associated with coronary revas-
cularization may have contributed to the lack of ICD efﬁcacy
in the Coronary Artery Bypass Graft (CABG) Patch Trial.265 In
patients undergoing revascularization surgery following
aborted cardiac arrest unrelated to an AMI, it is reasonable
to implant a deﬁbrillator after revascularization surgery in
view of the assumed high-risk state. However, it is reason-
able not to implant an ICD if there was direct, clear evi-
dence of myocardial ischemia immediately preceding the
onset of VF and there was no evidence for prior MI (see
also Sections 8.1 and 8.3).
7. Acute management of speciﬁc arrhythmias
7.1. Management of cardiac arrest
Cardiac arrest is characterized by an abrupt loss of
effective blood ﬂow, sufﬁcient to cause immediate loss of
consciousness, leading immediately to death if untreated.
The most common electrical mechanisms for cardiac arrest
are VF and pulseless VT (see Section 3), but substantial
numbers of cardiac arrests begin as severe bradyarrhyth-
mias, asystole, or pulseless electrical activity. Survival
probabilities are better for victims presenting with VT/VF
than for those with bradyarrhythmic or asystolic mechan-
isms. A rapid response time is the major determinant of
survival.
Recommendations
Class I
(1) After establishing the presence of deﬁnite, suspected,
or impending cardiac arrest, the ﬁrst priority should be
activation of a response team capable of identifying
the speciﬁc mechanism and carrying out prompt inter-
vention. (Level of Evidence: B)
(2) Cardiopulmonary resuscitation (CPR) should be
implemented immediately after contacting a response
team. (Level of Evidence: A)
(3) In an out-of-hospital setting, if an AED is available, it
should be applied immediately and shock therapy admi-
nistered according to the algorithms contained in the
documents on CPR 334,335 developed by the AHA in
association with the International Liaison Committee
on Resuscitation (ILCOR) and/or the European
Resuscitation Council (ERC). (Level of Evidence: C)
(4) For victims with ventricular tachyarrhythmic mechan-
isms of cardiac arrest, when recurrences occur after a
maximally deﬁbrillating shock (generally 360 J for mono-
phasic deﬁbrillators), intravenous amiodarone should be
the preferred antiarrhythmic drug for attempting a
stable rhythm after further deﬁbrillations. (Level of
Evidence: B)
(5) For recurrent ventricular tachyarrhythmias or nonta-
chyarrhythmic mechanisms of cardiac arrest, it is
recommended to follow the algorithms contained in
the documents on CPR334,335 developed by the AHA in
association with ILCOR and/or the ERC. (Level of
Evidence: C)
(6) Reversible causes and factors contributing to cardiac
arrest should be managed during advanced life
support, including management of hypoxia, electrolyte
disturbances, mechanical factors, and volume
depletion. (Level of Evidence: C)
Class IIa
For response times greater than or equal to 5 min, a
brief (less than 90 to 180 s) period of CPR is reasonable
prior to attempting deﬁbrillation. (Level of Evidence: B)
Class IIb
A single precordial thump may be considered by health
care professional providers when responding to a wit-
nessed cardiac arrest. (Level of Evidence: C)
A number of strategies for responding to unexpected
cardiac arrest have resulted in improved survival probabil-
ities for cardiac arrest victims.336 Nonetheless, the absolute
number and proportion of survivors remain low,337 except in
unique circumstances where there is an extraordinarily
rapid response time to victims in VF or VT. A decrease in
cardiac arrest survival occurs at about 7% to 10% per
minute if no CPR is initiated and at 3% to 4% per minute
with bystander CPR. In contrast, when immediate deﬁbrilla-
tion in highly protected environments is available, such as in
monitored intensive care units and EP laboratories, where
response times of less than 30 s are usually achievable,
survival from VF is greater than 90%, the exception being
patients with pathophysiological conditions that favor the
persistence of this potentially fatal arrhythmia.
Survivability falls off rapidly after the initial 2 min from
the onset of cardiac arrest, so that by 4 to 5 min survivability
may be 25% or less, and by 10 min it is less than 10%. Studies
have suggested that while immediate deﬁbrillation is the
preferred method within 1 to 2 min after the onset of
cardiac arrest, a brief period of CPR to provide oxygenation
of the victim improves survivability when time to deﬁbrilla-
tion is longer.338–340
Advanced life support activities, other than those directly
related to electrical methods for control of tachyarrhyth-
mias, led to the generation of complex protocols to guide
responders. These documents, published by the AHA334
and the ERC,335 cover the broad expanse of clinical circum-
stances and considerations of mechanisms. They provide
management information, stratiﬁed for special circum-
stances such as age of the victim (from infancy to the
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elderly), pathophysiological status, and survival probabil-
ities. The response algorithms to these various circumstances
are complex and the reader is referred to the source docu-
ments for details.334,335 As management guidelines, these
documents are classiﬁed as Level of Evidence: C, but they
are derived from a combination of varied studies and
opinion that range from Level of Evidence: A, B, or C. Abbre-
viated versions for tachyarrhythmias and nontachyarrhyth-
mic mechanisms are shown in Figure 3.
Consistent with the AHA/ERC 2005 guidelines, the amount
of energy and timing of shocks for treatment of VT in
patients with pulses are determined by the patient’s con-
dition and the morphological characteristics of the VT.
Unstable monomorphic VT is treated with synchronized car-
dioversion, while unstable polymorphic VT is treated as VF
using high-energy unsynchronized shocks at deﬁbrillation
doses. Monomorphic VT in patients with pulses generally
responds well to monophasic waveform cardioversion syn-
chronized shocks at initial energies of 100 J or higher.
More data are needed before speciﬁc comparative rec-
ommendations can be made for energy doses of biphasic
devices. Synchronized cardioversion is generally not rec-
ommended to treat unstable polymorphic VT because of
unreliable synchronization to a QRS complex and high-
energy unsynchronized shock at deﬁbrillation doses is rec-
ommended. If there is any doubt whether monomorphic or
polymorphic VT is present in the unstable patient, shock
delivery should not be delayed for detailed rhythm analysis.
The initial recommended shock energy with a biphasic deﬁ-
brillator is 150 to 200 J (use recommended device-speciﬁc
dose; in absence of a recommended dose, 200 J should be
used) and an equal or higher dose is recommended for
second and subsequent shocks. If a monophasic deﬁbrillator
is used, 360 J is used for all shocks. Lower energy levels
should not be used for unsynchronized shocks because they
can provoke VF when given in an unsynchronized mode.
After shock delivery, the health care provider should be pre-
pared to provide immediate CPR and follow the advanced
cardiac life support (ACLS) pulseless arrest algorithm if pul-
seless arrest develops (Figure 3).
The general goals of advanced life support are to establish
hemodynamically effective cardiac rhythm, to optimize
ventilation, and to maintain and support the restored
circulation. While 3 successive (‘stacked’) shocks were rec-
ommended in the previous version of the ECC guidelines,341
a 1-shock strategy is now recommended to minimize
time between chest compressions and shock delivery and
resumption of chest compressions6,334,335 (see Figure 3).
Epinephrine, 1 mg intravenously, is administered and
followed by repeated deﬁbrillation attempts at 360 J.
Epinephrine may be repeated at 3- to 5-min intervals with
deﬁbrillator shocks in-between doses,334 but high-dose
epinephrine does not appear to provide added beneﬁt.342
Intravenous amiodarone has replaced intravenous lido-
caine and other antiarrhythmic medications for the manage-
ment of resistant ventricular tachyarrhythmias causing
repeated episodes of ventricular tachyarrhythmias.343
Amiodarone need not be given routinely to the individual
who responds to initial deﬁbrillation with a stable rhythm.
If there is sufﬁcient clinical evidence that a cardiac arrest
was heralded by the onset of an ACS, intravenous lidocaine
may still be used for resistant arrhythmias. Beta blockers
may be preferred for ACSs if not already being taken. For
pharmacological hemodynamic support during cardiac
arrest management, vasopressin has been suggested as an
alternative to epinephrine,344 but the evidence for superior-
ity is not clearly established. Responses to nontachyarrhyth-
mic cardiac arrest largely focus on control of metabolic and
transient factors that may precipitate bradyarrhythmic
events or pulseless electrical activity (Figure 3).
Simultaneously, the rescuer should focus on ventilation to
correct the chemistry of the blood, efforts that render the
heart more likely to reestablish a stable rhythm (i.e.,
improved oxygenation, reversal of acidosis, and improve-
ment of the underlying EP condition). Although adequate
oxygenation of the blood is crucial in the immediate man-
agement of the metabolic acidosis of cardiac arrest,
additional correction can be achieved if necessary by intra-
venous administration of sodium bicarbonate. This is rec-
ommended for circumstances of known or suspected
preexisting bicarbonate-responsive causes of acidosis,
certain drug overdoses, and prolonged resuscitation
runs.334 The more general role for bicarbonate during
cardiac arrest has been questioned; but in any circum-
stance, much less sodium bicarbonate than was previously
recommended is adequate for treatment of acidosis in this
setting. Excessive quantities can be deleterious.
In patients in whom acute hyperkalemia is the triggering
event for resistant VF, or who have hypocalcemia or are
toxic from Ca2þ entry-blocking drugs, 10% calcium gluco-
nate, 5 mL to 20 mL infused at a rate of 2 to 4 mL/min,
may be helpful.334 Calcium should not be used routinely
during resuscitation, even though ionized Ca2þ levels may
be low during resuscitation from cardiac arrest. Some resist-
ant forms of polymorphic VT or torsades de pointes, rapid
monomorphic VT or ventricular ﬂutter (rate greater than
or equal to 260/min), or resistant VF may respond to intra-
venous beta-blocker therapy (propranolol, 1-mg intravenous
boluses to a total dose of up to 15 to 20 mg; metoprolol,
5 mg intravenously, up to 20 mg) or intravenous MgSO4
(1 to 2 g intravenously given over 1 to 2 min).
The approach to the patient with bradyarrhythmic or asys-
tolic arrest or pulseless electrical activity differs from the
approach to patients with tachyarrhythmic events of VT/
VF.334 Once this form of cardiac arrest is recognized,
efforts should focus ﬁrst on establishing control of the cardi-
orespiratory status (i.e., continue CPR, intubate, and estab-
lish intravenous access), then on reconﬁrming the rhythm (in
2 leads if possible), and ﬁnally on taking actions that favor
the emergence of a stable spontaneous rhythm or attempt
to pace the heart. Possible reversible causes, particularly
for bradyarrhythmia and asystole, should be considered
and excluded (or treated) promptly. These include pulmon-
ary embolus, AMI, hypovolemia, hypoxia, cardiac tampo-
nade, tension pneumothorax, preexisting acidosis, drug
overdose, hypothermia, and hyperkalemia. Cardiac pacing
for bradyarrhythmic or asystolic arrests is usually ineffec-
tive,345 but reversal of hypoxemia, acidosis, or electrolyte
imbalances may help in some instances. Epinephrine
(1.0 mg intravenously every 3 to 5 min) is commonly used
in an attempt to elicit spontaneous electrical activity or
increase the rate of a bradycardia. For asystole and pulse-
less electrical activity, atropine as 1.0 mg intravenously/
intraosseously, repeated every 3 to 5 min up to a total of 3
doses or 0.03 to 0.04 mg/kg is recommended. For bradycar-
dia, atropine 0.5 mg intravenously/intraosseously, repeated
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every 3 to 5 min up to a total dose of 0.04 mg/kg, is rec-
ommended. Sodium bicarbonate, 1 mEq/kg, may be tried
for known or suspected preexisting hyperkalemia or
bicarbonate-responsive acidosis.
7.1.1. Arrhythmias associated with acute coronary
syndromes
For recommendations, see Section 7.1 in these guidelines
and refer to the current guidelines on ACLS.334,335
Figure 3 Advanced cardiac life support pulseless arrest algorithm. Reprinted with permission from Circulation 2005;112:IV57–66. AED,
automated external deﬁbrillator; BLS, basic life support; CPR, cardiopulmonary resuscitation; IV/IO, intravenous/intraosseous; PEA, pulseless
electrical activity; VF, ventricular ﬁbrillation; VT, ventricular tachycardia.
ACC/AHA/ESC Guidelines 773
Downloaded from https://academic.oup.com/europace/article-abstract/8/9/746/534498
by guest
on 02 April 2018
ACS can give rise to a life-threatening arrhythmia that
may be the ﬁrst manifestation of ischemia. The mechanisms
of these arrhythmias may be different from those seen in
chronic stable ischemic heart disease. Arrhythmias during
acute ischemia may be related to re-entry, abnormal auto-
maticity, or triggered activity and are affected by a
variety of endogenous factors such as potassium levels and
autonomic states. These arrhythmias may cause many of
the reported sudden deaths in patients with ischemic syn-
dromes. VF or sustained VT has been reported in up to 20%
of AMIs.346,347
The incidence of VF (occurring within 48 h of the onset of
the ACS) may be decreasing owing to aggressive revascular-
ization limiting infarct size and to increased beta-
blocker use.348 VF occurring early in the ACS has been
associated with an increase in hospital mortality but not
with increased long-term mortality.346 Prophylaxis with
lidocaine may reduce the incidence of VF in the ACS but
appears to be associated with increased mortality likely
owing to bradycardia and this treatment has largely been
abandoned.349 Use of prophylactic beta blockers in the
setting of AMI reduces the incidence of VF, and this practice
is encouraged when appropriate. Similarly, correction of
hypomagnesemia and hypokalemia is encouraged because
of the potential contribution of electrolyte disturbances
to VF.350
More recent data showed the beneﬁt of the eplerenone,
an aldosterone antagonist, in reducing the risk of SCD
mortality by 37% (p ¼ 0.051) 30 d after randomization in
patients after AMI (when initiated at a mean of 7.3 d after
AMI) in addition to conventional therapy in patients with
an LVEF less than or equal to 40% and signs of HF.351
7.1.1.1. Pulseless ventricular tachycardia/ventricular
ﬁbrillation. In the event of pulseless VT or VF in ACS, the
standard ACLS protocol is initiated including unsynchronized
electric shock following basic assessment of airway and
initiation of CPR. Energy delivery consists of 1 or more
monophasic shocks at 360 J or biphasic shocks at a dose
range demonstrated by manufacturer to be effective. If
not available, a dose of 200 J is recommended for the ﬁrst
shock and an equal or higher dose for subsequent shocks.
The optimal dose for biphasic shocks has not been deter-
mined, and no waveform or escalating energy levels
recommendations can be made for biphasic deﬁbrillators
at this time. If return to normal rhythm is not accomplished
by deﬁbrillation, the ACLS protocol for pulseless VT or VF is
followed. This includes epinephrine (1 mg intravenously
every 3 to 5 min) or vasopressin (40 U intravenously once
only; 1 dose of vasopressin intravenously/intraosseously
may replace either the ﬁrst or second dose of epinephrine),
and amiodarone (300-mg or 5-mg/kg intravenous push, with
a possible repeat 150-mg intravenous push once only), or as
a second tier, lidocaine (1.0 to 1.5 mg/kg with repeat dose
of 0.5 to 0.75 mg intravenously/intraosseously up to a
total dose of 3 mg/kg). Additional second-tier therapy
includes intravenous magnesium (1 to 2 g) or procainamide
(30 mg/min up to 17 mg/kg). The latter is considered accep-
table but is no longer recommended.334
Following resuscitated VF, prophylactic drug infusion,
typically with amiodarone plus a beta blocker, may be con-
tinued. The antiarrhythmic should be withdrawn as appro-
priate to assess the presence of ongoing arrhythmias.
7.1.1.2. Idioventricular rhythm and nonsustained
ventricular tachycardia. Neither idioventricular rhythm nor
NSVT (lasting less than 30 s) occurring in the setting of ACS
serves as a reliably predictive marker for early VF. In fact,
accelerated idioventricular rhythm has been associated
with reperfusion.352 As such, these arrhythmias do not
warrant prophylactic antiarrhythmic therapy. However,
sustained and/or hemodynamically compromising VT in
ACS requires suppressive therapy.2 Management of pulseless
VT follows the ACLS guidelines for pulseless VT/VF.
7.1.1.3. Unstable sustained ventricular tachycardia. For
recurrent VT, if VT is monomorphic and the EF is normal,
either procainamide, sotalol, amiodarone, or lidocaine can
be used. Alternately, if the EF is low, amiodarone or lido-
caine is recommended (amiodarone 150 mg intravenously
over 10 min or lidocaine 0.5 to 0.75 mg/kg intravenous
push). If the VT is polymorphic and the baseline QT is
normal, correction of underlying ischemia and electrolyte
abnormalities is emphasized. This may be followed by, or
performed concurrently with, administration of a beta
blocker or lidocaine or amiodarone or procainamide or
sotalol. If the VT is polymorphic and the EF is low, treatment
with amiodarone 150 mg intravenously over 10 min or lido-
caine 0.5 to 0.75 mg/kg intravenous push is recommended.
In polymorphic VT, if the baseline QT is prolonged, correc-
tion of electrolytes is emphasized and other treatments
may include magnesium, overdrive pacing, isoproterenol,
phenytoin, or lidocaine.
7.1.1.4. Bradycardia and heart block. Bradycardia and heart
block can occur as a result of MI. The likelihood of developing
complete heart block complicating MI increases in the pre-
sence of underlying conduction system disease. Occurrence
of heart block as a result of MI has been associated with an
increase in hospital mortality but does not predict long-term
mortality in those surviving to discharge.353 The increase in
hospital mortality is related to the extensive amount of myo-
cardial damage required to develop heart block rather than
to the heart block itself. While pacing has not been shown
to increase long-term survival post-MI, it is still indicated in
symptomatic bradyarrhythmias associated with AMI, and
pacing guidelines are as stated in the 2004 ACC/AHA
Guidelines for the Management of Patients With ST-Elevation
Myocardial Infarction2 and the ACC/AHA/NASPE 2002
Guidelines Update for Implantation of Cardiac Pacemakers
and Antiarrhythmia Devices.1
7.1.2. Ventricular tachycardia associated with low
troponin myocardial infarction
Recommendations
Class I
Patients presenting with sustained VT in whom low-
level elevations in cardiac biomarkers of myocyte
injury/necrosis are documented should be treated
similarly to patients who have sustained VT and
in whom no biomarker rise is documented. (Level of
Evidence: C)
Prolonged episodes of sustained monomorphic VT may be
associated with rise in cardiac biomarkers due to myocardial
metabolic demands exceeding supply, especially in patients
with CHD. Such patients usually have a history of MI. It is
reasonable to evaluate for myocardial ischemia in patients
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exhibiting these ﬁndings. When sustained VT is accompanied
by a modest elevation in cardiac enzymes, it should not be
assumed that a new MI occurred to cause the tachycardia.
In the absence of other data, it should be assumed that
patients experiencing sustained monomorphic VT are at
risk for recurrent VT and should be treated for this arrhyth-
mia in the same manner as are patients without biomarker
release accompanying VT.
7.2. Sustained monomorphic ventricular
tachycardia
Recommendations
Class I
(1) Wide-QRS tachycardia should be presumed to be VT if
the diagnosis is unclear. (Level of Evidence: C)
(2) Direct current cardioversion with appropriate sedation is
recommended at any point in the treatment cascade in
patients with suspected sustained monomorphic VTwith
hemodynamic compromise. (Level of Evidence: C)
Class IIa
(1) Intravenous procainamide (or ajmaline in some
European countries) is reasonable for initial treatment
of patients with stable sustained monomorphic VT.
(Level of Evidence: B)
(2) Intravenous amiodarone is reasonable in patients with
sustained monomorphic VT that is hemodynamically
unstable, refractory to conversion with countershock,
or recurrent despite procainamide or other agents.
(Level of Evidence: C)
(3) Transvenous catheter pace termination can be useful to
treat patients with sustained monomorphic VT that is
refractory to cardioversion or is frequently recurrent
despite antiarrhythmic medication. (Level of Evidence: C)
Class IIb
Intravenous lidocaine might be reasonable for the initial
treatment of patients with stable sustained monomor-
phic VT speciﬁcally associated with acute myocardial
ischemia or infarction. (Level of Evidence: C)
Class III
Calcium channel blockers such as verapamil and diltia-
zem should not be used in patients to terminate
wide-QRS-complex tachycardia of unknown origin,
especially in patients with a history of myocardial
dysfunction. (Level of Evidence: C)
Electrical cardioversion is always indicated for hemodyna-
mically unstable tachycardia. Managing the patient present-
ing with well-tolerated, wide-QRS tachycardia is facilitated
by differentiating between VT, SVT with aberrant conduc-
tion, and preexcited tachycardia.354 This can usually be
accomplished by consideration of the history and examin-
ation of the 12-lead ECG during tachycardia. The hemody-
namic status of the patient is not helpful in distinguishing
these mechanisms. A working diagnosis of VT is appropriate
when the diagnosis is unclear because VT is more prevalent,
especially in the patient with structural heart disease, and
therapy directed inappropriately at SVT may have adverse
consequences.355,356 Monomorphic VT is usually related to
a structural abnormality such as MI scarring but is
mechanistically heterogeneous. Some ‘idiopathic’ VTs
respond well and terminate with intravenous verapamil or
adenosine, and those expert in arrhythmia management
may choose to treat the acute episode with these
agents.357,358 If these unique VT entities cannot be recog-
nized with conﬁdence, it is prudent to assume that one is
dealing with VT related to structural heart disease.
Correction of potentially causative or aggravating conditions
such as hypokalemia and ischemia is an early priority. Timely
termination is usually desirable even if VT is well tolerated.
This can be achieved with cardioversion, antiarrhythmic medi-
cations, or pacing techniques. DC cardioversion even at early
stage or as ‘ﬁrst line’ is reasonable.359,360 Advantages include
the absence of proarrhythmia and high efﬁcacy in a timely
fashion. Cardioversion does not prevent recurrence, and a
major disadvantage is the need for deep sedation or anesthesia.
Caution needs to be exercised if the patient also has concurrent
AF (e.g., double tachycardia). If such is the case, the ACC/AHA/
ESC 2006 Guidelines for the Management of Patients With Atrial
Fibrillation need to be followed when feasible.361
Initial treatment often includes the administration of intra-
venous antiarrhythmic medication. The advantages include
the lack of necessity for anesthesia and ready availability. Dis-
advantages include delay in termination, failure to terminate
in some patients, and adverse effects including hypotension
and proarrhythmia. Although drugs such as ﬂecainide, propafe-
none, and sotalol are available in intravenous preparations in
some countries, only intravenous procainamide, lidocaine,
and amiodarone are widely available. Intravenous ajmaline is
used frequently in some European countries. Intravenous amio-
darone loading has proved useful in unstable and recurrent VT,
especially when VT is recurrent after countershock and other
antiarrhythmicmeasures.362–366 It is also reasonable in patients
in whom oral amiodarone is required after the intravenous
phase. It has proved superior to lidocaine in improving survival
to hospital in patients with cardiac arrest and shock-resistant
VF.343 Although intravenous amiodarone has an early effect on
AV nodal conduction and early antiadrenergic effects, the
effects on myocardial conduction and refractoriness are
gradual in onset and maximum effect may not be seen for
weeks or months.367–369 Intravenous amiodarone is not ideal
for early conversion of stablemonomorphic VT. Intravenous pro-
cainamide is more appropriate when early slowing of the VT
rate and termination of monomorphic VT are desired.370,371
Close monitoring of blood pressure and cardiovascular
status is recommended in the presence of congestive HF or
severe LV dysfunction as intravenous procainamide can
cause transient hypotension.372 Lidocaine is effective when
VT is thought to be related to myocardial ischemia.373,374
7.3. Repetitive monomorphic ventricular
tachycardia
Recommendations
Class IIa
Intravenous amiodarone, beta blockers, and intravenous
procainamide (or sotalol or ajmaline in Europe) can be
useful for treating repetitive monomorphic VT in the
context of coronary disease375 and idiopathic VT.
(Level of Evidence: C)
Repetitive monomorphic VT is characterized electro-
cardiographically by frequent ventricular ectopy and salvos
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of NSVTwith intervening sinus rhythm. It typically occurs at
rest and is self-terminating although the arrhythmia can be
present for much of the time.376 Although this terminology
can refer to mechanistically diverse arrhythmias, it gener-
ally refers to idiopathic VT, most frequently the RV outﬂow
type.377–379 This tachycardia can cause palpitations or,
rarely, tachycardia-related cardiomyopathy.380 Many
patients have no symptoms related to the arrhythmia. In
some patients, tachycardia is provoked by exercise.297 An
electrocardiographically similar presentation is less fre-
quent in patients with structural heart disease and, speciﬁ-
cally, previous MI.375
Treatment is rarely required on an urgent basis, and
chronic management should be based on symptoms and fre-
quency of tachycardia. Tachycardia-induced cardiomyopathy
is unusual in this entity, and there is usually no need to treat
asymptomatic patients with preserved LV function. For
patients with mild symptoms, reassurance may be the only
treatment necessary. Repetitive monomorphic VT is usually
an issue of chronic management (pharmacologically or by
ablation), and the strategy will vary considerably dependent
on the clinical situation and etiology of the VT. Beta-blocking
agents or calcium channel blockers are often effective.
Ablation is generally successful in problematic RV outﬂow
tachycardia.381 When acute therapy is required, anti-
arrhythmic drug selection will depend on etiology and under-
lying ventricular function, with drug selection considerations
similar to that described for sustained monomorphic VT (see
Section 7.2 for further discussion).
7.4. Polymorphic VT
Recommendations
Class I
(1) Direct current cardioversion with appropriate sedation
as necessary is recommended for patients with sustained
polymorphic VT with hemodynamic compromise and is
reasonable at any point in the treatment cascade.
(Level of Evidence: B)
(2) Intravenous beta blockers are useful for patients with
recurrent polymorphic VT, especially if ischemia is
suspected or cannot be excluded. (Level of Evidence: B)
(3) Intravenous loading with amiodarone is useful for
patients with recurrent polymorphic VT in the absence
of abnormal repolarization related to congenital or
acquired LQTS. (Level of Evidence: C)
(4) Urgent angiography with a view to revascularization
should be considered for patients with polymorphic VT
when myocardial ischemia cannot be excluded. (Level
of Evidence: C)
Class IIb
Intravenous lidocaine may be reasonable for treatment
of polymorphic VT speciﬁcally associated with acute
myocardial ischemia or infarction. (Level of Evidence: C)
Polymorphic VT may be sustained, generally requiring
urgent electrical cardioversion, or self-terminating with
interludes of sinus rhythm. It is useful to distinguish poly-
morphic tachycardia associated with normal repolarization
from that associated with abnormal repolarization (e.g.,
prolonged QT interval). Both VTs may be similar with gross
irregularity of rate and QRS morphology with phasic increase
and decrease of QRS amplitude often described as ‘torsades
de pointes’ (see Section 7.5. for further discussion).
Polymorphic VTwith a normal QT interval during interven-
ing sinus rhythm is most frequently seen in the context of
acute ischemia or MI, but the QRS pattern during VT is not
speciﬁc and may be seen with other cardiac disease states
such as cardiomyopathy or HF or in the absence of overt
cardiac disease (e.g., idiopathic polymorphic VT, catechol-
aminergic VT).15,382,383 Intravenous beta blockers are
useful in this context and improve mortality in the setting
of recurrent polymorphic VT with AMI.384 Intravenous
loading with amiodarone is also useful.341,385,386 Urgent cor-
onary angiography should be considered in the setting or
recurrent polymorphic VT when ischemia is suspected or
cannot be excluded.387 In all instances, treatment of HF
and associated correctable conditions and repletion of pot-
assium and magnesium should be done concurrently with
the above.
7.5. Torsades de pointes
Recommendations
Class I
(1) Withdrawal of any offending drugs and correction of
electrolyte abnormalities are recommended in patients
presenting with torsades de pointes. (Level of
Evidence: A)
(2) Acute and long-term pacing is recommended for
patients presenting with torsades de pointes due to
heart block and symptomatic bradycardia. (Level of
Evidence: A)
Class IIa
(1) Management with intravenous magnesium sulfate is
reasonable for patients who present with LQTS and
few episodes of torsades de pointes. Magnesium is not
likely to be effective in patients with a normal QT inter-
val. (Level of Evidence: B)
(2) Acute and long-term pacing is reasonable for patients
who present with recurrent pause-dependent torsades
de pointes. (Level of Evidence: B)
(3) Beta blockade combined with pacing is reasonable acute
therapy for patients who present with torsades de
pointes and sinus bradycardia. (Level of Evidence: C)
(4) Isoproterenol is reasonable as temporary treatment in
acute patients who present with recurrent pause-
dependent torsades de pointes who do not have conge-
nital LQTS. (Level of Evidence: B)
Class IIb
(1) Potassium repletion to 4.5 to 5 mmol/L may be con-
sidered for patients who present with torsades de
pointes. (Level of Evidence: B)
(2) Intravenous lidocaine or oral mexiletine may be con-
sidered in patients who present with LQT3 and torsades
de pointes. (Level of Evidence: C)
Marked QT interval prolongation and the morphologically
distinctive polymorphic VT torsades de pointes occur in 3
common settings: in congenital LQTS, in a drug-associated
form, and in patients with advanced conduction system
disease that has progressed to heart block (see Section
11.1.1 for further discussion). Torsades de pointes
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complicating heart block is managed with temporary pacing
followed by permanent pacing. Other causes, such as severe
electrolyte abnormalities alone or central nervous system
injury, are less common. Presentation with frequently recur-
ring torsades de pointes in the congenital syndrome is
unusual. In this setting, catecholamines should be avoided.
However, other maneuvers useful in the drug-associated
form (magnesium, potassium, pacing) can be used, and
pacing along with beta blockade or lidocaine may be
considered.388
7.6. Incessant ventricular tachycardia
Recommendations
Class I
Revascularization and beta blockade followed by
intravenous antiarrythmic drugs such as procainamide
or amiodarone are recommended for patients with
recurrent or incessant polymorphic VT due to acute
myocardial ischemia. (Level of Evidence: C)
Class IIa
Intravenous amiodarone or procainamide followed by VT
ablation can be effective in the management of patients
with frequently recurring or incessant monomorphic VT.
(Level of Evidence: B)
Class IIb
(1) Intravenous amiodarone and intravenous beta blockers
separately or together may be reasonable in patients
with VT storm. (Level of Evidence: C)
(2) Overdrive pacing or general anesthesia may be con-
sidered for patients with frequently recurring or inces-
sant VT. (Level of Evidence: C)
(3) Spinal cord modulation may be considered for some
patients with frequently recurring or incessant VT.
(Level of Evidence: C)
7.6.1. Clinical features
The syndrome of very frequent episodes of VT requiring car-
dioversion has been termed ‘VT storm’ (see Section 13.5 for
further discussion). Frequent appropriate ICD shocks rep-
resent another variant. While a deﬁnition of greater than
2 episodes in 24 h has been used,389,390 much more frequent
episodes can also occur. Hemodynamically stable VT lasting
hours has been termed ‘incessant’. Management guidelines
for these syndromes rely on anecdotal evidence because
they are rare, there are multiple potential underlying mech-
anisms, and no randomized trials have been conducted.
Severe underlying heart disease is frequently present.
More rarely, VT storm can occur (e.g., in Brugada syndrome,
LQTS, catecholaminergic VT, or in drug overdose) in patients
who have a structurally normal heart. ‘VT storm’ can be
monomorphic or polymorphic. Polymorphic VT storm in a
patient with coronary disease is strongly suggestive of
acute myocardial ischemia; pauses may occur prior to poly-
morphic VT even in the absence of QT prolongation. Pause-
dependent VT with marked QT prolongation should be
managed as torsades de pointes (see Section 7.5), although
acute ischemia can also present in this fashion.391 Frequent
appropriate ICD shocks may represent part of the natural
history of advanced heart disease and may or may not
portend a serious deterioration in underlying prognosis.392
7.6.2. Management
The ﬁrst step in VT storm is to identify and correct inciting
factors, commonly including drugs, electrolyte disturb-
ances, and acute myocardial ischemia (see Sections 13.5
and 13.6 for further discussion). With frequent ICD shocks,
electrograms and programming should be reviewed to deter-
mine if device reprogramming is desirable.393,394
Intravenous beta blockade should be considered for a
polymorphic VT storm as it is the single most effective
therapy. Revascularization procedures may be urgently
needed. It is of utmost importance to try and understand
the substrate of incessant arrhythmias, because if a diagno-
sis is established, a targeted treatment may be possible. For
example, in Brugada syndrome, quinidine or isoproterenol
may terminate incessant arrhythmias.139,395 In acute ische-
mia, intravenous amiodarone seems more effective than
other antiarrhythmic drugs.396 Intra-aortic balloon counter-
pulsation can be tried. Pacing may be useful especially if the
tachycardia onset is pause dependent. Other potential
therapies include ablation397 or general anesthesia.398
Autonomic alternative via spinal cord modulation may be
tried.
Monomorphic VT storm can be managed by intravenous
antiarrhythmics (e.g., amiodarone, procainamide) to slow
the rate but may aggravate the tachycardia by promoting
frequent or incessant episodes. Ablation can also be effec-
tive. ICD therapy may eventually be needed.
8. Ventricular arrhythmia and sudden
cardiac death related to speciﬁc pathology
8.1. Left ventricular dysfunction due to prior
myocardial infarction
Recommendations
Class I
(1) Aggressive attempts should be made to treat HF that
may be present in some patients with LV dysfunction
due to prior MI and ventricular tachyarrhythmias.
(Level of Evidence: C)
(2) Aggressive attempts should be made to treat myocardial
ischemia that may be present in some patients with ven-
tricular tachyarrhythmias. (Level of Evidence: C)
(3) Coronary revascularization is indicated to reduce the
risk of SCD in patients with VF when direct, clear evi-
dence of acute myocardial ischemia is documented to
immediately precede the onset of VF. (Level of
Evidence: B)
(4) If coronary revascularization cannot be carried out and
there is evidence of prior MI and signiﬁcant LV dysfunc-
tion, the primary therapy of patients resuscitated from
VF should be the ICD in patients who are receiving
chronic optimal medical therapy and those who have
reasonable expectation of survival with a good func-
tional status for more than 1 y. (Level of Evidence: A)
(5) ICD therapy is recommended for primary prevention to
reduce total mortality by a reduction in SCD in patients
with LV dysfunction due to prior MI who are at least 40 d
post-MI, have an LVEF less than or equal to 30% to 40%,
are NYHA functional class II or III, are receiving chronic
optimal medical therapy, and who have reasonable expec-
tation of survival with a good functional status for more
than 1 y. (Level of Evidence: A) (See Section 1.2.)
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(6) The ICD is effective therapy to reduce mortality by a
reduction in SCD in patients with LV dysfunction due to
prior MI who present with hemodynamically unstable
sustained VT, are receiving chronic optimal medical
therapy, and who have reasonable expectation of
survival with a good functional status for more than
1 y. (Level of Evidence: A)
Class IIa
(1) Implantation of an ICD is reasonable in patients with LV
dysfunction due to prior MI who are at least 40 d post-MI,
have an LVEF of less than or equal to 30% to 35%, are
NYHA functional class I on chronic optimal medical
therapy, and who have reasonable expectation of survi-
val with a good functional status for more than
1 y. (Level of Evidence: B) (See Section 1.2.)
(2) Amiodarone, often in combination with beta blockers,
can be useful for patients with LV dysfunction due to
prior MI and symptoms due to VT unresponsive to
beta-adrenergic-blocking agents. (Level of Evidence: B)
(3) Sotalol is reasonable therapy to reduce symptoms result-
ing from VT for patients with LV dysfunction due to prior
MI unresponsive to beta-blocking agents. (Level of
Evidence: C)
(4) Adjunctive therapies to the ICD, including catheter abla-
tion or surgical resection, and pharmacological therapy
with agents such as amiodarone or sotalol are reason-
able to improve symptoms due to frequent episodes of
sustained VT or VF in patients with LV dysfunction due
to prior MI. (Level of Evidence: C)
(5) Amiodarone is reasonable therapy to reduce symptoms
due to recurrent hemodynamically stable VT for patients
with LV dysfunction due to prior MI who cannot or refuse
to have an ICD implanted. (Level of Evidence: C)
(6) Implantation is reasonable for treatment of recurrent
ventricular tachycardia in patients post-MI with normal
or near normal ventricular function who are receiving
chronic optimal medical therapy and who have reason-
able expectation of survival with a good functional
status for more than 1 y. (Level of Evidence: C)
Class IIb
(1) Curative catheter ablation or amiodarone may be con-
sidered in lieu of ICD therapy to improve symptoms in
patients with LV dysfunction due to prior MI and recur-
rent hemodynamically stable VT whose LVEF is greater
than 40%. (Level of Evidence: B)
(2) Amiodarone may be reasonable therapy for patients
with LV dysfunction due to prior MI with an ICD indi-
cation, as deﬁned above, in patients who cannot or
refuse to have an ICD implanted. (Level of Evidence: C)
Class III
(1) Prophylactic antiarrhythmic drug therapy is not indi-
cated to reduce mortality in patients with asymptomatic
nonsustained ventricular arrhythmias. (Level of
Evidence: B)
(2) Class IC antiarrhythmic drugs in patients with a past
history of MI should not be used. (Level of Evidence: A)
Considerations taken by the Writing Committee in formu-
lating recommendations for this section are discussed in
detail in the Introduction.
Patients with chronic CHD manifest 3 general types of ven-
tricular tachyarrhythmias: NSVT (deﬁned as 3 or more
repetitive ventricular beats in a row lasting up to 30 s in dur-
ation at a rate greater than 100 beats per minute), sustained
VT, and cardiac arrest resulting from VT or VF. The cardiac
mortality of patients with all types of ventricular tachyar-
rhythmias is high. The high mortality results from nonsud-
den, as well as sudden, cardiac death. These arrhythmias
may result from myocardial ischemia, or effects of HF, in
addition to primary electrical abnormalities. Aggressive
attempts should be made to treat HF and to search for
and correct myocardial ischemia in patients with ventricular
tachyarrhythmias. In some cases, appropriate treatment of
ischemia and HF will abolish the arrhythmia (primarily poly-
morphic VT, VF, and NSVT). Even if speciﬁc antiarrhythmic
therapy is necessary, the frequency and tolerance of
arrhythmias may be improved with appropriate therapy for
ischemia and HF.
8.1.1. Nonsustained ventricular tachycardia
Most NSVT in patients with chronic CHD is brief and does not
cause symptoms. There is no evidence that suppression of
asymptomatic NSVT prolongs life. Thus, there is no indi-
cation to treat NSVT, except in the relatively uncommon cir-
cumstances where frequent (incessant) or very rapid
episodes compromise hemodynamic stability. In such cases,
NSVT may be treated with pharmacological antiarrhythmic
therapy, catheter ablation, or surgical resection. When
NSVT causes symptoms that require therapy, attempts
should be made to characterize the NSVT electrocardiogra-
phically, in order to determine whether the NSVT is
related to prior MI or arises by a distinct mechanism that
may be especially amenable to RF catheter ablation, such
as tachycardia arising from the ventricular outﬂow tract.
Initial pharmacological therapy of symptomatic NSVT
should consist of beta adrenergic-blocking agents, if they
are not already being used at an adequate dosage.
Pharmacological therapy in patients with symptomatic
NSVT unresponsive to beta adrenergic–blocking agents
would most appropriately be amiodarone or sotalol.
8.1.2. Sustained ventricular tachycardia
The treatment of sustained VT in patients with chronic
CHD should be tempered by the clinical manifestations
produced by the tachycardia, as well as the frequency of
episodes. Patients who present with sustained monomorphic
VT that does not precipitate cardiac arrest or cause severe
hemodynamic instability are usually, but not always, at rela-
tively low risk for SCD (2% yearly).399,400 Twelve-lead ECGs
should be obtained during episodes of sustained VT, and
the morphology assessed to be certain that it is consistent
with location of prior MI(s). The possibility should be con-
sidered that patients with prior MI may develop sustained
VT unrelated to the infarction, due to other mechanisms
such as bundle-branch reentry or idiopathic VT. If episodes
are relatively infrequent, the ICD alone may be the most
appropriate initial therapy, because antitachycardia pacing
therapies or high-energy shock therapy may reduce the
need for hospitalization and pharmacological antiarrhythmic
therapy. Suitable adjunctive therapies include catheter
ablation, surgical resection, and pharmacological therapy
with agents such as sotalol or amiodarone.
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Curative therapy of sustained VT using either surgical
resection or catheter ablation should be considered in
patients with frequent recurrences of VT unresponsive to
antiarrhythmic drugs. Patients in whom the tachycardia is
hemodynamically stable may be considered for curative
catheter ablation. The major limitation to catheter ablation
is the fact that most patients with sustained VT resulting
from prior MI have multiple tachycardias, and it is often dif-
ﬁcult to ablate all tachycardias completely, using currently
available RF ablation technology. Some patients have only
1 or 2 tachycardia circuits and may be cured of their
arrhythmia by catheter ablation. However, they may
develop new VT in the future using a different circuit.
Although all morphologically distinct tachycardias may not
be cured by catheter ablation, the tachycardia substrate
may be modiﬁed sufﬁciently to decrease the frequency of
arrhythmia episodes. Ablation of the tachycardia using
surgery to resect or modify the arrhythmia substrate is an
alternative therapy that may be suitable for patients in
whom catheter ablation is unsuccessful.
Following correction of ischemia, patients who present
with sustained VT that causes severe hemodynamic compro-
mise may beneﬁt from EP testing. Such testing will occasion-
ally reveal curable arrhythmias such as bundle-branch
reentry. In addition, the results of testing often help in
appropriate programming of implantable deﬁbrillators. The
ICD is the primary therapy for such patients.
8.1.3. Treatment of ventricular ﬁbrillation and cardiac
arrest survivors
Patients experiencing cardiac arrest due to VF that does not
occur within the ﬁrst 24 to 48 h of AMI may be at risk for
recurrent cardiac arrest. As is the case for patients present-
ing with sustained VT, such patients should be evaluated and
treated for myocardial ischemia. If there is direct, clear evi-
dence of acute myocardial ischemia immediately preceding
the onset of VF and there is no evidence of prior MI, the
primary therapy should be complete coronary revasculariza-
tion. If coronary revascularization cannot be carried out and
there is evidence of prior MI and signiﬁcant LV dysfunction,
the primary therapy of patients resuscitated from VF
should be the ICD.
8.1.4. Primary prevention of sudden cardiac death
All patients with CHD are at risk for SCD, and most SCD
occurs in patients without severe LV dysfunction. However,
in the absence of symptomatic arrhythmias, patients
without prior MI and even those with prior MI whose LVEF
is greater than 40% are at such low risk that prophylactic
therapy is not indicated. Nevertheless, the risk for SCD in
patients who do not have symptomatic arrhythmias,
without prior MI, and those with prior MI whose LVEF is
greater than 40% is sufﬁciently low that prophylactic
therapy is not indicated at the present time. In addition,
when EF is greater than 40%, the risk of SCD is low enough
that prophylactic antiarrhythmic therapy is not indicated
for patients with asymptomatic arrhythmias, such as NSVT.
Subpopulations of patients remain at risk for SCD for years
after the AMI. Multiple factors in addition to reduced EF
have been demonstrated to contribute to the risk for SCD
after MI; these include the presence of NSVT, symptomatic
HF, and sustained monomorphic VT inducible by EP testing.
The only speciﬁc antiarrhythmic treatment proved
consistently effective to reduce risk of both SCD and total
mortality is the ICD. ICD therapy is indicated to reduce the
risk of SCD in 2 patient groups: patients whose LVEF is less
than or equal to 40% as a result of prior MI and who have
spontaneous NSVT and sustained monomorphic VT inducible
by EP testing,267 and patients whose LVEF is less than 30%
as a result of an MI that occurred greater than or equal to
40 d earlier when HF (NYHA functional class II or III symp-
toms) is present.248,268 The rationale for recommending
that an ICD be used in patients with symptomatic HF, in
addition to reduced EF, is that the evidence for ICD beneﬁt
is strongest in such patients; most patients enrolled in
primary prevention trials had symptomatic HF.8 Evaluation
of the need for an ICD and implantation should be deferred
until at least 3 mo after revascularization procedures (i.e.,
surgical bypass grafting or percutaneous angioplasty) to
allow adequate time for recovery of ventricular function fol-
lowing revascularization. In general, ICD implantation
should be deferred until at least 40 d after AMI in patients
meeting the above criteria in order to allow time for recov-
ery of ventricular function and because ICD therapy has not
been demonstrated to improve survival when implanted
within 40 d after MI.152,248,401–403 In cases of doubt, an EP
study could be considered.
Amiodarone therapy has been thought to be relatively safe
in patients with prior MI who had symptomatic arrhythmias
that required suppression. Although randomized trials have
not demonstrated a survival beneﬁt when empiric amiodar-
one is initiated early after MI, mortality was not increased,
and arrhythmic deaths showed a consistent trend toward
reduction with amiodarone treatment.404,405 However, in
patients with advanced HF (NYHA functional class III), amio-
darone may not be beneﬁcial.8,248 Thus, amiodarone should
not be used routinely after MI but is probably the safest
agent to use to suppress symptomatic arrhythmias.
8.1.5. Use of implantable cardioverter-deﬁbrillator
for ventricular tachycardia in patients with normal or
near normal left ventricular ejection fraction
Recurrent sustained VT is usually treated by management of
the underlying condition, prevention of predisposing and
trigger factors, and the use of antiarrhythmic therapies
such as class I and class III antiarrhythmic drugs. The use
of antiarrhythmic agents may predispose the patient to
proarrhythmic complications that might pose signiﬁcant
threats to life. Increasingly, the ICD is being used effectively
to treat these arrhythmias, which in themselves may not be
life-threatening, in order to avoid the relative ineffective-
ness and adverse complications of pharmaceutical therapy.
In the case of monomorphic VT, antitachycardia pacing is
often applied successfully without provocation of untoward
symptoms. On the other hand, polymorphic VT or VF,
whether or not related to antiarrhythmic drug treatment,
may require shock therapy. In any event, the strategy of
using devices to manage such arrhythmias appears to be
clinically successful, although expensive.
8.2. Valvular heart disease
Recommendations
Class I
Patients with valvular heart disease and ventricular
arrhythmias should be evaluated and treated following
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current recommendations for each disorder. (Level of
Evidence: C)
Class IIb
The effectiveness of mitral valve repair or replacement
to reduce the risk of SCD in patients with mitral
valve prolapse, severe mitral regurgitation, and serious
ventricular arrhythmias is not well established. (Level
of Evidence: C)
Ventricular arrhythmias occurring in patients with valvular
heart disease can be caused by any of the mechanisms respon-
sible for ventricular arrhythmias in other cardiac diseases.
These patients can have associated CHD, myocardial dysfunc-
tion, severe LVH, adrenergic-dependent rhythm disturbances,
or an inherited molecular abnormality. Valve abnormalities
are not likely to cause ventricular arrhythmias but may
contribute by virtue of their effect on the myocardium.
Although SCD in patients with signiﬁcant valvular lesions is
frequently caused by a serious ventricular arrhythmia, it is
uncertain whether the event is triggered by preexisting ventri-
cular arrhythmias. In general, there is more knowledge on the
risk for SCD in patients with aortic valve disease compared
with other valvular lesions. Although the overall risk is
small, sudden arrhythmic death appears to be more frequent
in aortic stenosis than in other lesions: approximately 0.4% per
year for aortic stenosis, less than 0.2% per year for regurgita-
tion, and less than 0.2% per year formitral valve disease.406,407
Most patients who die suddenly have been symptomatic
from their valvular disease.406 Although recurrent NSVT
may place a patient with severe aortic stenosis at risk for
syncope, the management of such a patient is usually
guided by the severity of the valvular lesion. To date,
there are insufﬁcient data demonstrating reduction in ven-
tricular arrhythmias as a result of valve repair or replace-
ment in most patients with valvular disease. For these
reasons, patients with valvular heart disease and ventricular
arrhythmias should be evaluated and treated following
current recommendations for each disorder.406 The presence
of a ventricular arrhythmia alone does not constitute an
indication for valve repair or replacement. An exception
to this general guideline has been suggested for patients
with myxomatous mitral valve prolapse (MVP) and serious
ventricular arrhythmias, in whom there may be an increased
risk for SCD, particularly in the subgroup that also has a ﬂail
leaﬂet.408,409 For this reason, the frequent occurrence of
ventricular arrhythmias in patients with severe myxomatous
mitral regurgitation has been considered a class IIb indi-
cation for surgery,406 although its effectiveness in reducing
SCD has not been established. The role of QT prolongation
in subgroups of patients with MVP remains unclear.3,410
Patients with mild valvular lesions who have no LV enlarge-
ment, LVH or depressed function should be managed as if
they had no structural heart disease.
8.3. Congenital heart disease
Recommendations
Class I
(1) ICD implantation is indicated in patients with congenital
heart disease who are survivors of cardiac arrest after
evaluation to deﬁne the cause of the event and
exclude any reversible causes. ICD implantation is
indicated in patients who are receiving chronic optimal
medical therapy and who have reasonable expectation
of survival with a good functional status for more than
1 y. (Level of Evidence: B)
(2) Patients with congenital heart disease and spontaneous
sustained VT should undergo invasive hemodynamic
and EP evaluation. Recommended therapy includes
catheter ablation or surgical resection to eliminate VT.
If that is not successful, ICD implantation is rec-
ommended. (Level of Evidence: C)
Class IIa
Invasive hemodynamic and EP evaluation is reasonable
in patients with congenital heart disease and unex-
plained syncope and impaired ventricular function. In
the absence of a deﬁned and reversible cause, ICD
implantation is reasonable in patients who are receiving
chronic optimal medical therapy and who have reason-
able expectation of survival with a good functional
status for more than 1 y. (Level of Evidence: B)
Class IIb
EP testing may be considered for patients with congeni-
tal heart disease and ventricular couplets or NSVT to
determine the risk of a sustained ventricular arrhyth-
mia. (Level of Evidence: C)
Class III
Prophylactic antiarrhythmic therapy is not indicated
for asymptomatic patients with congenital heart
disease and isolated PVCs. (Level of Evidence: C)
Congenital heart disease represents a diverse spectrum of
anatomical and physiological defects with signiﬁcant differ-
ences in respect to natural history, preoperative and post-
operative physiology, and the risk of arrhythmias and late
SCD. Overall, congenital heart defects are the leading
cause of infant mortality (less than 1 y of age) in the indus-
trialized world. However, with advances in cardiovascular
medicine, this mortality rate has been reduced from 105
to 59 deaths per 100 000 live births between 1980 and
1995.411 Nearly all defects can now be repaired or palliated,
with estimates of greater than 1 million worldwide long-
term survivors of surgery for congenital heart disease.412
Although the short- and long-term survival of these patients
is a matter of ongoing study, it is apparent that patients with
certain defects have an increased risk of late sudden and
total cardiac mortality.413 Given the overall low incidence
of late SCD in postoperative congenital heart disease
patients, no prospective randomized clinical trials have
been performed to deﬁne either risk factors for SCD or the
role of primary prevention therapies. Therefore, the level
of evidence for most recommendations is class C.
During infancy and childhood, greater than 75% of deaths
in patients with congenital heart disease are in-hospital
events, most occurring during the perioperative period.414
The remaining deaths occur as out-of-hospital or emergency
department events, often in patients with other congenital
anomalies or sepsis. Therefore, the number of very young
patients with congenital heart disease who are victims of
arrhythmic SCD is quite small.
Beyond 20 y of age, there is a progressive increase in the
incidence of sudden and total cardiac mortality in
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postoperative congenital heart disease patients.413 Hence,
most studies of sudden death in congenital heart disease
have evaluated adolescents and young adults.415 Five conge-
nital heart defects have been associated with the greatest
risks of late SCD: tetralogy of Fallot, D- and L-transposition
of the great arteries, aortic stenosis, and functional single
ventricle.413,416,417
The largest number of late SCD studies in postoperative
patients with congenital heart disease have been for tetral-
ogy of Fallot. A meta-analysis of 39 studies including 4627
patients showed that the combination of ventricular dys-
function and complex ventricular ectopy was the primary
correlate of late SCD.418 Although more than 20 risk
factors for SCD have been proposed,419 volume overload
due to pulmonary insufﬁciency and QRS duration greater
than 160 ms appear to be the additional factors most
likely to be associated with an increased risk of SCD due
to ventricular arrhythmias.420,421 The results of EP testing
for risk stratiﬁcation in these patients have been inconsist-
ent, in part due to variable study protocols and deﬁnitions
of response to such testing.422–424
Postoperative patients with D-transposition of the great
arteries appear to have a differing risks for late SCD, based
on whether they have undergone an atrial (Mustard or
Senning) or arterial switch procedure. A very high incidence
of late atrial arrhythmias has been noted in patients following
atrial switch procedures, complicated by profound sinus
bradycardia.425,426 The mechanism of SCD appears to be
atrial ﬂutter with 1:1 AV conduction, followed by myocardial
ischemia resulting in polymorphic VT or VF.427 In both D- and
L-transposition, progressive ventricular dysfunction may also
result in ventricular arrhythmias as the cause of SCD.416,428
In general, postoperative patients with unexplained
syncope should undergo both hemodynamic and EP evalu-
ation. A high incidence of inducible sustained ventricular
arrhythmias has been reported in syncopal postoperative
patients who have complex ventricular ectopy.429,430
Furthermore, a positive response to EP testing, independent
of the clinical indication, may identify patients with a high-
risk of late SCD.423 Conversely, isolated ventricular ectopy is
common in older postoperative congenital heart disease
patients. In the absence of ventricular dysfunction or symp-
toms, isolated ventricular ectopy has minimal prognostic
signiﬁcance, and the risks of antiarrhythmic drug treatment
can exceed any potential beneﬁt.431 There remain many
patients with simple or complex ventricular ectopy, with
vague symptoms, or modest impairment of ventricular func-
tion who require individual judgment regarding the need for
evaluation and treatment.432 Also, there are nonarrhythmic
causes of late sudden death in postoperative patients,
including cerebral or pulmonary embolism, endocarditis,
and aneurysm rupture.413,416
Another class of congenital anomalies that may result in
SCD is coronary artery abnormalities. The most common
congenital coronary artery anomaly causing SCD in the
young is anomalous origin of the left coronary artery from
the right sinus of Valsalva. The proposed mechanism of
SCD is that either acute angulation of the coronary ostium
or compression of the left coronary artery as it traverses
the region between the aortic wall and RVOT results in
acute myocardial ischemia and the development of VT or
VF. The risk of SCD appears greatest during the ﬁrst 3
decades of life. Diagnosis may be difﬁcult as only one third
of patients have a prior history or exertional syncope or
angina. Deﬁnitive diagnosis by coronary angiography is an
indication for surgical revascularization. Similar risks for
SCD have also been reported for anomalous origin of the
right coronary artery from the left sinus of Valsalva.433
Anomalous origin of the left coronary artery from the pul-
monary artery generally presents during the ﬁrst month of
life. With the normal decline in pulmonary vascular resist-
ance, myocardial ischemia and dysfunction develop as cor-
onary perfusion is shunted to the pulmonary circulation.
When the diagnosis is established by echocardiography
during infancy, surgical reimplantation of the left coronary
ostium is generally associated with recovery of ventricular
function. However, a small percentage of these patients
may survive an early MI and subsequently develop extensive
right to left coronary artery collateral circulation. These
patients may present years or decades later with angina,
HF, or ventricular arrhythmias.434
8.4. Metabolic and inﬂammatory conditions
Although disorders in this category are important causes of
life-threatening ventricular arrhythmias, the occurrence of
VT/SCD is relatively rare and hence, in most cases, there
are few trial data as to how the arrhythmias should best
be managed. Data relating to the prevention of life-
threatening ventricular arrhythmias are even more sparse.
All recommendations in this section therefore have Level
of Evidence B or C.
Acute emergencies, as a consequence of any underlying
ailment in this section, should be managed conventionally.
8.4.1. Myocarditis, rheumatic disease, and endocarditis
Recommendations
Class I
(1) Temporary pacemaker insertion is indicated in patients
with symptomatic bradycardia and/or heart block
during the acute phase of myocarditis. (Level of
Evidence: C)
(2) Acute aortic regurgitation associated with VT should be
treated surgically unless otherwise contraindicated.
(Level of Evidence: C)
(3) Acute endocarditis complicated by aortic or annular
abscess and AV block should be treated surgically
unless otherwise contraindicated. (Level of Evidence: C)
Class IIa
(1) ICD implantation can be beneﬁcial in patients with life-
threatening ventricular arrhythmias who are not in the
acute phase of myocarditis, as indicated in the ACC/
AHA/NASPE 2002 Guideline Update for Implantation of
Cardiac Pacemakers and Antiarrhythmia Devices,1 who
are receiving chronic optimal medical therapy, and
who have reasonable expectation of survival with a
good functional status for more than 1 y. (Level of
Evidence: C)
(2) Antiarrhythmic therapy can be useful in patients with
symptomatic NSVT or sustained VT during the acute
phase of myocarditis. (Level of Evidence: C)
Class III
ICD implantation is not indicated during the acute phase
of myocarditis. (Level of Evidence: C)
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8.4.1.1. Myocarditis. Myocarditis is an inﬂammatory
process affecting the cardiac myocardium and is most
often related to infection. However, other toxic exposures,
such as exposure to radiation, chemicals, and other physical
agents, can lead to cardiac inﬂammation. The most
common infectious agents leading to myocarditis are
viruses.435,436 Other infective agents causing myocarditis
include bacteria, fungi, protozoa, metazoa, spirochete,
and rickettsia.435,437–453 Immunosuppression does not
appear to reliably inﬂuence prognosis signiﬁcantly and is
not recommended at this time.453
The acute course of myocarditis varies, as does its presen-
tation.454 Presentation ranges from an asymptomatic ﬁnding
detected because of transient ST-T changes noted on an ECG
to a fulminant and life-threatening condition with symptoms
that mimic ischemia. Acute management is largely suppor-
tive but may be quite aggressive depending on the presen-
tation.455 Cardiac arrhythmias associated with acute
myocarditis can range from conduction abnormalities to dif-
ﬁcult to suppress life-threatening ventricular arrhythmias.
Death can occur related to HF and arrhythmias including
heart block.444,445,455–460 Patients with arrhythmias or
syncope may require antiarrhythmic drugs and/or device
therapy.461 Temporary pacemaker insertion is indicated in
patients with acute myocarditis who present with sympto-
matic heart block as it would be in other causes of acute
symptomatic heart block. Pacing is indicated in patients
with symptomatic sinus node dysfunction or AV block as a
sequela of myocarditis as it would be in other causes of
sinus or AV node dysfunction.
Acute myocarditis can lead to chronic cardiomyopathy
through a variety of mechanisms.455 In patients with residual
severe cardiomyopathy and ventricular arrhythmias, deﬁ-
brillators and/or biventricular devices are implanted for
the same indications as recommended in the sections on
HF and cardiomyopathy.
Idiopathic giant cell myocarditis is fairly uncommon but is
of particular note as it typically affects young individuals
and is usually fatal if untreated.462–467 The diagnosis is con-
ﬁrmed by endomyocardial biopsy. Patients may develop
heart block, requiring temporary or permanent pacemakers.
An ICD and antiarrhythmic drugs such as amiodarone may be
needed for VT.462
Lyme carditis is a complication of Lyme disease affecting
between 0.3% and 8% of those infected with Borrelia
burgdorferi.468–471 Patients can develop varying degrees of
AV conduction abnormalities. Junctional rhythm and asysto-
lic pauses can occur. LV dysfunction is generally mild, and
the process is usually self-limiting when treated with anti-
biotics.468 Persistent heart block is rare, but in such cases
permanent pacing may be needed.469,472 VT, usually nonsus-
tained, has been reported infrequently.473–475
Cardiac involvement has been frequently reported in
patients with acquired immunodeﬁciency syndrome (AIDS)
and is also seen in patients with human immunodeﬁciency
virus (HIV) infection without AIDS.476–479 SCD has been
reported with primary myocardial HIV involvement.480,481
QT prolongation and arrhythmias have been attributed to
drug therapy.482–484
Chagas disease is caused by the protozoan Trypanosoma
cruzi; it is transmitted by an insect vector and is common
in Central and South America. Acute myocarditis is rare
but over one third develop late myocardial damage with
progressive HF and have poor survival. Conduction defects
with progression to complete heart block are common. Life-
threatening ventricular arrhythmias are common.
Amiodarone appears to be effective in treating ventricular
tachyarrhythmias, and death occurs as a result of either
refractory HF or arrhythmias.485 Device therapy including
the ICD is frequently used in the late phase.486 In those
with good functional status (e.g., NYHA functional class I
and II), SCD is a rare event when patients are treated with
amiodarone. However, VT recurrence rate is high at 30%
per year. RF ablation from the epicardial surface has been
reported to be useful therapy in this indication. In those
with advanced HF, drug therapy is of little beneﬁt and
arrhythmia recurrence rates approach 100%. Mortality is
high in these patients, on average 40% mortality in 1 y.487
8.4.1.2. Rheumatic disease. Acute rheumatic fever causes a
pancarditis involving the pericardium, myocardium, and
endocardium. Sinus tachycardia and PR prolongation are
common. Bundle-branch block, nonspeciﬁc ST-T wave
changes, and atrial and ventricular premature complexes
may occur. Complete heart block and ventricular arrhyth-
mias are rare.488–490 It has been associated with prolonged
QT interval and torsades de pointes.489
8.4.1.3. Endocarditis. Infective endocarditis can occur as
subacute bacterial endocarditis or acute bacterial endocar-
ditis. Subacute bacterial endocarditis is most often related
to infections with streptococcal species and less commonly
with Staphylococcus aureus, S. epidermidis, and fastidious
Haemophilus sp. Typically, it will develop on abnormal
valves after asymptomatic bacteremias from infected
gums or the genitourinary or gastrointestinal tract. Acute
endocarditis more often is related to infections with S.
aureus, group A hemolytic streptococci, pneumococci, or
gonococci and with less virulent microorganisms. It can
develop on normal valves.491 Untreated endocarditis is
almost always fatal. Prosthetic valve endocarditis comprises
a substantial proportion of all cases of infective endo-
carditis. Although the overall incidence of infective
endocarditis has not changed over the past 3 decades, the
age of presentation has increased. Where right-sided
endocarditis occurs, it is often related to intravenous drug
abuse.
Endocarditis of the aortic and mitral valves has been
associated with rapid death owing to acute valvular disrup-
tion, emboli to the coronary arteries, or abscesses in the
valvular rings or the septum.492,493 While these deaths are
often rapid, they typically are not classiﬁed as sudden
deaths. Uncommonly, endocarditis has been associated
with SCD related to tamponade secondary to
rupture.494,495 The development of cardiac rhythm disturb-
ances portends poorly in infective endocarditis.496 Abscess
formation in the valve annulus can result in ﬁrst- or second-
degree heart block. This occurs more often in aortic than
mitral valve endocarditis.497 More advanced heart block
can occur if the abscess erodes into the septum and disrupts
the conduction system. New-onset heart block in a patient
with endocarditis is highly speciﬁc for abscess.498 Patients
with perivalvular abscess are at higher risk for other compli-
cations such as embolization and death.499
Antimicrobial therapy will be given as appropriate to the
speciﬁc causative organism.500 Surgery is recommended in
those with recurrent emboli or refractory HF or those who
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do not respond to antimicrobial therapy. Most physicians
believe that abscess formation or fungal endocarditis is an
indication for surgery.501,502 The acute hemodynamic com-
promise related to acute aortic regurgitation secondary to
endocarditis can result in VT and is an indication for early
surgery.498,499,503 Drug treatment of arrhythmias does not
differ from generally accepted clinical principles. Surgery
may be indicated in the presence of documented myocardial
involvement or abscess formation.504
8.4.2. Inﬁltrative cardiomyopathies
Recommendations
Class I
In addition to managing the underlying inﬁltrative
cardiomyopathy, life-threatening arrhythmias should
be treated in the same manner that such arrhythmias
are treated in patients with other cardiomyopathies,
including the use of ICD and pacemakers in patients
who are receiving chronic optimal medical therapy and
who have reasonable expectation of survival with a
good functional status for more than 1 y. (Level of
Evidence: C)
The association between the inﬁltrative cardiomyopathies
and VT/SCD is well documented. In all cases, where appro-
priate, treatment of the underlying condition must accom-
pany management of cardiac manifestations.
8.4.2.1. Sarcoidosis. One quarter of patients with sarcoido-
sis have cardiac lesions, but there is a poor correlation
between symptoms and myocardial involvement even in
the most advanced cases, and hence SCD may be the ﬁrst
manifestation.505 In proven cases of cardiac sarcoidosis,
supraventricular and ventricular arrhythmias occur fre-
quently (73%) and bundle-branch block is present in about
two thirds of patients.
Approximately one quarter of these patients develop com-
plete heart block; a similar proportion has congestive
cardiac failure. The ECG and Holter monitor are not sensi-
tive or speciﬁc enough for detecting myocardial involvement
but can be useful for the identiﬁcation of rhythm disturb-
ances once the diagnosis has been conﬁrmed by other
means (e.g., thallium-201 and gallium-67 SPECT or MRI).
Myocardial biopsy, although insensitive, has a high speci-
ﬁcity for the diagnosis of myocardial sarcoidosis.
Corticosteroid therapy may reduce the number of prema-
ture ventricular complexes and episodes of tachycardia,
rendering the arrhythmia easier to treat;506 the danger of
SCD may also be diminished and an improvement may also
be seen in conduction defects. The use of immunosuppres-
sion by no means eliminates the risk of further occurrence
of arrhythmias. The resolution of granulomas may leave a
substrate for arrhythmogenesis. Prospective trial data do
not exist, but spontaneous VT, severe LV dysfunction, and
severe intraventricular conduction disturbance warrant ICD
and/or pacemaker therapy as appropriate.507
8.4.2.2. Amyloidosis. Cardiac involvement in amyloidosis,
irrespective of the subtype or chemotherapeutic interven-
tion, carries a very poor prognosis. In the AL subtype, the
median survival is 6 mo with a 6% 3-y survival rate.508,509
Progressive HF is usually the mode of death, but bradyar-
rhythmia and especially VT may be the terminal event.
Complex ventricular arrhythmias are common, affecting
57% of patients; 29% have couplets and 18% have NSVT.510
Cardiac troponins, especially troponin T;511 the presence
of couplets on Holter recordings;510 LV wall thickness,
especially greater than 12 to 15 mm on 2-dimensional echo-
cardiography;512 the presence of late potentials on
SAECG;513 and prolonged infra-His (HV) conduction time on
EP studies514 may all be independent predictors of mortality.
Elevated cardiac troponins may inﬂuence the ﬁnal decision
as median survival in patients with detectable values is 6
to 8 mo compared with 21 to 22 mo in those with undetect-
able levels.511 QTc is prolonged in patients with cardiac
amyloid, but this does not seem to correlate with life-
threatening arrhythmias.515 The use of permanent pace-
makers and ICD devices may not inﬂuence long-term
outcome but in familial cases may be used as a bridge to
transplantation.516
8.4.2.3. Fabry disease. Fabry disease is an X-linked
recessive lysosomal storage disorder caused by deﬁciency
of lysosomal alpha-galactosidase. Fabry cardiomyopathy
has a prevalence of 3% to 6% in male patients with unex-
plained LVH.517,518 Female carriers with low alpha-1 galacto-
sidase activity may also exhibit cardiac manifestations.519
Although cardiac involvement causes a range of ECG
abnormalities and conduction disturbances with AV block,
ventricular arrhythmias and SCD appear to be very
rare.520–525 Improvements of cardiac hypertrophy and
conduction abnormalities have been obtained with enzyme
replacement therapy.526
8.4.2.4. Hemochromatosis. Up to one third of homozygotes
with hemochromatosis have cardiac involvement. Although
the natural course of untreated cardiac involvement is
progressive HF, ventricular arrhythmias have been
reported;527,528 their incidence and that of SCD are
however, unknown. Early detection and appropriate man-
agement of hemochromatosis are essential for a favorable
outcome as cardiac and liver involvement may be reversible
in the early stages of the disease.529 Arrhythmias are
managed conventionally.
8.4.3. Endocrine disorders and diabetes
Recommendations
Class I
(1) The management of ventricular arrhythmias secondary
to endocrine disorders should address the electrolyte
(potassium, magnesium, and calcium) imbalance and
the treatment of the underlying endocrinopathy.
(Level of Evidence: C)
(2) Persistent life-threatening ventricular arrhythmias that
develop in patients with endocrine disorders should be
treated in the same manner that such arrhythmias are
treated in patients with other diseases, including use of
ICD and pacemaker implantation as required in those
who are receiving chronic optimal medical therapy and
who have reasonable expectation of survival with a good
functional status for more than 1 y. (Level of Evidence: C)
(3) Patients with diabetes with ventricular arrhythmias
should generally be treated in the same manner as
patients without diabetes. (Level of Evidence: A)
8.4.3.1. Introduction. Endocrine disorders can induce VT/
SCD by excess or insufﬁcient hormone activity on myocardial
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receptors (e.g., pheochromocytoma, hypothyroidism).
The endocrinopathy can also cause myocardial changes
(e.g., acromegaly) or electrolyte disturbances produced by
hormone excess (e.g., hyperkalemia in Addison disease
and hypokalemia in Conn syndrome), and certain endocrine
disorders can accelerate the progression of conditions such
as underlying structural heart disease secondary to dyslipi-
demia or hypertension, increasing the risk of serious
arrhythmias.
8.4.3.2. Thyroid disorders. Thyrotoxicosis commonly causes
atrial arrhythmias; cases of VT/SCD are extremely uncom-
mon but may occur with concomitant electrolyte disturb-
ances.530 VT/SCD are more common in hypothyroidism, the
basic underlying mechanism being possibly related to pro-
longation of the QT interval.531,532 Thyroxin replacement
therapy usually corrects this abnormality and prevents any
further arrhythmias, but antiarrhythmic drugs, such as pro-
cainamide, have been used successfully in an emergency.531
8.4.3.3. Pheochromocytoma. Pheochromocytoma may
present with VT/SCD, but there are no data to quantify its
incidence, best mode of management, or response to
treatment. The incidence is likely to be low and possibly
exacerbated by reversible catecholamine-induced HCM/
DCM.533 Not only will conventional antagonism of catechol-
amine excess with alpha receptor blockers followed by beta
blockade help control hypertension and reverse or prevent
any further structural deterioration,534 but there is anecdotal
evidence that it prevents recurrence of ventricular arrhyth-
mia.535 Early deﬁnite surgical treatment of the pheochromo-
cytoma should be a priority, especially in cases with
documented life-threatening arrhythmias. In some patients
with VT associated with pheochromocytoma, a long QT inter-
val has been identiﬁed.536,537
8.4.3.4. Acromegaly. SCD is an established manifestation of
acromegaly, and life-threatening arrhythmias are likely to
be an important cause.538 Up to one half of all acromegalic
patients have complex ventricular arrhythmias on 24-h
Holter recordings, and of these, approximately two thirds
are repetitive.539 There is a strong correlation between
these ventricular arrhythmias and LV mass and duration of
the disease but not hormone levels.539 Appropriate surgical
management of the pituitary tumor is paramount for
improved long-term outcome, as cardiac changes are revers-
ible, especially in the young.540,541 Somatostatin analogues
such as octreotide and lanreotide have both been shown
to reduce LVH and improve the ventricular arrhythmia
proﬁle.542–544
8.4.3.5. Primary aldosteronism, addison disease, hyper-
parathyroidism, and hypoparathyroidism. Severe electrolyte
disturbances form the basis of arrhythmogenesis and VT/SCD
associated with the previously mentioned endocrinopathies.
ECG changes including prolongation of QRS and QTc intervals
can accompany the electrolyte disturbance. Electrolyte
imbalance requires immediate attention before deﬁnitive
treatment of the underlying cause.545–549
8.4.3.6. Diabetes. Diabetes is a major risk factor for prema-
ture and accelerated atherosclerosis, resulting in an
increased incidence of MI, stroke, and death compared
with a similar age- and gender-matched population
without diabetes.95 The management of atherosclerotic
complications that predispose to ventricular arrhythmias
and SCD in patients with diabetes is similar to that in
patients with diabetes.550
In addition to atherosclerosis and hyperglycemia that pre-
dispose the patient with diabetes to ventricular arrhythmias
and SCD, autonomic neuropathy, transient hypoglycemic
episodes that may occur with drug therapy, and target
end-organ damage, such as renal failure, that results in
hyperkalemia and occasionally hypokalemic episodes as a
result of treatment, augment the risk of SCD.551–557
Restrictive cardiomyopathy may be a late complication in
some patients with diabetes.
Hypoglycemic episodes increase sympathetic tone. The
likelihood of ventricular arrhythmias is enhanced, particu-
larly when they occur in a patient with autonomic neuropa-
thy. Severe hypoglycemia is associated with ventricular
repolarization abnormalities, prolongation of the QT inter-
val, and ventricular arrhythmias.551,552 Beta blockers have
been shown to reduce the magnitude of these abnormalities
during experimental hypoglycemia.558 Although they may
mask symptoms of hypoglycemia, beta blockers signiﬁcantly
improve survival rates in patients with diabetes, and indi-
cations for their use are similar to those for patients with
diabetes.559 In a prespeciﬁed diabetic subgroup of patients
with diabetes and LVH enrolled in the Losartan
Intervention for Endpoint Reduction in Hypertension (LIFE)
trial, losartan appeared to afford better protection against
SCD than atenolol.560 ACE inhibitors or angiotensin-2 block-
ers are recommended in all patients with vascular compli-
cations of diabetes if no contraindications exist.
8.4.4. End-stage renal failure
Recommendations
Class I
(1) The acute management of ventricular arrhythmias in
end-stage renal failure should immediately address
hemodynamic status and electrolyte (potassium, mag-
nesium, and calcium) imbalance. (Level of Evidence: C)
(2) Life-threatening ventricular arrhythmias, especially in
patients awaiting renal transplantation, should be
treated conventionally, including the use of ICD and
pacemaker as required, in patients who are receiving
chronic optimal medical therapy and who have reason-
able expectation of survival with a good functional
status for more than 1 y. (Level of Evidence: C)
Cardiovascular causes account for at least 40% of deaths in
patients with end-stage renal failure and 20% of these are
sudden. Arrhythmias often occur during hemodialysis ses-
sions and for at least 4 to 5 h afterward. During this
period, hemodynamic status and ﬂuctuations in electro-
lytes, especially potassium, magnesium, and calcium, are
likely to play a crucial role in triggering events and should
be monitored carefully. LQTS has been reported occasion-
ally, sometimes related to therapy with sotalol.561 Risk
factors predisposing to ventricular arrhythmias include
LVH, hypertension, anemia, cardiac dysfunction, and under-
lying CHD.562 Of these, systolic blood pressure and myocar-
dial dysfunction have been suggested to be the more
important determinants of complex arrhythmia.563
Unfortunately, there are few data on how individuals at
highest risk might be identiﬁed and treated. Restricted
vascular access may inﬂuence the choice of therapy.
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8.4.5. Obesity, dieting, and anorexia
Recommendations
Class I
Life-threatening ventricular arrhythmias in patients
with obesity, anorexia, or when dieting should be
treated in the same manner that such arrhythmias are
treated in patients with other diseases, including ICD
and pacemaker implantation as required. Patients
receiving ICD implantation should be receiving chronic
optimal medical therapy and have reasonable expec-
tation of survival with a good functional status for
more than 1 y. (Level of Evidence: C)
Class IIa
Programmed weight reduction in obesity and carefully
controlled re-feeding in anorexia can effectively
reduce the risk of ventricular arrhythmias and SCD.
(Level of Evidence: C)
Class III
Prolonged, unbalanced, very low calorie, semistarvation
diets are not recommended; they may be harmful and
provoke life-threatening ventricular arrhythmias.
(Level of Evidence: C)
Extreme disorders of eating, and overzealous methods of
rectifying them quickly, are all associated with SCD. In over-
weight individuals, this risk is particularly evident in the
severely obese with a 40 to 60 times higher incidence com-
pared with that in the aged-matched general popu-
lation.564,565 This is most likely to be related to
life-threatening ventricular arrhythmias, but changes in
the conduction system of young obese victims of SCD have
also been reported.566 Some obese individuals have pro-
longed QTc intervals567,568 and studies have also documen-
ted an increased QT dispersion in these individuals.569
Cardiomyopathy of obesity (e.g., cardiomegaly, LV dilatation,
andmyocyte hypertrophy in the absence of interstitial ﬁbrosis)
is the most common association with SCD,92 and this can occur
in normotensive individuals.570 Ventricular premature com-
plexes are 30 times more common in obese patients with LVH
compared with lean subjects. The complexity of the ventricu-
lar ectopy correlates with ventricular diastolic diameter and
LV mass.571 Obstructive sleep apnea may play a role in the
genesis of arrhythmias and HF in obese individuals.572
The risk of SCD in obesity can be signiﬁcantly reduced by
weight loss. Cardiomyopathy of obesity is reversible, at least
in the early stages of the disease,573,574 as are most ECG
changes including prolonged QTc intervals.568,569,575 Weight
reduction strategies must therefore be advocated in all
obese patients at risk, but these must involve well-balanced
low-calorie diets. Prolonged, unbalanced, very low calorie,
semistarvation diets (especially liquid protein diets) have
been reported to cause cardiac arrhythmias and SCD by a
variety of mechanisms. Such diets must be avoided especially
in those with underlying cardiac abnormalities.576–580
Reported mortality rates in anorexia nervosa ﬂuctuate
from 5% to 20%, but the actual rate is likely to be around
6%.581 Up to one third of these deaths, including those
occurring during re-feeding, are said to be due to cardiac
causes but no precise data exist on SCD. Prolonged periods
of starvation result in not only anatomical abnormalities
such as cardiac muscle atrophy and pericardial effusions,582
but also ECG abnormalities, including sinus bradycardia and
prolongation of the QTc interval, an effect that is likely to be
compounded by the presence of concurrent electrolyte dis-
turbances.582–584 SCD is therefore a frequent cause of mor-
tality in this cohort. Low weight, low body mass index,
and rapid weight loss immediately preceding assessment
are the most important independent predictors of QTc inter-
val prolongation.582 Most of the cardiac manifestations of
anorexia nervosa are completely reversible by appropriate
re-feeding.582 The ‘re-feeding syndrome’ is characterized
by cardiac, neurological, and hematological complications
triggered by ﬂuid and electrolyte disturbances during the
re-feeding of chronically starved individuals.585 Cardiac com-
plications of this syndrome usually occur within the ﬁrst week
of re-feeding and are typically associated with severe degrees
of malnutrition (less than 70% ideal body weight),586
hypophosphatemia,587 and total parenteral nutrition.588
8.5. Pericardial diseases
Recommendations
Class I
Ventricular arrhythmias that develop in patients with
pericardial disease should be treated in the same
manner that such arrhythmias are treated in patients
with other diseases including ICD and pacemaker
implantation as required. Patients receiving ICD implan-
tation should be receiving chronic optimal medical
therapy and have reasonable expectation of survival
with a good functional status for more than 1 y. (Level
of Evidence: C)
SCD can occur in the course of pericardial disease result-
ing from a variety of pathological processes; these include
both constrictive and restrictive processes, resulting from
trauma, inﬂammation, neoplastic, and infectious etiologies.
There is no evidence linking speciﬁc ventricular arrhythmias
with these diseases. Reports of SCD in patients with pericar-
dial diseases suggest that primary hemodynamic processes
(i.e., acute tamponade, herniation of myocardium through
pericardium) are responsible for the vast majority of SCD
in such patients.589–592
8.6. Pulmonary arterial hypertension
Recommendations
Class III
Prophylactic antiarrhythmic therapy generally is not
indicated for primary prevention of SCD in patients
with pulmonary arterial hypertension (PAH) or other
pulmonary conditions. (Level of Evidence: C)
SCD is responsible for 30% to 40% of mortality in patients
with PAH. It appears more commonly in patients with
primary PAH than in those with thromboembolic PAH.593
Patients experiencing SCD have lower partial pressure of
oxygen than do those free of sudden death.594 SCD in
patients with severe PAH appears to occur not only as a
result of (presumed) ventricular arrhythmias but also as a
result of pulmonary artery rupture or dissection.595,596
Cardiac arrhythmias may also result from ischemia. Marked
dilatation of the main pulmonary artery has been reported
to cause myocardial ischemia as a result of compression of
the left main coronary artery.597 Cardiac catheterization is
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associated with increased risk of death, including documen-
ted VF in this population.598 In addition to patients with PAH,
ventricular arrhythmias occur in persons with sleep disor-
dered breathing and may be responsible for SCD in patients
with sleep apnea.599
No trials of prophylactic antiarrhythmic therapy have
been conducted in patients with PAH or other pulmonary
conditions. Antiarrhythmic therapy is not indicated for pre-
vention of SCD in patients with PAH or other pulmonary con-
ditions.600,601 Good clinical judgment should be used in the
management of asymptomatic arrhythmias in such patients,
as they may be prone to proarrhythmic effects of anti-
arrhythmic agents. Furthermore, such patients may be at
high risk during surgical procedures, such as ICD
implantation.
8.7. Transient arrhythmias of reversible cause
Recommendations
Class I
(1) Myocardial revascularization should be performed, when
appropriate, to reduce the risk of SCD in patients experi-
encing cardiac arrest due to VF or polymorphic VT in the
setting of acute ischemia or MI. (Level of Evidence: C)
(2) Unless electrolyte abnormalities are proved to be the
cause, survivors of cardiac arrest due to VF or poly-
morphic VT in whom electrolyte abnormalities are dis-
covered in general should be evaluated and treated in a
manner similar to that of cardiac arrest without electro-
lyte abnormalities. (Level of Evidence: C)
(3) Patients who experience sustained monomorphic VT in
the presence of antiarrhythmic drugs or electrolyte
abnormalities should be evaluated and treated in a
manner similar to that of patients with VTwithout elec-
trolyte abnormalities or antiarrhythmic drugs present.
Antiarrhythmic drugs or electrolyte abnormalities
should not be assumed to be the sole cause of sustained
monomorphic VT. (Level of Evidence: B)
(4) Patients who experience polymorphic VT in association
with prolonged QT interval due to antiarrhythmic medi-
cations or other drugs should be advised to avoid
exposure to all agents associated with QT prolongation.
A list of such drugs can be found on the Web sites
www.qtdrugs.org and www.torsades.org. (Level of
Evidence: B)
The mortality of cardiac arrest survivors is high, even
when the cause of the initial arrest appears to be a transient
or correctable abnormality, and much of the mortality
appears due to recurrent cardiac arrest.33,602 The most
common putative reversible causes of arrest are acute
ischemia and electrolyte imbalance. Other common poten-
tial causes to which cardiac arrest is attributed include
proarrhythmic effects of antiarrhythmic drugs.603 No con-
trolled trials have evaluated the effects of myocardial revas-
cularization on VT or VF. However, observational studies
suggest that:
. Sustained monomorphic VT in patients with prior MI is unli-
kely to be affected by revascularization.330
. Myocardial revascularization is sufﬁcient therapy only in
patients surviving VF in association with myocardial ische-
mia when ventricular function is normal and there is no
history of MI.604
The short-term (hospital) mortality of patients in
whom primary VF complicates the acute phase of MI is
high. However, patients who survive the initial hospitaliz-
ation after Q-wave MI have survival virtually identical to
patients without VF in the acute phase of infarction.605
The low risk for late cardiac arrest appears to apply only
to patients experiencing Q-wave infarction; patients with
an infarction deﬁned by biomarker elevations without devel-
opment of new Q waves have a signiﬁcantly higher risk of
late cardiac arrest.606,607 Transient ischemia resulting from
coronary artery spasm may cause polymorphic VT or VF.608
In such cases, treatment of coronary spasm is may be
sufﬁcient to prevent recurrent arrhythmia.609,610 Coronary
artery spasm may increase the risk of ventricular arrhy-
thmias and SCD.
Electrolyte abnormalities, including hypokalemia and
hypomagnesemia, facilitate development of VT in predis-
posed patients receiving antiarrhythmic agents and other
drugs associated with the LQTS. However, hypokalemia can
also result from cardiac arrest and should not otherwise be
assumed to be the cause of cardiac arrest, except under
unusual circumstances.611 Correction of hypokalemia does
not affect inducibility of monomorphic VT occurring after
MI. Electrolyte abnormalities should not be assumed to be
the cause of cardiac arrest, except in the presence of
drug-induced LQTS.
In patients who develop polymorphic VT in association
with drug-induced QT prolongation, withdrawal of the
offending antiarrhythmic or other agent is usually sufﬁcient
to prevent arrhythmia recurrence. If ventricular function is
normal, no therapy beyond drug withdrawal, avoidance of
future drug exposure, and correction of electrolyte abnorm-
alities is necessary. However, if ventricular function is
abnormal, cardiac arrest or syncope should not be attribu-
ted solely to antiarrhythmic drugs, and evaluation and treat-
ment should be similar to patients experiencing such events
in the absence of antiarrhythmic drugs.
Occasionally, patients develop monomorphic sustained VT
only in the presence of antiarrhythmic drugs without QT pro-
longation. In such cases, it may appear that the develop-
ment of spontaneous VT is dependent on drug
administration. In most patients exhibiting this behavior,
the monomorphic VT is inducible by EP testing in the
absence of antiarrhythmic drugs.612,613
9. Ventricular arrhythmias associated with
cardiomyopathies
9.1. Dilated cardiomyopathy (nonischemic)
Recommendations
Class I
(1) EP testing is useful to diagnose bundle-branch reentrant
tachycardia and to guide ablation in patients with nonis-
chemic DCM. (Level of Evidence: C)
(2) EP testing is useful for diagnostic evaluation in patients
with nonischemic DCM with sustained palpitations,
wide-QRS-complex tachycardia, presyncope, or
syncope. (Level of Evidence: C)
(3) An ICD should be implanted in patients with nonischemic
DCM and signiﬁcant LV dysfunction who have sustained
VT or VF, are receiving chronic optimal medical
therapy, and who have reasonable expectation of
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survival with a good functional status for more than 1 y.
(Level of Evidence: A)
(4) ICD therapy is recommended for primary prevention to
reduce total mortality by a reduction in SCD in patients
with nonischemic DCM who have an LVEF less than or
equal to 30% to 35%, are NYHA functional class II or III,
who are receiving chronic optimal medical therapy, and
who have reasonable expectation of survival with a
good functional status for more than 1 y. (Level of
Evidence: B) (See Section 1.2.)
Class IIa
(1) ICD implantation can be beneﬁcial for patients with
unexplained syncope, signiﬁcant LV dysfunction, and
nonischemic DCM who are receiving chronic optimal
medical therapy and who have reasonable expectation
of survival with a good functional status for more than
1 y. (Level of Evidence: C)
(2) ICD implantation can be effective for termination of sus-
tained VT in patients with normal or near normal ventri-
cular function and nonischemic DCM who are receiving
chronic optimal medical therapy and who have reason-
able expectation of survival with a good functional
status for more than 1 y. (Level of Evidence: C)
Class IIb
(1) Amiodarone may be considered for sustained VT or VF in
patients with nonischemic DCM. (Level of Evidence: C)
(2) Placement of an ICD might be considered in patients
who have nonischemic DCM, LVEF of less than or equal
to 30% to 35%, who are NYHA functional class I receiving
chronic optimal medical therapy, and who have reason-
able expectation of survival with a good functional
status for more than 1 y. (Level of Evidence: C) (See
Section 1.2.)
Considerations taken by the Writing Committee in formu-
lating recommendations for this section are discussed in
detail in the Introduction.
9.1.1. Risk stratiﬁcation
The 5-y mortality for DCM has been recently estimated at
20% with SCD accounting for approximately 30% (8% to
51%) of deaths.614,615 Ventricular arrhythmias, both sympto-
matic and asymptomatic, are common, but syncope and SCD
are infrequent initial manifestations of the disease.616,617
The incidence of SCD is highest in patients with indicators
of more advanced cardiac disease who are also at highest
risk of all cause mortality. Although VT and/or VF is con-
sidered the most common mechanism of SCD, bradycardia,
pulmonary embolus, electromechanical dissociation and
other causes account for up to 50% of SCDs in patients
with advanced HF.107,618,619 Risk stratiﬁcation is difﬁcult in
DCM. SCD occurs less frequently in patients with less
advanced cardiac disease but the proportion of SCD to all-
cause death is higher in this group.617,618,620 Predictors of
overall outcome also predict SCD and generally reﬂect
severity of disease (EF, end-diastolic volume, older age,
hyponatremia, pulmonary capillary wedge pressure, sys-
temic hypotension, AF).614 Unfortunately, they do not
speciﬁcally predict arrhythmic death and are not useful in
the patient with less severe disease.3,621 Even a low EF
(less than 20%) may not have high positive predictive value
for SCD.622–624 Syncope has been associated with a higher
risk of SCD regardless of the proven etiology of the
syncope223,625 and patients with ICD implantation receive
appropriate shocks comparable to a secondary prevention
cohort.223,625,626 Premature ventricular complexes and
NSVT correlate with the severity of cardiac disease and
occur in the majority of patients with severe LV dysfunc-
tion.619,627,628 This limits the utility of ventricular arrhyth-
mias as risk stratiﬁers as they would be expected to be
sensitive but not speciﬁc. It has been suggested that the
presence of NSVT may be more speciﬁc in the individual
with better LV function.3 Induction of VT by EP testing has
been shown to predict SCD625 but unfortunately failure to
induce VT misses most individuals destined to die sud-
denly.129,627,629,630 Microvolt TWA has been suggested to
predict SCD in a cohort study of 137 patients with DCM.151
The study included 37 patients with an indication for ICD
and most endpoints occurred in this group. Nonetheless,
the positive predictive value was relatively modest (0.22),
as was EF less than 35% (0.15). Idiopathic DCM has hetero-
geneous etiologies but is familial in at least 40% of cases,
being usually autosomal dominant with variable penetrance
but also X-linked.631–634 Unfortunately, genetic information
is not currently useful for risk stratiﬁcation.
9.1.2. Electrophysiological testing
In DCM, EP testing plays a minor role in the evaluation and
management of VT. This is related to low inducibility, low
reproducibility of EP testing, and low predictive value of
induced VT.203,204 The multicenter CAT trial included
104 patients with DCM and LVEF less than 30% without sus-
tained VT/VF.635 NSVT during Holter monitoring was
recorded in 52%. With use of a complete EP testing protocol,
only 2.9% of patients had sustained VT and 9.6% had VF
induced. However, symptomatic patients may have various
supraventricular tachyarrhythmias, typical and atypical
atrial ﬂutter or AF, requiring EP testing for diagnostic
purposes or to guide ablation. Bundle-branch reentry may
be suspected in patients with DCM, intraventricular conduc-
tion defects during sinus rhythm, and LBBB pattern
tachycardia.636
9.1.3. Management
The treatment of DCM is often based on individual patient
presentation and local physician experience.
Pharmaceuticals that have improved overall mortality in
patients with HF, such as beta blockers and ACE inhibitors,
have also reduced SCD.622,637–640 Amiodarone is generally
preferred to treat patients with symptomatic arrhythmias
because of the absence of signiﬁcant negative hemodynamic
effects and low proarrhythmic potential, although con-
trolled comparative trials of drugs are not available.
Amiodarone has been suggested to improve mortality in
uncontrolled trials.641 In controlled trials, amiodarone
reduced the incidence of SCD in a population of patients
with predominately nonischemic DCM637 but not in a study
of HF patients where the majority had CHD.638 The ICD has
been shown to be superior to amiodarone for secondary pre-
vention of VT and VF in studies where the majority of
patients had CHD.266,642,643 The subgroup with nonischemic
DCM in these studies beneﬁted from the ICD more than did
those with CHD.644
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The role of the ICD in primary prophylaxis has been con-
troversial. The Cardiomyopathy Trial (CAT) enrolled patients
with recently diagnosed DCM and was discontinued early
due to futility largely because of a lower-than-expected
incidence of all-cause mortality.635 This was a relatively
small study (50 patients in the ICD arm and 54 in the
control group), although the 5-y follow-up showed fewer
deaths in the ICD group versus control (13 vs. 17, respect-
ively). In the AMIOVERT study,645 103 patients with DCM,
EF less than 35%, and NSVTwere randomized to amiodarone
or ICD. The primary endpoint was total mortality, and the
study was stopped prematurely due to futility. The
Deﬁbrillators in Nonischemic Cardiomyopathy Treatment
Evaluation (DEFINITE)646–648 randomized 458 patients with
nonischemic cardiomyopathy, EF less than 35%, and frequent
PVCs or NSVT to receive best medical therapy with or
without ICD. There was a trend toward reduction of mor-
tality with ICD therapy, but this was not signiﬁcant.
The DEFINITE patients were randomized to receive best
medical therapy with or without an ICD, and the primary
endpoint was all-cause mortality. After 2 y, mortality was
13.8% in the standard therapy group versus 8.1% among
those receiving an ICD, amounting to a 5.7% absolute
reduction and a 35% relative risk reduction with ICD implan-
tation. This failed to reach statistical signiﬁcance
(p ¼ 0.06), but the ﬁndings are comparable to those of
other similar trials.647,648 The SCD-HeFT compared amiodar-
one, ICD, and best medical therapy in 2521 patients with
CHD or nonischemic cardiomyopathy who were in NYHA
functional class II or III HF with EF less than 35%. The drug
arm (amiodarone) was double blinded and placebo con-
trolled. The median follow-up was 45.5 mo. The total mor-
tality in the medical group was 7.2% per year over 5 y with a
risk reduction of 23% in the ICD group versus placebo (CI 0.62
to 0.96, p ¼ 0.007). Relative risk reduction was comparable
for LV dysfunction due to prior MI and nonischemic groups,
but absolute mortality was lower in the nonischemic
group, resulting in a greater number to treat per life
saved. There was no mortality difference between the amio-
darone and placebo groups.8 Further risk stratiﬁcation may
decrease the number of individuals needed to treat to
save a life in this population.649 With the exception of DEFI-
NITE (25% in the ICD arm), trials assessing ICD in primary pro-
phylaxis of DCM did not generally include asymptomatic
patients with NYHA functional class I and therefore the efﬁ-
cacy of ICD in this population is not fully known.650 Because
mortality is low in this subgroup, the beneﬁt of ICD therapy
is at best moderate.
9.1.4. Genetic analysis
The clinical applicability of genetic analysis to DCM is still
limited as knowledge in this area does not allow genotyping
of most individuals clinically affected by the disease.
Patients with DCM and AV block and patients with DCM and
skeletal muscle diseases have a higher probability of being
successfully genotyped. When a pathogenetic mutation is
identiﬁed, it becomes possible to establish a presympto-
matic diagnosis of the disease among family members and
to provide them with genetic counseling to monitor pro-
gression of the disease and to assess the risk of transmitting
the disease to offspring. Based on current knowledge,
genetic analysis does not contribute to further risk stratiﬁ-
cation in DCM.
9.2. Hypertrophic cardiomyopathy
Recommendations
Class I
ICD therapy should be used for treatment in patients with
HCM who have sustained VT and/or VF and who are
receiving chronic optimal medical therapy and who
have reasonable expectation of survival with a good
functional status for more than 1 y. (Level of Evidence: B)
Class IIa
(1) ICD implantation can be effective for primary prophylaxis
against SCD in patients with HCM who have 1 or more
major risk factor (see Table 7) for SCD and who are
receiving chronic optimal medical therapy and in patients
who have reasonable expectation of survival with a good
functional status for more than 1 y. (Level of Evidence: C)
(2) Amiodarone therapy can be effective for treatment in
patients with HCM with a history of sustained VT and/
or VF when an ICD is not feasible. (Level of Evidence: C)
Class IIb
(1) EP testing may be considered for risk assessment for SCD
in patients with HCM. (Level of Evidence: C)
(2) Amiodarone may be considered for primary prophylaxis
against SCD in patients with HCM who have 1 or more
major risk factor for SCD (see Table 7) if ICD implan-
tation is not feasible. (Level of Evidence: C)
9.2.1. Risk Stratiﬁcation
Most individuals with HCM are asymptomatic and the ﬁrst
manifestation may be SCD.651–657 SCD is usually related to
ventricular arrhythmia with varying contribution of triggers
such as ischemia, outﬂow obstruction, or AF.653–656,658 SCD
is less frequently due to bradycardia.659 The annual mor-
tality from HCM has been estimated as high as 6% from ter-
tiary centers,653,660,661 but community-based studies
suggest a more benign disease in the majority of individuals,
with an annual mortality in the range of 1% or less.662–667
This relatively low incidence creates a challenge for risk
stratiﬁcation because the false-positive values for any
Table 7 Risk factors for sudden cardiac death in hypertrophic
cardiomyopathy
Major risk factor Possible in individual patients
Cardiac arrest (VF) AF
Spontaneous sustained VT Myocardial ischemia
Family history of premature
sudden death
LV outﬂow obstruction
Unexplained syncope High-risk mutation
LV thickness greater than or
equal to 30 mm
Intense (competitive)
physical exertion
Abnormal exercise BP
Nonsustained spontaneous VT
AF, atrial ﬁbrillation; BP, blood pressure; LV, left ventricular; VF, ventri-
cular ﬁbrillation; VT, ventricular tachycardia.
Modiﬁed with permission from Maron BJ, McKenna WJ, Danielson GK, et al.
American College of Cardiology/European Society of Cardiology clinical
expert consensus document on hypertrophic cardiomyopathy. A report of
the American College of Cardiology Foundation Task Force on Clinical
Expert Consensus Documents and the European Society of Cardiology
Committee for Practice Guidelines. J Am Coll Cardiol 2003;42:1687–713.
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stratiﬁer may overwhelm the true-positive values.668
Features suggesting higher risk of SCD have been derived
from observational studies.98,662,669–677 In one study, 23
of 480 patients died suddenly over a mean follow-up of
6.5 y.678 The risk of SCD was directly related to LV wall
thickness with essentially no mortality over 20 y with wall
thickness less than 20 mm and mortality of almost 40% for
wall thickness greater than or equal to 30 mm. Patients
with such extreme wall thickness were the youngest and
frequently asymptomatic. Five of 12 patients in this cat-
egory under the age of 18 died suddenly. Others have
suggested that patients with extreme septal hypertrophy
also have other risk factors, and the independent value of
extreme septal hypertrophy is less clear.98,679 The degree
of outﬂow obstruction has been shown to predict cardiovas-
cular death674,678 but not SCD.678 Athletes with HCM should
not participate in most competitive sports with the possible
exception of sports of low dynamic and low static inten-
sity.680–682 Participation in low-to-moderate athletic activi-
ties may be allowed in selected low-risk patients.683
Cardiac MRI684 and CT685 have been suggested to be
helpful in assessing extent of disease and predicting SCD.
A history of SCD in one or more family members has been
considered to signify higher risk.653,660,686 This is intuitively
logical and related closely to the suggestion that certain
speciﬁc genetic abnormalities have been associated with
increased risk of SCD;687–691 the role of genetic testing as
a predictor of SCD is likely to increase.687 Syncope has
been associated with increased risk of SCD.657,692–695 The
severity of other symptoms such as dyspnea, chest pain,
and effort intolerance has not been correlated with
increased risk of SCD.695,696 A ﬂat or hypotensive response
to upright or supine exercise testing in patients younger
than 40 y has been shown to be a risk factor for SCD,
although the positive predictive value of this ﬁnding is
low.658 A normal blood pressure response identiﬁes a
low-risk group.658,697–699 The presence of VTon Holter moni-
toring665,696,700–702 has been associated with a higher risk of
SCD, although the positive predictive accuracy is relatively
low. The absence of VT appears to have good negative pre-
dictive value. VT induced in the EP laboratory97 has also
been associated with a higher risk of SCD, although others
have suggested that VT induced in this setting with aggres-
sive stimulation techniques is not speciﬁc.703,704
A consensus document on HCM from the American College
of Cardiology and European Society of Cardiology categor-
ized known risk factors for SCD as ‘major’ and ‘possible in
individual patients’705 (see Table 7).
It is clear that many of the risk factors listed in Table 7 are
interdependent, and the major independent risk factors
may prove to be the extent of disease and the genetic
abnormality. The absence of risk factors identiﬁes a
low-risk group, but the positive predictive value of any
single risk factor is limited. Risk stratiﬁcation based on
incorporation of multiple risk factors would likely improve
positive predictive accuracy.693
9.2.2. Electrophysiological testing
The value of EP testing in HCM has been controversial.706 In
1989, Fananapazir et al.707 showed by using 2 premature
stimuli that only 16% of patients with cardiac arrest or
syncope in the setting of HCM had inducible sustained VT.
In a later study, the same group published data on 230
patients, including 155 patients reported earlier.97,707
Patients with inducible VT had a poorer prognosis than
those without inducible VT. Induced VT was often poly-
morphic. The response to EP testing was considered to be
an important predictive factor for outcome, together with
a history of syncope or cardiac arrest. In a prospective
study of 29 patients with HCM, 8 of them presenting with
syncope, EP testing with up to 3 extrastimuli at 3 cycle
lengths including LV stimulation failed to distinguish patients
with from those without syncope.224 In patients who
received an ICD for primary prevention, the estimated
appropriate discharge rate was 5% per year.708
9.2.3. Management
The mainstay of pharmacological management for the
symptomatic patient has been beta blockers or verapamil,
which probably exert their effect by reducing heart rate
and decreasing contractility.653,660 Disopyramide has been
similarly used presumably for its negative inotropic
effect.709 AF can be especially problematic,710,711 with
sudden clinical deterioration as a result of high ventricular
rates and loss of atrial ﬁlling. In addition, it is associated
with increased risk of embolism, HF, and death. The high
rate of embolism warrants anticoagulation with warfarin
even though this has not been validated in this group of
patients by a large randomized trial. Amiodarone is widely
used and considered the most effective antiarrhythmic
agent, although large controlled comparative trials are not
available.710,712 Medical therapy has not been proved to be
beneﬁcial in the prevention of disease progression in the
asymptomatic individual and is generally not indicated.
Nonetheless, treatment with beta blockers and/or calcium
antagonists is tempting even in asymptomatic individuals if
they are younger and have severe hypertrophy or signiﬁcant
gradients.660 It is intuitively reasonable that optimal
medical therapy and control of comorbidities will also
reduce the risk of SCD, although this has not been rigidly
demonstrated.
Although no randomized studies are available, the ICD has
been used in patients with cardiac arrest, sustained VT, or
VF, with a high percentage of patients receiving appropriate
discharge during follow-up at a rate of 11% per year.708 The
ICD implanted in a subgroup of patients for primary prophy-
laxis on the basis of perceived high risk for SCD (syncope,
family history of SCD, NSVT, inducible VT, septal thickness
greater than or equal to 30 mm) resulted in a lower rate
of appropriate discharge of 5% per year.708 Amiodarone has
been shown useful in prevention of SCD in nonrandomized
studies,712,713 while other studies have suggested sympto-
matic improvement but have not shown complete preven-
tion of SCD.714,715 Placebo-controlled studies or studies
that compared ICD with amiodarone are not available, and
the role of amiodarone in prevention of SCD is unclear.
Amiodarone is unlikely to be superior to the ICD for this
purpose, and a comparative study may never be done.716
The ICD is not indicated in the majority of asymptomatic
patients with HCM, who will have a relatively benign
course. Its role is individualized in the patient considered
to be at high risk for SCD.3,717,718 Although precise risk stra-
tiﬁcation has not been validated, patients with multiple risk
factors (especially severe septal hypertrophy, greater than
or equal to 30 mm) and those with SCD (especially multiple
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SCDs) in close relatives appear to be at sufﬁciently high risk
to merit consideration of ICD therapy.
9.2.4. Genetic analysis
Genetic analysis is useful in families with HCM because
whenever a pathogenetic mutation is identiﬁed, it
becomes possible to establish a presymptomatic diagnosis
of the disease among family members and to provide them
with genetic counseling to assess the risk of disease develop-
ment and transmission of the disease to offspring. Genetic
analysis may contribute to risk stratiﬁcation in selected
circumstances.
9.3. Arrhythmogenic right ventricular
cardiomyopathy
Recommendations
Class I
ICD implantation is recommended for the prevention of
SCD in patients with ARVC with documented sustained
VT or VF who are receiving chronic optimal medical
therapy and who have reasonable expectation of survi-
val with a good functional status for more than
1 y. (Level of Evidence: B)
Class IIa
(1) ICD implantation can be effective for the prevention of
SCD in patients with ARVC with extensive disease,
including those with LV involvement, 1 or more affected
family member with SCD, or undiagnosed syncope when
VT or VF has not been excluded as the cause of syncope,
who are receiving chronic optimal medical therapy,
and who have reasonable expectation of survival with
a good functional status for more than 1 y. (Level of
Evidence: C)
(2) Amiodarone or sotalol can be effective for treatment of
sustained VT or VF in patients with ARVC when ICD
implantation is not feasible. (Level of Evidence: C)
(3) Ablation can be useful as adjunctive therapy in manage-
ment of patients with ARVC with recurrent VT, despite
optimal antiarrhythmic drug therapy. (Level of
Evidence: C)
Class IIb
EP testing might be useful for risk assessment of SCD in
patients with ARVC. (Level of Evidence: C)
9.3.1. Risk stratiﬁcation
ARVC (‘dysplasia’) is suspected in patients, typically a young
man, with RV arrhythmias or in relatives of individuals with
known ARVC. Syncope, presyncope, and, less frequently,
biventricular failure are also observed.719,720 The ventricu-
lar arrhythmias have LBBB morphology that spans the spec-
trum of simple ventricular ectopy, sustained and NSVT, or VF.
ARVC needs to be considered along with idiopathic RV
outﬂow VT in the individual with ventricular ectopy and
VT coming from the RV outﬂow region. In contrast to
ARVC, idiopathic RV outﬂow VT is usually not associated
with the ECG abnormalities seen with ARVC, is more
common in women, and is initiated by isoproterenol infusion
instead of by EP testing.721,722 The ECG in ARVC frequently
shows precordial T-wave inversion, usually over V1 to V3,
and QRS duration greater than 110 ms.721 Low voltage
potentials following the QRS (epsilon waves) are character-
istic but seen relatively infrequently, and late potentials
are observed on the SAECG in greater than 50% of
individuals.721,723,724
Unfortunately, SCD is frequently the ﬁrst manifestation of
the disease.96,725,726 A standardized diagnostic scheme has
been formulated to establish a clinical diagnosis on a point
score basis.727 The annual incidence of SCD has varied,
ranging from 0.08% to 9%.720,728–730 In an autopsy series,
24 of 27 patients were determined to have died suddenly
and 3 to have died of congestive HF.731 SCD occurs relatively
frequently during exercise or during stress, but SCD with no
apparent provocation is not uncommon.732 In one Italian
series, up to 25% of SCD in athletes was related to
ARVC.733 Although SCD usually occurs in individuals with
grossly visible RV abnormalities, it can occur in those with
only microscopic abnormalities and no obvious RV enlarge-
ment.734 RV dilation, precordial repolarization abnormal-
ities, and LV involvement have been associated with risk of
sudden death.730,735,736 Certain genetic types may be associ-
ated with higher risk of SCD.737 SCD in 1 or more family
members intuitively suggests a higher risk of SCD in an
affected individual, but this has not been well quantiﬁed.170
9.3.2. Electrophysiological testing
The arrhythmic manifestations of the disease are variable.96
The prognostic role of EP testing in patients presenting with
isolated PVCs or NSVT is not known. The response to EP
testing may be inﬂuenced by the severity of the disease.
Progression of disease has to be considered. EP testing has
been evaluated in a limited number of patients for risk stra-
tiﬁcation. Di Biase et al.738 used EP testing in 17 patients
with ‘mild’ dysplasia and induced VT only in patients with
spontaneous sustained VT. VT was induced in 90% of 12
patients with spontaneous sustained VT.739 The positive pre-
dictive value for recurrent VT was only 55%. Sustained VT
could not be induced in 20 patients presenting with
NSVT.736 In this study, inducibility was 88% in 24 of 27
patients presenting with sustained VT. EP testing, in
general, is used to reproduce clinical VT and to guide
ablation.740,741
9.3.3. Management
The treatment of ARVC is often based on individual patient
presentation and local physician experience. The ICD has
been used in patients with unexplained syncope, sustained
VT, or VF with a high incidence of appropriate shocks.742
Although there are no speciﬁc large randomized trials in
ARVC to support this, the situation is sufﬁciently ‘similar’
to those disease states such as previous MI where these indi-
cations are well established.266,718,741,743 ICD treatment in
individuals with a known family history of SCD or unex-
plained syncope is intuitively compelling but not rigidly
proved. The impact of medical therapy on mortality is not
established. RF ablation has been used in selected patients
for VT in medically refractory patients.744 Elimination of 1
or more clinical tachycardias by RF ablation is useful for
management of symptoms but may not be sufﬁcient to
prevent SCD. Operative therapy in the form of total electri-
cal RV disconnection has proved successful in medically
refractory patients with normal LV function but does carry
a risk of postoperative right HF.745 Heart transplantation
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and ventricular assist devices are an option in patients with
biventricular failure.
9.3.4. Genetic analysis
Genetic analysis is useful in families with RV cardiomyopa-
thy, because whenever a pathogenetic mutation is ident-
iﬁed, it becomes possible to establish a presymptomatic
diagnosis of the disease among family members and to
provide them with genetic counseling to monitor the devel-
opment of the disease and to assess the risk of transmitting
the disease to offspring. Based on current knowledge,
genetic analysis does not contribute to risk stratiﬁcation in
RV cardiomyopathy.
9.4. Neuromuscular disorders
Recommendations
Class I
Patients with neuromuscular disorders who have ventri-
cular arrhythmias should generally be treated in the
same manner as patients without neuromuscular
disorders. (Level of Evidence: A)
Class IIb
Permanent pacemaker insertion may be considered for
neuromuscular diseases such as myotonic muscular
dystrophy, Kearns-Sayre syndrome, Erb dystrophy, and
peroneal muscular atrophy with any degree of AV block
(including ﬁrst-degree AV block) with or without symp-
toms, because there may be unpredictable progression
of AV conduction disease. (Level of Evidence: B)
The inherited neuromuscular disorders may predispose to
atrial arrhythmias, conduction defects, advanced AV block,
monomorphic VT, polymorphic VT, and SCD.746–755 An exhaus-
tive list of the inherited neuromuscular disorders is beyond
the scope of this guideline. Table 8 lists some of the more
common disorders associated with cardiovascular manifes-
tations, produced in some cases by degeneration of the special-
ized conduction tissue and in others by degenerative changes in
atrial and myocardial tissue predisposing to cardiomyopathy
and ventricular arrhythmias. In many cases, the resting ECG
is abnormal, with ﬁrst-degree AV block, bundle-branch block,
Q waves, ST-T abnormalities, or PVCs.753,754
The clinical presentation, indicating the potential sub-
strate for SCD, is quite variable, ranging from asymptomatic
to the symptoms of syncope, lightheadedness, and palpita-
tions. There are no large series of asymptomatic patients
treated with devices and the timing of pacemaker/ICD
implantation is not clear based on the available literature.
In general, the more advanced the cardiac involvement is
(conduction or structural), the more likely it is that a
serious arrhythmia will occur. SCD is a well-recognized com-
plication of some of the neuromuscular diseases and pro-
gression of the conduction abnormalities may be
unpredictable.756–762 Once cardiac involvement occurs, par-
ticularly with the muscular dystrophies, the clinician should
maintain a low threshold for investigating symptoms or ECG
ﬁndings to determine the need for pacemaker insertion,
invasive EP studies, or ICD implantation. Screening for
underlying cardiovascular manifestations with a resting
12-lead ECG or echocardiogram to determine cardiac invol-
vement should be part of the routine clinical assessment,
independent of symptom status. The relative likelihood of
a patient with an inherited neuromuscular disorder develop-
ing a conduction disturbance, ventricular arrhythmia, or
cardiomyopathy is listed in Table 8. In general, the indi-
cations for device therapy in patients with Duchenne,
Becker, X-linked cardiomyopathies, limb-girdle 2C to 2F,
and Friedreich ataxia should follow standard pacing/ICD
guidelines as for patients with dilated cardiomyopathies.
The reader is referred to the ACC/AHA/NASPE 2002
Guidelines Update for Implantation of Cardiac Pacemakers
and Antiarrhythmic Devices for a comprehensive listing of
indications.1 In an asymptomatic subject with normal ECG
and no cardiovascular manifestations, pacemaker or ICD
implantation is generally not indicated.
Indications for pharmacological or device therapy in
patients with myasthenia gravis, Guillain-Barre syndrome,
or an acute cerebrovascular event are quite different than
those for the above-mentioned inherited neuromuscular dis-
orders. Treatment is often temporary to manage the acute
event and not usually required on a long-term basis.
10. Heart failure
Recommendations
Class I
(1) ICD therapy is recommended for secondary prevention
of SCD in patients who survived VF or hemodynamically
unstable VT, or VT with syncope and who have an LVEF
less than or equal to 40%, who are receiving chronic
optimal medical therapy, and who have a reasonable
expectation of survival with a good functional status
for more than 1 y. (Level of Evidence: A)
(2) ICD therapy is recommended for primary prevention to
reduce total mortality by a reduction in SCD in patients
with LV dysfunction due to prior MI who are at least
40 d post-MI, have an LVEF less than or equal to 30% to
40%, are NYHA functional class II or III receiving chronic
optimal medical therapy, and who have reasonable
expectation of survival with a good functional status for
more than 1 y. (Level of Evidence: A) (See Section 1.2.)
Table 8 Frequency of events in neuromuscular disorders
associated with heart disease
Inheritance HB VA CM
Muscular dystrophies
Duchenne X-linked þ þ þþþ
Becker X-linked þ þ þþþ
X-lined dilated CM X-linked — þ þþþ
Limb-girdle 1B AD þþþ þþþ þþ
Limb-girdle 2C–2F AR þ þ þþþ
Myotonic MD AD þþþ þþþ þ
Emery-Dreifuss MD and
associated disorders
X-linked,
AD, AR
þþþ þþþ þþ
Other conditions
Friedreich’s ataxia AR — þ þþþ
Kearns-Sayre syndrome — þþþ þþ þ
þ To þþþ represents a comparison between the various medical
conditions and the relative frequency of an event. AD, autosomal domi-
nant; AR, autosomal recessive; CM, cardiomyopathy; HB, heart block;
MD, muscular dystrophy; VA, ventricular arrhythmias; þ, low-frequency
event; þþ, intermediate-frequency event; þþþ, high-frequency event.
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(3) ICD therapy is recommended for primary prevention to
reduce total mortality by a reduction in SCD in patients
with nonischemic heart disease who have an LVEF less
than or equal to 30% to 35%, are NYHA functional class II
or III, are receiving chronic optimal medical therapy, and
who have reasonable expectation of survival with a good
functional status for more than 1 y. (Level of Evidence:
B) (See Section 1.2.)
(4) Amiodarone, sotalol, and/or other beta blockers are
recommended pharmacological adjuncts to ICD therapy
to suppress symptomatic ventricular tachyarrhythmias
(both sustained and nonsustained) in otherwise opti-
mally treated patients with HF. (Level of Evidence: C)
(5) Amiodarone is indicated for the suppression of acute
hemodynamically compromising ventricular or supraven-
tricular tachyarrhythmias when cardioversion and/or
correction of reversible causes have failed to terminate
the arrhythmia or prevent its early recurrence. (Level of
Evidence: B)
Class IIa
(1) ICD therapy combined with biventricular pacing can be
effective for primary prevention to reduce total mor-
tality by a reduction in SCD in patients with NYHA func-
tional class III or IV, are receiving optimal medical
therapy, in sinus rhythm with a QRS complex of at
least 120 ms, and who have reasonable expectation of
survival with a good functional status for more than
1 y. (Level of Evidence: B)
(2) ICD therapy is reasonable for primary prevention to
reduce total mortality by a reduction in SCD in patients
with LV dysfunction due to prior MI who are at least 40 d
post-MI, have an LVEF of less than or equal to 30% to 35%,
are NYHA functional class I, are receiving chronic
optimal medical therapy, and have reasonable expec-
tation of survival with a good functional status for
more than 1 y. (Level of Evidence: B) (See Section 1.2.)
(3) ICD therapy is reasonable in patients who have recurrent
stable VT, a normal or near normal LVEF, and optimally
treated HF and who have a reasonable expectation of
survival with a good functional status for more than
1 y. (Level of Evidence: C)
(4) Biventricular pacing in the absence of ICD therapy is
reasonable for the prevention of SCD in patients with
NYHA functional class III or IV HF, an LVEF less than or
equal to 35%, and a QRS complex equal to or wider
than 160 ms (or at least 120 ms in the presence of
other evidence of ventricular dyssynchrony) who are
receiving chronic optimal medical therapy and who
have reasonable expectation of survival with a good
functional status for more than 1 y. (Level of
Evidence: B)
Class IIb
(1) Amiodarone, sotalol, and/or beta blockers may be con-
sidered as pharmacological alternatives to ICD therapy
to suppress symptomatic ventricular tachyarrhythmias
(both sustained and nonsustained) in optimally treated
patients with HF for whom ICD therapy is not feasible.
(Level of Evidence: C)
(2) ICD therapy may be considered for primary prevention
to reduce total mortality by a reduction in SCD in
patients with nonischemic heart disease who have an
LVEF of less than or equal to 30% to 35%, are NYHA func-
tional class I receiving chronic optimal medical therapy,
and who have a reasonable expectation of survival with
a good functional status for more than 1 y. (Level of
Evidence: B) (See Section 1.2.)
Considerations taken by the Writing Committee in formu-
lating recommendations for this section are discussed in
detail in the Introduction.
Ventricular arrhythmias and SCD are common in patients
with symptomatic acute and chronic HF and LV systolic dys-
function. The cause of HF likely inﬂuences the mechanisms
and types of ventricular arrhythmias. The guidelines and
comments in this section refer to patients with the sympto-
matic HF; not just abnormal LVEF (refer to the ACC/AHA
Guideline Update for the Diagnosis and Management of
Chronic Heart Failure in the Adult for deﬁnitions.6
Arrhythmia management in the setting of acute HF takes
place concurrently with attempts at hemodynamic stabiliz-
ation. Evaluation of arrhythmias in the setting of acute HF
necessitates a search for correctable mechanical problems
such as catheters placed for hemodynamic monitoring that
are causing ventricular or supraventricular arrhythmias. In
addition, meticulous attention needs to be given to such
factors as pharmacological agents used in the management
of acute heart failure and electrolyte and oxygen status.
Given its relatively rapid onset of action and its superior
safety proﬁle in patients with HF, the use of intravenous
amiodarone for the management of life-threatening arrhyth-
mias during acute HF has gained widespread acceptance.
In the acutely ill patient with HF, SVT and AF or atrial
ﬂutter may impose hemodynamic decompensation, and
aggressive therapy may be needed. Vagotonic measures
rarely work in the setting of acute HF. Poorly tolerated
SVT may be better treated acutely by synchronous cardio-
version, which may be accomplished at relatively low ener-
gies (e.g., 50 to 100 J biphasic). Verapamil may be effective
at suppressing reentrant SVTs that are dependent on the AV
node. Care should be taken to avoid excessive myocardial
suppression related to the negative inotropic effects of ver-
apamil. Intravenous amiodarone may be more effective at
rate control of AF or atrial ﬂutter and may restore sinus
rhythm. In HF patients, amiodarone either alone or with
electrical cardioversion is effective at slowing the heart
rate and achieving cardioversion.763,764
In the setting of acute HF, ventricular arrhythmias may be
especially poorly tolerated and early cardioversion should
be performed, rather than attempting pharmacological ter-
mination of arrhythmia. Patients with advanced myocardial
disease often have intraventricular conduction delays,
making the distinction of ventricular from supraventricular
arrhythmias challenging. Regardless of the origin of an
unstable arrhythmia, cardioversion is appropriate.
Amiodarone is preferred for longer-term administration
and is generally well tolerated hemodynamically.765
Catheter ablation may be an appropriate adjunctive
therapy in selected patients.
NSVT can be documented on 24-h ambulatory ECG moni-
toring in 30% to 80% of chronic HF patients without arrhyth-
mia symptoms.25,766,767 Although NSVT is associated with
increased mortality risk in this population, the weight of
evidence does not show a speciﬁc link between NSVT and
SCD,25,766,768 although one trial has suggested a link.767
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There is no evidence that suppression of NSVT has a favor-
able effect on prognosis in patients with HF.638 Thus, asymp-
tomatic NSVT should not be treated by antiarrhythmic
medication. If NSVT causes symptoms that require therapy,
amiodarone is probably the safest agent to use for treat-
ment, although amiodarone treatment in NYHA functional
class III patients in the SCD-HeFT trial was associated with
possibly increased mortality.8,248
Polymorphic VT in association with or not in association
with QT prolongation may occur during exacerbation of HF.
These arrhythmias may resolve with the treatment of HF.
SCD accounts for approximately 50% of deaths in patients
with HF. However, there is little evidence that empiric anti-
arrhythmic therapy can reduce the risk of SCD. Earlier trials
of empiric therapy with amiodarone have yielded conﬂicting
results, with some demonstrating reduced mortality and
others showing no improvement in survival.637,638 The
SCD-HeFT trial showed no survival beneﬁt to patients with
HF (NYHA functional class II and III) and LVEF less than or
equal to 35% treated with amiodarone empirically.8
ICD therapy did not improve the survival of patients with
HF due to nonischemic DCM in 2 small trials.635,645 However,
the SCD-HeFT trial demonstrated a 23% reduction in total
mortality with ICD treatment in comparison to placebo.8
These results are consistent with the results of DEFINITE
and earlier trials of patients with CHD and LV dysfunction,
some of whom had symptomatic HF.192,267,268 ICD in combi-
nation with biventricular pacing may improve survival and
improve symptoms of patients with advanced HF (NYHA func-
tional class III and IV) over short-term follow-up (1 to 2 y).
Biventricular pacing may be used to synchronize the con-
traction of the LV in patients with abnormal ventricular acti-
vation. Cardiac resynchronization therapy has been shown
to improve hemodynamics, increase LVEF, extend exercise
tolerance, and improve quality of life.769,770 In patients
with a poor functional status (NYHA functional class III or
IV), reduced ventricular function (LVEF less than or equal
to 35%), and a wide-QRS complex (at least 120 ms), biventri-
cular pacing without ICD therapy has consistently led to a
reduction of mortality and hospital admissions for the treat-
ment of HF.771,772 It has therefore been strongly rec-
ommended (class I) elsewhere6 that biventricular pacing
should be considered for the treatment of such patients.
This guideline considers therapies for the management of
ventricular arrhythmias and SCD. In 1 recent study772 that
recruited patients with NYHA class III through IV HF, an EF
equal to or less than 35%, and a QRS complex equal to or
greater than 160 ms (or at least 120 ms in the presence of
other evidence of ventricular dyssynchrony), sudden death
was also signiﬁcantly reduced when biventricular pacing
was applied. However, in another study771 that recruited
similar patients, except that the QRS complex had simply
to equal or exceed 120 ms, sudden death was not prevented
by resynchronization therapy alone. The value of biventricu-
lar pacing without additional ICD support for the reduction
of sudden death remains controversial.773,774
11. Genetic arrhythmia syndromes
11.1. General concepts for risk stratiﬁcation
LQTS, Brugada syndrome, and catecholaminergic poly-
morphic ventricular tachycardia (CPVT) (Online Mendelian
Inheritance in Man [OMIM] Nos. 192500, 152427, 603830,
600919, 176261, 603796, 601144, and 604772)775 are inher-
ited arrhythmogenic diseases. They share genetically deter-
mined susceptibility to VT and SCD in the absence of
recognizable structural abnormalities of the heart. These
syndromes are by deﬁnition rare diseases, because they
have an estimated prevalence below 5 in 10 000 (Deﬁnition
1295/1999/EC of the European Parliament 770).
Given the limited number of individuals affected by these
diseases, certain aspects should be considered before devel-
oping recommendations for risk stratiﬁcation and manage-
ment of patients with these diseases.
. Most of the data available for these conditions derive from
large registries that have followed patients over time,
recording outcome information. No randomized studies
are available, and most likely they will never be con-
ducted in these uncommon conditions. Therefore, the
level of evidence for recommendation in these conditions
is B or C depending on the size of the available registries
and on the duration of the follow-up of enrolled patients.
(This Writing Committee has decided to consider Level of
Evidence: B for data collected by the registries on LQTS
because they are based on large number of patients with
a long follow-up and to use a Level of Evidence: C for
the Brugada syndrome and CPVT registries, which have a
much shorter observation time for enrolled patients.)
. Data on the natural history of these diseases are poten-
tially biased by the fact that it is more likely that a
highly symptomatic case is referred to a registry. This
potential bias is likely to be more pronounced in the
more recent registries (ARVC, Brugada syndrome, and
CPVT) than in those that have been collecting patient
information for decades (LQTS).
. Some concepts applied for risk stratiﬁcation are common
to the different inherited arrhythmogenic diseases. For
example, the severity of the ECG phenotype is generally
a marker of increased risk of SCD in most of these diseases.
In LQTS, the ‘severe’ phenotype is represented by the pre-
sence of a QTc exceeding 500 ms,103,776 in the Brugada syn-
drome by the spontaneous presence of ST-segment
elevation in the right precordial leads,104,777 and in CPVT
by VT induced by exercise stress testing.105,778
. Because these diseases are characterized by electrical
abnormalities occurring in the structurally intact heart,
the use of the ICD is always indicated with a class I indi-
cation in the secondary prevention of cardiac arrest. Its
use in primary prevention is more debated, considering
the young age of patients at diagnosis. In LQTS and in
CPVT, pharmacological therapy with beta blockers is
effective in reducing the risk of cardiac events. In these
diseases, therefore, beta blockers are recommended as
ﬁrst-line treatment in all affected individuals, class I indi-
cation, and the use of the ICD is recommended for higher-
risk subgroups.104,105,777,779 In the Brugada syndrome, no
effective pharmacological treatment is known and there-
fore the use of prophylactic ICD should be targeted to
high-risk patients.104,777
. Genetic information is progressively entering clinical prac-
tice and is being integrated in the risk stratiﬁcation
schemes.103,780
. In general, a family history of SCD has not proved useful in
stratifying risk in affected patients.
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. Avoidance of competitive sports is recommended by some,
but not others, for all patients affected by inherited
arrhythmogenic disorders even when physical activity is
not considered to be the trigger for arrhythmic episodes,
such as in patients with Brugada syndrome and LQT3
(see Section 13.1).
A concise overview of clinical manifestations and the rec-
ommendations for risk stratiﬁcation and management of the
individual diseases is outlined in the following subsections.
11.1.1. Long QT syndrome
Recommendations
Class I
(1) Lifestyle modiﬁcation is recommended for patients with
an LQTS diagnosis (clinical and/or molecular). (Level of
Evidence: B)
(2) Beta blockers are recommended for patients with an
LQTS clinical diagnosis (i.e., in the presence of pro-
longed QT interval). (Level of Evidence: B)
(3) Implantation of an ICD along with use of beta blockers is
recommended for LQTS patients with previous cardiac
arrest and who have reasonable expectation of survival
with a good functional status for more than 1 y. (Level
of Evidence: A)
Class IIa
(1) Beta blockers can be effective to reduce SCD in patients
with a molecular LQTS analysis and normal QT interval.
(Level of Evidence: B)
(2) Implantation of an ICD with continued use of beta block-
ers can be effective to reduce SCD in LQTS patients
experiencing syncope and/or VT while receiving beta
blockers and who have reasonable expectation of
survival with a good functional status for more than
1 y. (Level of Evidence: B)
Class IIb
(1) Left cardiac sympathetic neural denervation may be
considered for LQTS patients with syncope, torsades
de pointes, or cardiac arrest while receiving beta block-
ers. (Level of Evidence: B)
(2) Implantation of an ICD with the use of beta blockers may
be considered for prophylaxis of SCD for patients in cat-
egories possibly associated with higher risk of cardiac
arrest such as LQT2 and LQT3 and who have reasonable
expectation of survival with a good functional status for
more than 1 y. (Level of Evidence: B)
11.1.1.1. Causes and risk factors. The LQTS is an inherited
disease characterized by prolonged ventricular repolarization
(QT interval) and by ventricular tachyarrhythmias that may
manifest as syncopal events. Cardiac arrhythmias are often
elicited by stress and emotion, although in some cases they
may also occur at rest or during sleep.781 Two patterns of
inheritance have been identiﬁed: the more common autoso-
mal dominant Romano-Ward and Timothy syndromes782,783
and the much rarer autosomal recessive cases. The latter
are usually more severe, often but not always involving con-
sanguineous marriages, and are often associated with conge-
nital deafness (the Jervell Lange-Nielsen syndrome784).
Mutations in 8 genes have been identiﬁed: 7 of them
encode cardiac ion channel subunits785–790 and 1 encodes an
anchoring protein that has been implicated in controlling
ion channel targeting speciﬁc membrane sites.791 The dis-
tinguishing features of some of the genetic variants of the
disease have been identiﬁed and incorporated in risk stratiﬁ-
cation algorithms.
11.1.1.2. Risk stratiﬁcation. Even before the identiﬁcation
of the genetic subtypes, QT interval duration was identiﬁed
as the strongest predictor of risk for cardiac events
(syncope, SCD) in LQTS,776 and it remains so. A normal QT
interval in an ungenotyped family member portends a
good prognosis.792 A QTc exceeding 500 ms (corresponding
to the upper QTc quartile among affected genotyped individ-
uals) identiﬁes patients with the highest risk of becoming
symptomatic by age 40.103 Patients with the Jervell
Lange-Nielsen and other homozygous syndromes and
patients with LQTS associated with syndactyly790,793 are at
higher risk. A family history of SCD has not proved to be a
risk factor for SCD.779,794
Genetic testing is often useful in probands with a clinical
diagnosis of LQTS to provide more accurate risk stratiﬁca-
tion and to guide therapeutic strategies.
Symptoms in LQTS range from SCD to syncope and near
syncope. Patients resuscitated from SCD have an especially
ominous prognosis, with a relative risk of 12.9 of experien-
cing another cardiac arrest.779 In addition, affected patients
may be identiﬁed because of QT prolongation detected inci-
dentally or because they are relatives of affected individuals
and are found to be mutation carriers in genetic screening;
prognosis in such family members tends to be better than
that for the proband. Risk is increased during the immediate
postpartum period.795
It has been shown that the interplay between genetic
defect, QT duration, and gender may provide an algorithm
for risk stratiﬁcation.103 Patients with the highest risk of
becoming symptomatic are LQT1 and LQT2 patients with a
QTc greater than 500 ms and males with LQT3 irrespective
of QT interval duration.103 LQT3 patients may represent a
group at higher risk.780 Among LQT2 patients, those with a
mutation resulting in a change in the pore region of the
protein796 appear to be at higher risk of cardiac events
than are those with mutations in other regions of the
gene. Beta blockers are highly effective in LQT1, whereas
they offer incomplete protection in LQT2 and LQT3.797
11.1.1.3. Ventricular arrhythmias. Syncope in LQTS patients
is usually attributed to severe ventricular arrhythmias
(although other causes can occur). Syncopal events are
usually associated with stress, emotion, or exercise;
however, gene-speciﬁc triggers for cardiac events have been
identiﬁed in the 3 most common genetic variants of the
disease. Individuals affected by the LQT1 form of the disease
(mutations in the KCNQ1 or KvLQT1 gene encoding the ion
channel that conducts the potassium current IKs) are more
susceptible to cardiac events occurring during exercise798
and particularly during swimming.799,800 LQT2 patients
harbor mutations in the KCNH2 (or HERG) gene encoding the
channel conducting the potassium current IKr are susceptible
to cardiac events occurring during rest or emotion, and
characteristically with acoustic stimuli.800,801 Finally, LQT3
patients carrying mutations in the SCN5A gene encoding the
cardiac sodium channel are susceptible to cardiac events
occurring at rest and during sleep.798 A description of the
long QT subtypes is given in Table 9.
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The mean age for ﬁrst manifestation of the disease is 12 y,
but there is a wide range from the ﬁrst year of life to as late
as the ﬁfth through sixth decades. Documentation of the
arrhythmia during cardiac events is relatively uncommon
in LQTS: when arrhythmias are recorded, the characteristic
polymorphic VT, ‘torsades de pointes’, is identiﬁed;781,802
SCD may be the ﬁrst manifestation of the disease.
11.1.1.4. Lifestyle changes. It is recommended that all
patients affected by LQTS avoid competitive sports
activity.682 For LQT1 patients, swimming should be speciﬁ-
cally limited or performed under supervision. LQT2 patients
should avoid exposure to acoustic stimuli especially during
sleep (avoidance of telephone and alarm clock on the
night stand). All patients with LQTS should avoid drugs
known to prolong the QT interval and those that deplete
potassium and magnesium.
11.1.1.5. Andersen syndrome. In 1971, Andersen et al.803
reported the case of an 8-y-old with short stature, hyperte-
lorism, broad nasal root, and defect of the soft and hard
palate. The deﬁnition of Andersen syndrome was used for
the ﬁrst time in 1994 by Tawil et al.804 to describe a clinical
disorder consisting of 3 major features: potassium-sensitive
periodic paralysis, ventricular arrhythmias, and dysmorphic
features (similar to those described by Andersen in 1971).
The presence of a varying degree of QT interval prolongation
was pointed out in the ﬁrst systematic description of the
disease.804 Subsequently, Sansone et al.805 strengthened
its crucial diagnostic signiﬁcance. Besides showing QT
interval prolongation, Andersen syndrome patients may
also present with repolarization abnormalities consisting in
a late repolarization component resembling an enlarged U
wave. Bidirectional VT has been also reported as a dis-
tinguishing pattern of arrhythmias in Andersen syndrome.
Andersen syndrome is also referred to as LQT7 even if it
has been debated whether it should be considered part of
the spectrum of the LQTSs.806 Despite SCD being
reported,807 arrhythmias do not appear to be a major
cause of death in Andersen syndrome and the disease
often has a benign outcome.805,808
The genetic background of Andersen syndrome was
recently elucidated through genomewide linkage analysis
by Plaster et al.,804 who successfully linked this disorder
to the locus 17q23 in a large family. A candidate gene
screening was carried out in the critical region and a mis-
sense mutation was identiﬁed in the KCNJ2 gene.
Additional mutations were subsequently identiﬁed in 8
unrelated individuals, thus providing the proof that KCNJ2
is the cause of at least some of the Andersen syndrome
cases. KCNJ2 encodes an inwardly rectiﬁer potassium
channel, Kir2.1, that is highly expressed in the heart,
where it appears to act as a determinant factor of phase 4
repolarization and of resting membrane potential.
Mutations in KCNJ2 are found in approximately 40% of
patients with Andersen syndrome.
Little is known about risk stratiﬁcation and management
of patients with Andersen syndrome. Patients seem to
have ventricular arrhythmias but not a high incidence of
cardiac arrest. The beneﬁt of prophylactic treatment with
beta blockers has not been deﬁned even if most patients
with prolonged QT are usually treated with these agents
on empiric grounds. The beneﬁcial role of calcium channel
blockers has also been proposed based on the arrhythmia
suppression observed in a single patient.809
11.1.1.6. Genetic analysis. Genetic analysis is very import-
ant for identifying all mutation carriers within an LQTS
family. Once identiﬁed, silent carriers of LQTS genetic
defects may be treated with beta blockers for prophylaxis
of life-threatening arrhythmias. Furthermore, silent
mutation carriers should receive genetic counseling to
learn about the risk of transmitting LQTS to offspring.
In patients affected by LQTS, genetic analysis is useful for
risk stratiﬁcation103 and for making therapeutic decisions.810
Although genetic analysis is not yet widely available, it is
advisable to try to make it accessible to LQTS patients.
11.1.2. Short QT syndrome
The ﬁrst report of a clinical condition characterized by
abnormally short repolarization was made by Gussak et al.
in 2000.140 These authors described 2 siblings and their
mother, all with a persistently short QT interval (260 to
275 ms) with peaked and narrow T waves in the absence of
structural heart disease. These authors proposed that a QT
interval shorter than 300 ms is diagnostic for SQTS. In
2003, Gaita et al.811 reported 2 families with SQTS and
showed that all affected patients had a QTc less than
300 ms with a QT interval less than 280 ms. Shortly there-
after, a novel form of SQTS in patients with a QTc up to
320 ms was identiﬁed.812 At present, it is still undeﬁned
whether the diagnosis of SQTS should be based on QT or
QTc and which is the sensitivity and speciﬁcity of different
QT/QTc interval cutoff values.
Morphological T-wave abnormalities accompany the
abbreviated repolarization in SQTS. Several patients have
tall and peaked T waves or asymmetrical T waves with a
normal ascending phase and a very rapid descending limb.
Clinical parameters for diagnosis are not yet known, so
genetic analysis seems useful to conﬁrm diagnosis in sus-
pected cases.
Up to now, only 23 cases of SQTS from 6 different families
have been reported813 and the present experience suggests
that the disease may be highly lethal. It should be con-
sidered, however, that when only a very limited cohort of
patients is available, the severity of a disease tends to be
overestimated, because symptomatic patients are identiﬁed
because of their life-threatening arrhythmias while asymp-
tomatic patients remain underdiagnosed. No information is
available on whether speciﬁc triggers may precipitate
cardiac events, as cardiac arrest has occurred both at rest
Table 9 Long QT syndrome subtypes
Variant Gene Chromosome Function
LQT1 KCNQ1 11p15.5 IKs alpha subunit
LQT2 KCNH2 7q35–35 IKr alpha subunit
LQT3 SCN5A 3p21–23 INa alpha subunit
LQT4 ANK2 4q25-2 targeting protein
LQT5 KCNE1 21p22.1–22.2 IKs beta subunit
LQT6 KCNE2 21p22.1–22.2 IKr beta subunit
LQT7 KCNJ2 17p23.1–24.2 IK1
LQT8 CACNA1C 12p13.3 ICa alpha subunit
JLN1 KCNQ1 11p15.5 IKs alpha subunit
JLN2 KCNE1 21p22.1–22.2 IKr beta subunit
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and under stress. Mutations in at least 3 genes encoding for
cardiac ion channel proteins highly expressed in the cardiac
muscle may cause SQTS.
The ﬁrst identiﬁed SQTS gene is KCNH2,814 which was
found to harbor mutation leading to a remarkable increase
in the IKr current. Bellocq et al.
815 reported another
gain-of-function mutation affecting the KCNQ1 gene in a
70-y-old man presenting with idiopathic VF and short QT
interval at the ECG. The third gene is KCNJ2, identiﬁed as
the cause of abnormally short ventricular repolarization
with a peculiar T-wave morphology (extremely fast terminal
limb and a quasi-normal ST segment and ascending T-wave
phase) by Priori et al.816
It is interesting to note that all 3 SQTS genes (KCNH2,
KCNQ1, and KCNJ2) also cause LQTS. The ECG phenotypes
depend on the opposite biophysical consequences of the
underlying mutations, with loss-of-function mutations
being associated with LQTS and gain-of-function mutation
being the cause of SQTS.
EP investigations have shown that both atrial and ventri-
cular effective refractory periods are shortened in SQTS
and programmed electrical stimulation usually induces ven-
tricular tachyarrhythmias. Whether inducibility of ventricu-
lar arrhythmias is predictive of adverse clinical outcome
remains unclear (Table 10).
The management of patients with SQTS is still poorly
deﬁned.817 In patients with mutation on the KCNH2 gene,
it has been suggested that quidinidine may be effective in
suppressing inducibility at programmed electrical stimu-
lation, but whether this also confers long-term prevention
of cardiac arrest is unknown. For the other genetic forms
of SQTS, the efﬁcacy of quinidine is less clear and the use
of the ICD may be considered, even if it may be associated
with an increased risk of inappropriate shocks due to
T-wave oversensing.817
11.1.2.1. Genetic analysis. Genetic analysis may help ident-
ify silent carriers of SQTS-related mutations; however, the
risk of cardiac events in genetically affected individuals
with a normal ECG is currently not known. Similarly, given
the limited number of patients with SQTS so far identiﬁed,
at present, genetic analysis does not contribute to risk
stratiﬁcation.
11.1.3. Brugada syndrome
Recommendations
Class I
An ICD is indicated for Brugada syndrome patients with
previous cardiac arrest receiving chronic optimal
medical therapy and who have reasonable expectation
of survival with a good functional status for more than
1 y. (Level of Evidence: C)
Class IIa
(1) An ICD is reasonable for Brugada syndrome patients with
spontaneous ST-segment elevation in V1, V2, or V3 who
have had syncope with or without mutations demon-
strated in the SCN5A gene and who have reasonable
expectation of survival with a good functional status
for more than 1 y. (Level of Evidence: C)
(2) Clinical monitoring for the development of a spon-
taneous ST-segment elevation pattern is reasonable for
the management of patients with ST-segment elevation
induced only with provocative pharmacological chal-
lenge with or without symptoms. (Level of Evidence: C)
(3) An ICD is reasonable for Brugada syndrome patients with
documented VT that has not resulted in cardiac arrest
and who have reasonable expectation of survival with
a good functional status for more than 1 y. (Level of
Evidence: C)
(4) Isoproterenol can be useful to treat an electrical storm
in the Brugada syndrome. (Level of Evidence: C)
Class IIb
(1) EP testing may be considered for risk stratiﬁcation in
asymptomatic Brugada syndrome patients with spon-
taneous ST elevation with or without a mutation in the
SCN5A gene. (Level of Evidence: C)
(2) Quinidine might be reasonable for the treatment of
electrical storm in patients with Brugada syndrome.
(Level of Evidence: C)
11.1.3.1. Causes and risk factors. The Brugada syndrome is
associated with a characteristically abnormal ECG and a high
risk of SCD in individuals with a structurally normal heart.818
The Brugada pattern ECG shows J-point segment elevation in
leads V1 to V3 and RBBB in some patients; the ECG pattern
can be present always or intermittently. Occasionally,
J-point elevation has been reported in other (e.g., inferior)
leads. The disease is transmitted with an autosomal domi-
nant pattern of inheritance. The clinical expression of the
phenotype is modiﬁed by gender as 90% of the affected
individuals with a diagnostic ECG are male. Only 1 Brugada
syndrome disease gene has been identiﬁed so far, the
cardiac sodium channel gene (SCN5A);819 non-SCN5A loci
have also been reported but the disease gene(s) at these
loci remain to be identiﬁed. Cardiac events (syncope or
cardiac arrest) occur predominantly in males in the third
and fourth decades of life, although presentation
with cardiac arrest in neonates or children have been
reported.104,777,820 Fever is a predisposing factor for
cardiac arrest in the Brugada syndrome.800,818,821–824
11.1.3.2. Risk stratiﬁcation. Because implantation of an ICD
is the only prophylactic measure able to prevent SCD, risk
stratiﬁcation is of major importance in these patients.
Table 10 Genetic variants of short QT syndrome
Locus
name
Chromosomal
locus
Inheritance Gene
symbol
Protein Reference
SQTS1 7q3p2135–q36 Autosomal dominant KCNH2 IKr potassium channel alpha subunit (HERG) Brugada et al.
813
SQTS2 11p15.5 Autosomal dominant KCNQ1 IKs potassium channel alpha subunit (KvLQT1) Bellocq et al.
814
SQTS3 17q23.1–q24.2 Autosomal dominant KCNJ2 IK1 potassium channel (Kir2.1) Priori et al.
815
796 ACC/AHA/ESC Guidelines
Downloaded from https://academic.oup.com/europace/article-abstract/8/9/746/534498
by guest
on 02 April 2018
11.1.3.3. Family history. As with LQTS, there are no data
showing that family history predicts cardiac events among
family members. Therefore, it should not be assumed
that asymptomatic individuals with the characteristic
ECG but without family history are at low risk or that
family members of an individual with SCD are at
increased risk.104
11.1.3.4. Electrocardiography. ST-segment elevation can
occur spontaneously or be exposed by administration of
sodium channel blockers such as ﬂecainide, procainamide,
or ajmaline.825 There is agreement that patients with a
spontaneous pattern have a worse prognosis than individuals
in whom the typical ECG is observed only after pharmaco-
logical drug challenge.104,777
11.1.3.5. Clinical symptoms. Patients with history of
syncope and the ECG pattern of spontaneous ST-segment
elevation have a 6-fold higher risk of cardiac arrest than
patients without syncope and the spontaneous ECG
pattern.104
11.1.3.6. Electrophysiological testing. The role of EP
testing for risk stratiﬁcation is debated. Brugada
et al.206,207 suggested that EP testing has a pivotal role in
risk stratiﬁcation: in their large study, EP testing had a low
positive predictive value (23%), but over a 3-y follow-up,
it had a very high negative predictive value (93%). By con-
trast, Priori et al.104,826 reported that EP testing has a low
accuracy in predicting individuals who will experience
cardiac arrest. Priori et al.104,208 proposed that noninvasive
risk stratiﬁcation based on the ECG and symptoms provides
an accurate alternative for risk stratiﬁcation.
11.1.3.7. Genetic defect. Because only a single gene has
been linked to the Brugada syndrome, there is still insufﬁ-
cient information about the contribution of genetic
defects in predicting clinical outcome. Mutations in the
SCN5A gene do not identify a subset of patients at higher
risk of cardiac events.104
11.1.3.8. Ventricular arrhythmias. SCD is caused by rapid
polymorphic VT or VF frequently occurring at rest or
during sleep. Patients with Brugada syndrome usually do
not have ventricular extrasystoles or nonsustained runs
of VT at Holter recording. Therefore, the therapeutic
approach for these patients is centered on the preven-
tion of cardiac arrest. Basic science studies and clinical
studies suggest a role for block of the transient outward
potassium current by quinidine in reducing arrhythmia
frequency.827,828 Quinidine and isoproterenol may be
useful in patients with arrhythmia storm even in the
presence of an ICD.139,395,829
11.1.3.9. Genetic analysis. Genetic analysis may help
identify silent carriers of Brugada syndrome-related
mutations so that they can remain under clinical monitoring
to detect early manifestations of the syndrome.
Furthermore, once identiﬁed, silent mutation carriers
should receive genetic counseling and discussion of the
risk of transmitting the disease to offspring. Based on
current knowledge, genetic analysis does not contribute to
risk stratiﬁcation.
11.1.4. Catecholaminergic polymorphic ventricular
tachycardia
Recommendations
Class I
(1) Beta blockers are indicated for patients who are
clinically diagnosed with CPVT on the basis of the pre-
sence of spontaneous or documented stress-induced
ventricular arrhythmias. (Level of Evidence: C)
(2) Implantation of an ICD with use of beta blockers is indi-
cated for patients with CPVT who are survivors of
cardiac arrest and who have reasonable expectation of
survival with a good functional status for more than
1 y. (Level of Evidence: C)
Class IIa
(1) Beta blockers can be effective in patients without clini-
cal manifestations when the diagnosis of CPVT is estab-
lished during childhood based on genetic analysis. (Level
of Evidence: C)
(2) Implantation of an ICD with the use of beta blockers can
be effective for affected patients with CPVT with
syncope and/or documented sustained VT while receiv-
ing beta blockers and who have reasonable expectation
of survival with a good functional status for more than
1 y. (Level of Evidence: C)
Class IIb
Beta blockers may be considered for patients with CPVT
who were genetically diagnosed in adulthood and never
manifested clinical symptoms of tachyarrhythmias.
(Level of Evidence: C)
11.1.4.1. Causes and risk factors. CPVT is characterized by
ventricular tachyarrhythmias that develop during physical
activity or acute emotion in the presence of an unremark-
able resting ECG.778 The ﬁrst episodes often manifest
during childhood, although late-onset cases have been
described.830
The disease can be transmitted as an autosomal dominant
as well as an autosomal recessive trait. Half of the
autosomal dominant cases are caused by mutations in the
gene encoding the cardiac ryanodine receptor (RyR2),
responsible for calcium release from the stores of the
sarcoplasmic reticulum.831,832 The recessive form is
caused by mutations in the gene encoding calsequestrin
(CASQ2), a calcium-buffering protein in the sarcoplasmic
reticulum.833
11.1.4.2. Risk stratiﬁcation. Too few patients with CPVT
have been reported to allow the deﬁnition of a risk stratiﬁ-
cation scheme. Beta blockers appear to be effective.
Patients who have had an episode of VF are considered at
higher risk and are usually implanted with an ICD along
with beta-blocker therapy. The recurrence of sustained VT
or of hemodynamically nontolerated VT while receiving
beta blockers is usually considered a marker of higher risk
and an ICD is often recommended in these patients. EP
testing is not useful for management and risk stratiﬁcation
because CPVT patients are usually not inducible.105,778
11.1.4.3. Ventricular arrhythmias. Supraventricular and
ventricular arrhythmias are usually reproducibly induced
by exercise stress when the heart rate reaches a threshold
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of 120 to 130 beats per minute. Isolated PVCs usually
develop ﬁrst and are followed shortly after by short runs
of NSVT. If the patient continues to exercise, the duration
of VT runs progressively increase and VT may become sus-
tained. A beat-to-beat alternating QRS axis that rotates by
1808, ‘bidirectional VT,’ is the typical pattern of
CPVT-related arrhythmias. CPVT patients can also present
with irregular polymorphic VT or VF.105,778
Beta blockers prevent recurrences of syncope in the
majority of patients,105,778 even if VT and SVT usually can
still be elicited during exercise stress test. If syncope
occurs in a patient taking a beta blocker, the implantation
of an ICD is recommended.105 However, ICD therapy requires
careful programming of the device to prevent needless
therapy for nonsustained episodes of ventricular
tachyarrhythmia.
11.1.4.4. Genetic analysis. Genetic analysis may help
identify silent carriers of catecholaminergic VT-related
mutations; once identiﬁed silent carriers may be treated
with beta blockers to reduce the risk of cardiac events and
may receive appropriate genetic counseling to assess the
risk of transmitting the disease to offspring. Based on
current knowledge, genetic analysis does not contribute to
risk stratiﬁcation.
12. Arrhythmias in structurally normal hearts
12.1. Idiopathic ventricular tachycardia
Recommendations
Class I
Catheter ablation is useful in patients with structurally
normal hearts with symptomatic, drug-refractory VT
arising from the RV or LV or in those who are drug
intolerant or who do not desire long-term drug
therapy. (Level of Evidence: C)
Class IIa
(1) EP testing is reasonable for diagnostic evaluation in
patients with structurally normal hearts with palpitations
or suspected outﬂow tract VT. (Level of Evidence: B)
(2) Drug therapy with beta blockers and/or calcium channel
blockers (and/or IC agents in RVOT VT) can be useful in
patients with structurally normal hearts with sympto-
matic VT arising from the RV. (Level of Evidence: C)
(3) ICD implantation can be effective therapy for the ter-
mination of sustained VT in patients with normal or
near normal ventricular function and no structural
heart disease who are receiving chronic optimal
medical therapy and who have reasonable expectation
of survival for more than 1 y. (Level of Evidence: C)
12.1.1. Demographics and presentation of outﬂow
tract ventricular tachycardia
VT arising from the RV is the most common form of VT in
apparently healthy people and is associated with a good
prognosis in those without overt structural heart
disease.291,294,297,377,834–844 This VTusually has a left bundle-
branch, inferior-axis morphology. It often presents as nonis-
chemic exercise-induced and/or repetitive monomorphic
VT. Symptoms tend to be mild and syncope is rare.722 Left
ventricular outﬂow tract (LVOT) VT can arise in the
absence of overt structural abnormalities and accounts for
a small percentage of the overall cases of VT. The
ECG recorded during sinus rhythm in patients with
RVOT tachycardia helps distinguish it from the more
serious condition of RV dysplasia where the ECG is
more often abnormal.722 RVOT has long been thought to
be idiopathic in nature, but this characterization has
relied on conventional imaging and diagnostic techniques
such as stress testing, echocardiography, and coronary
angiography.297,834,835,843,845–847 More recently, MRI has
been applied to the evaluation of patients with VT arising
from the RV in the absence of deﬁned abnormalities on con-
ventional testing particularly to exclude ARVC.210,262 LVOT
VT can be classiﬁed by site of origin to either an endocardial
origin; coronary cusp origin; or epicardial origin.232 VT
arising from the LVOT and from the LV septum typically pre-
sents in the third to ﬁfth decades of life.694 LVOT VT is more
common in men than in women. This VT may be incessant
and may be provoked by exercise.
12.1.2. Mechanisms
Several EP mechanisms have been associated with RVOT VT,
including abnormal automaticity and triggered activity. The
most common form of RVOT VT is related to triggered
activity arising from delayed afterdepolarizations and is
thought to be dependent on intracellular calcium overload
and cyclic adenosine monophosphate.377,840,841 RVOT VT is
frequently adenosine sensitive, may terminate with vagal
maneuvers, and is facilitated by catecholamines. As such,
it is often not easily inducible at baseline EP testing and
may require rapid burst pacing or stimulation by
isoproterenol.210,722 LV VT arising from the outﬂow tract
may be reentrant but can also result from enhanced auto-
maticity. Incessant LV VT has been related to a triggered
mechanism associated with delayed afterdepolariza-
tions.4,694 Idiopathic LV tachycardia can be verapamil sensi-
tive, adenosine sensitive, and propranolol sensitive.697–702
12.1.3. Electrophysiological testing
EP is motivated by the need to establish precise diagnosis to
guide curative catheter ablation.209,210 Outﬂow tract VT in
the absence of concomitant cardiac disease does not carry
an adverse prognosis, although syncope can occur.848 The
prognostic value of inducibility of ventricular arrhythmias
has not been systematically evaluated. Inducibility of 80%
has been reported in 35 patients with RVOT when EP
testing was performed with up to 3 extrastimuli and isopro-
terenol infusion if required.300 In another study, a rate of
induction of only 3% was observed, but this increased to
by 80% with isoproterenol infusion alone.210 Induction with
burst pacing has also been useful.297
VTs arising from the LVOT or aortic cusps have been
described. These appear to be mechanistically and prognos-
tically similar to RVOT VT. Induction of LVOT VT by EP testing
is not consistent, although the arrhythmia may be provoked.
It can be provoked during isoproterenol infusion.378
12.1.4. Management
Clinical treatment of RVOT or LVOT VT often involves beta
and calcium channel blockers. Type IC antiarrhythmic drugs
have been found to be useful in RVOT VT.297,837,849–852 In
patients who remain symptomatic or for whom drug
therapy fails, catheter ablation of the arrhythmia focus in
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the RVOTshould be considered. Acute success rates for RVOT
ablation have been reported in excess of 90%.210,722
However, long-term success varies and may depend on the
degree or presence of other abnormalities.
12.1.5. Demographics and presentation of other
idiopathic left ventricular tachycardias
So-called idiopathic LV VT can arise from the LVOT or from
the fascicles of the specialized conduction system.
Fascicular VT can be classiﬁed into 3 types according to
origin and QRS morphology during VT. Left posterior fascicu-
lar VT typically has an RBBB and superior axis morphology
and is the more common form of fascicular VT. VT arising
from the left anterior fascicle has an RBBB and right-axis
deviation conﬁguration and is less common. Rarely, fascicu-
lar VT will arise from fascicular location high in the septum
and has a narrow QRS and normal axis conﬁguration. This
VT presents in the third to ﬁfth decades of life695 and is
equally distributed between the sexes.
12.1.6. Mechanisms and treatment
Left fascicular VT typically is reentrant and may respond to
beta or calcium channel blockers. However, in patients who
do not tolerate medical treatment or for whom medical
treatment has failed, ablation can be considered. Ablation
of posterior fascicular VT is guided by recording made
either during sinus rhythm or in VT demonstrating a discrete
potential preceding the earliest ventricular electro-
gram.703,704,709,853 Newer 3-dimensional mapping devices
that do not require the presence of sustained VT can facili-
tate ablation in these patients.710
12.2. Electrolyte disturbances
Recommendations
Class I
Potassium (and magnesium) salts are useful in treating
ventricular arrhythmias secondary to hypokalemia (or
hypomagnesmia) resulting from diuretic use in patients
with structurally normal hearts. (Level of Evidence: B)
Class IIa
(1) It is reasonable to maintain serum potassium levels
above 4.0 mM/L in any patient with documented life-
threatening ventricular arrhythmias and a structurally
normal heart. (Level of Evidence: C)
(2) It is reasonable to maintain serum potassium levels above
4.0 mM/L in patients with acute MI. (Level of Evidence: B)
(3) Magnesium salts can be beneﬁcial in the management of
VT secondary to digoxin toxicity in patients with structu-
rally normal hearts. (Level of Evidence: B)
Although changes in extracellular potassium, extracellular
and intracellular magnesium (especially with associated
hypokalemia), and intracellular calcium are all associated
with EP changes that are arrhythmogenic, life-threatening
ventricular arrhythmias in patients with structural heart
disease should not be attributed solely to changes in these
ionic concentrations. Changes in potassium concentration
may occur after cardiac arrest or may accompany certain
disease states such as periodic paralysis.
A rapid rise in extracellular potassium, hypokalemia (less
than 3.5 mM), and hypomagnesemia are all associated with
ventricular arrhythmias and SCD in patients with structurally
normal hearts (some of whom may have underlying channe-
lopathies) and in an AMI setting.591,854–867 Hypomagnesemia
is classically associated with polymorphic VT or torsades de
pointes, which together with ventricular arrhythmias in an
AMI setting may respond to intravenous magnesium.868–871
Hypokalemia with or without hypomagnesemia may be
responsible for ventricular arrhythmias in subjects with
hypertension and congestive cardiac failure (precipitated
by the use of thiazide and loop diuretics),855,856,872 acute
starvation,873 acute alcohol toxicity/withdrawal, and those
with ventricular arrhythmias associated with digoxin
and other Vaughan Williams class 1 antiarrhythmic
drugs.865,874,875 Signiﬁcant hypocalcemia can prolong the
QT interval.
Changes in the extracellular ionic concentrations of
calcium required to produce EP changes that may contribute
to ventricular arrhythmias are not encountered in clinical
practice. Occasionally, hyperparathyroidism can cause
important elevations in serum calcium concentrations.
Intracellular ﬂuctuations in calcium concentration inﬂu-
enced by drugs (e.g., digitalis glycosides), exercise (e.g.,
catecholamines), and reperfusion following myocardial
ischemia, however, can trigger EP changes that may lead
to life-threatening arrhythmias. The protective effects of
beta blockade in the latter settings may in part be due to
the inhibition of calcium inﬂux into myocytes.
12.3. Physical and toxic agents
12.3.1. Alcohol
Recommendations
Class I
(1) Complete abstinence from alcohol is recommended in
cases where there is a suspected correlation between
alcohol intake and ventricular arrhythmias. (Level of
Evidence: C)
(2) Persistent life-threatening ventricular arrhythmias
despite abstinence from alcohol should be treated in
the same manner that such arrhythmias are treated in
patients with other diseases, including an ICD, as
required, in patients receiving chronic optimal medical
therapy and who have reasonable expectation of survi-
val for more than 1 y. (Level of Evidence: C)
The relationship between alcohol ingestion and VT/SCD is
indisputable; what is controversial however, is its exact
nature.876 A number of studies claim a J-shaped relationship
with risk lowest in individuals with low alcohol intake (i.e., 2
to 6 drinks per week) compared with those who rarely or
never consume alcohol877 and those with a high alcohol
intake (i.e., more than 3 to 5 drinks per day)878,879 and
binge drinking habits, the ‘holiday heart syndrome’.880–883
The reason for this relationship is probably the protective
effects of low to moderate alcohol consumption on the
risk of CHD.884 This is contested by a meta-analysis where
lower protective and harmful effects were found in
women, in men living in countries outside the
Mediterranean area, and in studies where fatal events
were used as the outcome. Furthermore, unlike low-risk
patients without CHD, in middle-aged men with established
CHD, low to moderate alcohol intake (1 to 14 units per
week) was not associated with any signiﬁcant beneﬁt.885
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Alcohol ingestion may therefore reduce the incidence of
VT/SCD due to coronary events, but its effect on
life-threatening arrhythmias correlates directly with the
amount and duration of alcohol intake and even small
quantities may be signiﬁcant in susceptible individuals.
The mechanisms associated with alcohol-induced VT/SCD
are complex and not entirely related to the presence of
alcohol-induced cardiomyopathy. Alcohol has a negative ino-
tropic effect mediated by direct interaction with cardiac
muscle cells, although this action is often masked by the
indirect actions from enhanced release of catechol-
amines.886 EP studies have shown alcohol to induce various
arrhythmias including VT in patients with and without cardi-
omyopathy.887,888 LVH and remodeling is an early response to
heavy drinking;889 one third of alcoholics demonstrate dias-
tolic dysfunction correlating with consumption890 and 20% to
26% develop DCM within 5 y.891 In these patients, myocyte
and nuclear hypertrophy, interstitial ﬁbrosis, and myocyte
necrosis provide the substrate for arrhythmogenesis.892
QTc is prolonged in patients with proved alcoholic liver
disease in the absence of electrolyte disturbances and may
act as the trigger to life-threatening arrhythmias.893
12.3.2. Smoking
Recommendations
Class I
Smoking should be strongly discouraged in all patients
with suspected or documented ventricular arrhythmias
and/or aborted SCD. (Level of Evidence: B)
Cigarette smoking is an independent risk factor for SCD
regardless of underlying CHD.58,894–897 The vast majority of
these deaths are arrhythmic. In females who smoke 25 or
more cigarettes per day, the risk of ventricular arrhythmia
and SCD is increased 4-fold, similar to that conferred by a
history of MI.62 It is a long-term risk factor898 and continues
to be so in survivors of out-of-hospital cardiac arrest who fail
to give up smoking.74 Cessation of smoking signiﬁcantly
reduces risk of SCD. There are no data available to allow
identiﬁcation of individuals at greatest risk.
12.3.3. Lipids
Recommendations
Class I
Statin therapy is beneﬁcial in patients with CHD to
reduce the risk of vascular events, possibly ventricular
arrhythmias, and SCD. (Level of Evidence: A)
Class IIb
n-3 polyunsaturated fatty acid supplementation may be
considered for patients with ventricular arrhythmias and
underlying CHD. (Level of Evidence: B)
The association of high total, very low-density lipoprotein
(VLDL), or low-density lipoprotein (LDL) cholesterol levels, a
low HDL cholesterol level together with high triglyceride
and apolipoprotein B levels with increased risk of VT/SCD
is almost entirely due to concurrent CHD. Appropriate lipid
management strategies, especially the use of statins,
reduces the risk of SCD by preventing recurrent fatal MI
and ventricular arrhythmia.899–901 The effect of lipid lower-
ing on SCD in primary prevention has not been addressed,
but a relative risk reduction of 30% to 40% would be
expected in parallel with the reduction in the risk of CHD
death.902,903
Free fatty acid or nonesteriﬁed fatty acid levels are also
an independent risk factors for SCD but not fatal MI.94
However, the widely held belief from clinical studies that
dietary n-3 PUFA may confer protection from arrhythmic
death in subjects with and without documented underlying
CHD,904,905 in patients who have manifest previously,904–911
has been challenged by a small multicenter, double-blinded,
randomized, placebo-controlled trial of n-3 PUFA in 200
patients with ICD and a recent episode of ventricular
arrhythmia.262 This study showed a trend toward a higher
incidence of VT/VF in patients randomized to ﬁsh oil, a
trend that correlated with n-3 PUFA levels. An actuarial
analysis of time to recurrent events showed signiﬁcantly
more events in patients randomized to ﬁsh oil.
13. Ventricular arrhythmias and sudden
cardiac death related to speciﬁc populations
13.1. Athletes
Recommendations
Class I
(1) Preparticipation history and physical examination,
including family history of premature or SCD and speciﬁc
evidence of cardiovascular diseases such as cardiomyo-
pathies and ion channel abnormalities, is recommended
in athletes. (Level of Evidence: C)
(2) Athletes presenting with rhythm disorders, structural
heart disease, or other signs or symptoms suspicious
for cardiovascular disorders should be evaluated as any
other patient but with recognition of the potential
uniqueness of their activity. (Level of Evidence: C)
(3) Athletes presenting with syncope should be carefully
evaluated to uncover underlying cardiovascular disease
or rhythm disorder. (Level of Evidence: B)
(4) Athletes with serious symptoms should cease compe-
tition while cardiovascular abnormalities are being
fully evaluated. (Level of Evidence: C)
Class IIb
Twelve-lead ECG and possibly echocardiography may be
considered as preparticipation screening for heart dis-
orders in athletes. (Level of Evidence: B)
It is generally accepted that preparticipation screening
for medical conditions should be a requirement for clear-
ance to participate in competitive athletics, but there are
no uniformly accepted standards for screening. Because
the risk of SCD among athletes appears to exceed the risk
in comparably aged populations,912 attention to cardiovas-
cular screening is of special importance.
Competitive athletics has been deﬁned as ‘participation
in an organized team or individual sport that requires
regular competition against others as a central component,
that places a high premium on excellence and achievement
and requires some form of systematic training’.913,914
Preparticipation screening of athletes has been discussed
in various conferences, and policy statements,
although802,915,916 the screening programs vary greatly in
different countries. The major causes of SCD in athletes
are HCM (36%), coronary artery anomalies (19%), ARVC,
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and myocarditis. In Italy, the incidence of the former as a
cause of SCD has been reduced considerably due to an ECG
and echocardiographic screening program.917
13.1.1. Screening and management
13.1.1.1. Screening. Preparticipation cardiovascular
screening focuses in general on a young population group
(aged less than 30 y), among whom most anomalies will be
congenital, although some might be acquired dis-
orders.680,915,918 The multiple mechanisms and diseases
involved in sudden death in young athletes have been
reviewed.919 Drug intake may have an important effect on
the cardiovascular system and may lead to coronary
artery spasm (cocaine), modiﬁcation of repolarization by
drugs in susceptible individuals (i.e., antibiotics, anti-
arrhythmics, antidepressant agents), and blunted heart
rate response during exercise (beta blockers).920 Special
consideration is required in athletes who are middle-aged
and older.914
Screening of athletes is a difﬁcult task. The low incidence
of anomalies makes screening not very cost effective,
although one study has suggested that ECG screening is
more cost effective than echocardiographic screening.921,922
Routine physical examination might not reveal clinically sig-
niﬁcant anomalies, and personal or family histories have
limited value. The resting ECG can disclose rhythm disturb-
ances, abnormal repolarization syndromes such as the LQTS,
the Brugada syndrome, the WPW syndrome, and the
depolarization and repolarization abnormalities associated
with HCM. However, nonspeciﬁc variations commonly
observed on ECGs recorded from adolescents and young ath-
letes may be confounding. Echocardiography may show
structural anomalies but will not disclose anomalies of the
coronary arteries.
Nonetheless, it is recommended that all candidates
undergo screening tests, such as ECG and, when appropri-
ate, echocardiography (e.g., abnormal ECG, family
history), beyond the history and physical examination. The
impact of additional screening requires further clariﬁcation;
the ﬁnancial burden for subsequent investigation in case of
suspected anomalies might be considerable.
13.1.1.2. Management of arrhythmias, cardiac arrest, and
syncope in athletes. In athletes, risk factors might be aggra-
vated or attenuated but not abolished by regular physical
activity. For legal and ethical reasons, athletes receiving
cardiovascular drugs and devices such as pacemakers and
ICDs are generally not allowed to participate in high-grade
competition. Exceptions, such as beta adrenergic-blocking
agents, depend on legal and regulatory guidelines.
According to the World Anti-Doping Code established by
the World Anti-Doping Agency (WADA), one of the bodies
of the International Olympic Committee and accepted by
all international sports federations, beta blockers and
diuretics are prohibited in some particular sports. The list
of particular sports can be found on the WADA World Wide
Web site at www.wada-ama.org and is available as a down-
loadable ﬁle.923
Athletes presenting with syncope or presyncope should
not participate in competitive sports until the cause is
determined to be both benign and treatable. Increase of
PVCs during exercise requires careful evaluation. They
might be caused by structural anomalies, including coronary
artery anomalies, abnormal origin of coronary artery, mitral
valve prolapse, ARVC, and HCM or DCM. Endurance training
is commonly accompanied by sinus bradycardia, junctional
rhythm, and Wenckebach AV conduction on ECG. These are
generally adaptive responses in apparently normal individ-
uals. The distinction between adaptive LV chamber enlarge-
ment and a mild form of cardiomyopathy might be difﬁcult.
Athletes with nonsustained and asymptomatic
exercise-induced ventricular arrhythmias may participate
in low-intensity competitive sports provided that no struc-
tural heart disease has been demonstrated.924
Recommendations for disqualiﬁcation from high-intensity
sports have been stated in an advisory paper914 and a
Bethesda Conference.682,802
Athletes presenting with rhythm disorders, cardiac
anomalies, or syncope should be treated as any other
patients. One must keep in mind that high-grade physical
activity may aggravate the anomaly.
13.2. Gender and pregnancy
Recommendations
Class I
(1) Pregnant women developing hemodynamically unstable
VT or VF should be electrically cardioverted or deﬁbril-
lated. (Level of Evidence: B) (See Section 7.)
(2) In pregnant women with the LQTS who have had symp-
toms, it is beneﬁcial to continue beta-blocker medi-
cations throughout pregnancy and afterward, unless
there are deﬁnite contraindications. (Level of Evidence: C)
13.2.1. QT Interval
Typically, women have longer QT intervals than do men, and
this difference is more pronounced at slower heart rates.
The corrected QT interval in males decreases at puberty
and then gradually increases as androgen levels fall. By
age 50, gender differences in QT intervals have largely
equalized.925 A similar shortening of the QT interval at
puberty has been noted in males genotypically character-
ized with LQTSs.926 These observations strongly support a
hormonal effect on QT and hence arrhythmia susceptibility.
In women with the congenital LQTS, the risk of cardiac
arrest is greater during the postpartum period compared
with before or during pregnancy.795 The relative tachycardia
seen during pregnancy may serve to shorten the QT interval
and be protective. Beta blockers have a major beneﬁt
during the postpartum period when the heart rate naturally
falls. Beta blockers can generally be used safely during preg-
nancy. Most are excreted in breast milk. Use during preg-
nancy is generally well tolerated by both the mother and
the fetus, although a decrease in fetal heart rate can be
seen. Several studies have demonstrated an increased sus-
ceptibility in women to torsades de pointes, likely related
to the longer baseline QT interval and perhaps to differences
in drug pharmacodynamics.927 The incidence of both conge-
nital and acquired forms of long QT intervals and resultant
torsades de pointes is higher in women than in men.776,928
In the Long QT Registry, 70% of the subjects and 58% of
affected family members are women.929 Until puberty,
males in the registry were found to be more likely than
females to have cardiac arrests or syncope, but sub-
sequently, the incidence of these potentially fatal events
predominated in females.926 Several studies have shown
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that drug-induced torsades de pointes is more common in
women than in men.930–933 ICD therapy should be strongly
considered in patients with long-term QT syndromes who
are drug resistant and those with marked potential for life-
threatening arrhythmias.1
13.2.2. Pregnancy and postpartum
Recommendations on management of cardiovascular dis-
eases during pregnancy, including ventricular arrhythmias,
have been summarized elsewhere.934 Palpitations are extre-
mely common during pregnancy, and several studies have
shown an increase in the symptoms of SVT during preg-
nancy.935–937 While most palpitations are benign during
pregnancy, new-onset VT is of concern.938,939 Although the
presence of structural heart disease should be sought in
these women, often VToccurs in the absence of overt struc-
tural heart disease and may be related to elevated catechol-
amines.938 As such, these arrhythmias may be beta blocker
sensitive. In women presenting with new-onset VT during
the last 6 wk of pregnancy or in the early postpartum
period, the possibility of postpartum cardiomyopathy
should be ruled out.940 In women with non-long QT-related
sustained VT during pregnancy, antiarrhythmic therapy
may be indicated with intravenous lidocaine acutely or pro-
cainamide long term. Amiodarone can have deleterious
effects on the fetus, including hypothyroidism, growth
retardation, and premature birth. Prophylactic therapy
with a cardioselective beta blocker may be effective.
Sotalol can be considered if beta-blocker therapy is ineffec-
tive.941 For women with known structural heart disease,
pregnancy may present signiﬁcant risk. Pulmonary edema,
stroke, or cardiac death can occur in up to 13% of such preg-
nancies.942 Independent predictors of risk in women with
heart disease include prior history of arrhythmias, cyanosis,
poor functional class, LV systolic dysfunction, and LV outﬂow
obstruction.942 Potentially life-threatening ventricular
tachyarrhythmias should be terminated by electrical cardio-
version. Beta 1-selective beta blockers alone, amiodarone
alone (noting cautions about birth defects above), or in
combination may be used, and ICD may be needed as its pre-
sence does not contraindicate future pregnancies.
13.2.3. Special concerns regarding speciﬁc arrhythmias
WPW syndrome and orthodromic AV reciprocating tachycar-
dia are more common in men than in women.943,944 In
addition, in patients with WPW syndrome manifest pathways
are more common in men. Conversely, antidromic AV ventri-
cular reciprocating tachycardia is more common in women
than in men. However, AF degenerating to VF is more
common in men than in women.100 For symptomatic WPW
syndrome, the treatment of choice is RF ablation. The out-
comes are similar in both sexes.945–947 Management of symp-
tomatic WPW during pregnancy may require initiation of
antiarrhythmic drugs to block the accessory pathway and,
in some, long-term monitoring.
The incidence of SCD at any age is greater in men than in
women.948 In part, this may be related to the more common
occurrence of coronary disease in men. However, even
matched cohorts without CHD show a male preponderance.
Classic predictors such as obesity, LVH, hyperlipidemia, and
tobacco use are associated with CHD and VT more in men
than in women.898 For women, hyperglycemia, elevated
hematocrit, and decreased vital capacity are more important
predictors for CHD and VT.898 The impact of diabetes is seen
in both sexes but is much more pronounced in women. While
NSVT and PVCs have been associated with increased risk of
sudden death in men with or without CHD, no such associ-
ation has been seen in women.898 Similarly, while PVCs
post-MI in men have been associated with increased mor-
tality, this does not hold true for women.949
13.3. Elderly patients
Recommendations
Class I
(1) Elderly patients with ventricular arrhythmias should
generally be treated in the same manner as younger
individuals. (Level of Evidence: A)
(2) The dosing and titration schedule of antiarrhythmic
drugs prescribed to elderly patients should be adjusted
to the altered pharmacokinetics of such patients.
(Level of Evidence: C)
Class III
Elderly patients with projected life expectancy less than
1 y due to major comorbidities should not receive ICD
therapy. (Level of Evidence: C)
13.3.1. Epidemiology
Ventricular arrhythmias are common in elderly populations,
and the incidence increases in the presence of structural
heart disease.404,950–952 It must be noted that the elderly
are a heterogeneous group. In different studies, elderly
patients are deﬁned anywhere from greater than 60 y to
greater than 85 y of age. This lack of uniformity raises con-
cerns regarding the applicability of study results to the
entire elderly population.
Ventricular arrhythmias can be found in 70% to 80% of
persons over the age of 60 y and complex ventricular
ectopy is common in this age group, although many such
persons are often asymptomatic.953–956 Complex ventricular
arrhythmias often presage new major coronary events and
SCD in patients with CHD and other types of structural
heart disease.957,958 The incidence of SCD increases with
advancing age.959,960 In elderly patients with CHD, the pro-
portion of cardiac deaths that are sudden decreases,36,961
whereas the proportion of ‘out of hospital’ SCD increases
progressively with advancing age.36,414
Although greater than 80% of patients who die suddenly
from cardiac causes have CHD, elderly patients with DCM
and valvular heart disease are also at risk.957,961 SCD has
also been documented in elderly patients with HCM,662
ARVC,962 and surgically repaired tetralogy of Fallot,963 par-
ticularly in patients with LV dysfunction. Brugada syndrome
and congenital LQTS are uncommon causes of SCD in elderly
patients.929,964
In the peri-infarction period, cardiac arrest (used as SCD
surrogate) is more common in elderly patients. Data from
the Second National Registry of Myocardial Infarction
(NRMI-2) indicate that age greater than 75 y was associated
with a higher likelihood of in-hospital cardiac arrest with an
odds ratio of 1.6 (CI 1.5 to 1.7).965
13.3.2. Pharmacological therapy
The management of ventricular arrhythmias and the preven-
tion of SCD in elderly patients do not differ appreciably from
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those recommended for the general population. However,
when prescribing antiarrhythmic drugs to elderly patients,
one must take into account the physiological changes that
occur with advancing age and adjust drug regimens accord-
ingly. Such changes include decreased renal and hepatic
clearance and altered volume of distribution of pharmaco-
logical agents. Additionally, changes in body composition
and the presence of comorbidities must be considered.
Therefore, drug therapy should be initiated at lower than
the usual dose and titration of the drug should take place
at longer intervals and smaller doses.
The empiric use of most antiarrhythmic drugs to treat
NSVT and other complex ventricular ectopy has been
shown to be ineffective in preventing SCD and is even dele-
terious under certain circumstances.966–970 Advanced age
has been found to increase the susceptibility to adverse
cardiac events from class IC antiarrhythmic drugs.969
Amiodarone is the only antiarrhythmic drug shown to
improve prognosis in survivors of cardiac arrest, based on
a meta-analysis of 15 randomized trials971 (see Section
6.3.1 for further discussion).
Amiodarone, however, is a drug associated with numerous
side effects particularly in elderly patients who are prone to
develop side effects and who are commonly on multiple
drugs increasing the risk of drug interactions.404,972
Therefore, when considering amiodarone therapy for the
prevention of SCD in an elderly patient who is receiving mul-
tiple drugs for comorbid conditions, the treating physician
must weigh the potential beneﬁt of such therapy against
its potential side effects and decide whether amiodarone,
device therapy, or no therapy is most appropriate for this
particular patient.
Beta blockers, along with several agents that do not
possess classic antiarrhythmic properties (e.g., ACE inhibi-
tors, angiotensin receptor blockers, statins), have been
shown in many studies to reduce all-cause mortality and
SCD after AMI in all age groups, including the
elderly.110,973–976 In the Beta Blocker Heart Attack trial, sub-
group analysis demonstrated that the greatest beneﬁt of
beta blockers occurred in the group aged 60 to 69 y.973
The combination of beta blockers and amiodarone may
reduce all-cause mortality and SCD to a greater extent
than amiodarone alone,404,405 and in a post-hoc analysis of
the CAST data, patients treated with an antiarrhythmic
drug who were also receiving beta blockers had a lower
SCD rate than those treated only with an antiarrhythmic
drug.977 Beta blockers have also been shown to reduce all-
cause mortality and SCD in patients with severe HF.978,979
In these studies, subgroup analysis showed equivalent
beneﬁt from beta blocker therapy in younger and older
patients.
Despite the demonstrated efﬁcacy in reducing all-cause
mortality and SCD, beta blockers are underused in the
elderly. A retrospective analysis of the use of beta blockers
after MI in patients greater than age 65 y found that only
21% of 3737 patients without contraindications were so
treated. Patients who received these agents had a 43%
lower 2-y mortality than patients not so treated.980
Similarly, a study of clinical practices and sources of thera-
peutic variation found a strong, independent negative
association between age and odds of treatment with beta
blockers after MI.981 These ﬁndings are a matter of great
public health concern.
13.3.3. Device therapy
Several randomized, prospective trials have demonstrated
the efﬁcacy of ICDs in reducing SCD in patients with CHD
at high risk for SCD (primary prevention) and in patients
resuscitated from SCD (secondary prevention) compared
with antiarrhythmic drug therapy.192,266–268,642,643
All of the above-referenced studies included substantial
numbers of patients over the age of 65 y. Subgroup analysis
in AVID and MADIT II trials demonstrated equivalent beneﬁts
from ICD implantation in older and younger patients.266,268
In the Cardiac Arrest Study Hamburg (CASH) study, patients
older than 65 y derived a greater beneﬁt from ICD implan-
tation than younger patients.643 It is therefore appropriate
to infer that the results of these trials are applicable to
elderly patients across the board.
Data comparing the efﬁcacy and complications of ICD
therapy in older and younger patients are sparse. In a retro-
spective study comparing the efﬁcacy of ICD therapy in
patients over age 65 with that of patients under 65,982 no
signiﬁcant difference in surgical morbidity or length of
hospital stay following ICD implantation was noted
between the 2 groups. Furthermore, similar survival rates
were calculated for the 2 groups at 1, 2, and 3 y post-ICD
implantation.
Similarly in an observational study983 of 450 patients who
received either epicardial (46%) or transvenous (54%) ICDs,
the 3-, 5-, and 7-y survival for arrhythmic mortality was
similar for younger and older patients. Perioperative
morbidity was also similar in all patient groups.
Despite these documented beneﬁts of ICD implantation,
many physicians have been hesitant to subject elderly
patients to such interventions and the role of device
therapy in this age group has been controversial. However,
several observational studies have shown that the invasive
approach in managing patients with life-threatening ventri-
cular arrhythmias is equally beneﬁcial in the elderly and in
younger patients.984–986 From 1985 to 1995, the use of
ICDs in older patients grew from 1% to 13%; this was associ-
ated with improved medium-term survival.987
Very elderly patients with multiple comorbidities and
limited life expectancy may not be appropriate candidates
for ICD therapy even if they meet standard criteria. In
such circumstances, the clinical judgment of the primary
treating physician and the desires of the patient and/or
his or her family take precedence over general guideline
recommendations. Nevertheless, there is evidence from a
study988 that octogenarians who die suddenly can be highly
functional even in the month before their death. This infor-
mation supports the concept that SCD often strikes fully
functional elderly patients who could beneﬁt from an ICD
implantation if they meet appropriate criteria.
13.4. Pediatric patients
Recommendations
Class I
(1) An ICD should be implanted in pediatric survivors of a
cardiac arrest when a thorough search for a correctable
cause is negative and the patients are receiving optimal
medical therapy and have reasonable expectation of
survival with a good functional status for more than
1 y. (Level of Evidence: C)
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(2) Hemodynamic and EP evaluation should be performed in
the young patient with symptomatic, sustained VT.
(Level of Evidence: C)
(3) ICD therapy in conjunction with pharmacological
therapy is indicated for high-risk pediatric patients
with a genetic basis (ion channel defects or cardiomyo-
pathy) for either SCD or sustained ventricular arrhyth-
mias. The decision to implant an ICD in a child must
consider the risk of SCD associated with the disease,
the potential equivalent beneﬁt of medical therapy, as
well as risk of device malfunction, infection, or lead
failure and that there is reasonable expectation of survi-
val with a good functional status for more than
1 y. (Level of Evidence: C)
Class IIa
(1) ICD therapy is reasonable for pediatric patients with
spontaneous sustained ventricular arrhythmias associ-
ated with impaired (LVEF of 35% or less) ventricular
function who are receiving chronic optimal medical
therapy and who have reasonable expectation of survi-
val with a good functional status for more than
1 y. (Level of Evidence: B)
(2) Ablation can be useful in pediatric patients with sympto-
matic outﬂow tract or septal VT that is drug resistant,
when the patient is drug intolerant or wishes not to
take drugs. (Level of Evidence: C)
Class III
(1) Pharmacological treatment of isolated PVCs in pediatric
patients is not recommended. (Level of Evidence: C)
(2) Digoxin or verapamil should not be used for treatment of
sustained tachycardia in infants when VT has not been
excluded as a potential diagnosis. (Level of Evidence: C)
(3) Ablation is not indicated in young patients with asymp-
tomatic NSVT and normal ventricular function. (Level
of Evidence: C)
The incidence of SCD due to cardiovascular disease is sig-
niﬁcantly less in pediatric than in adult patients. Current
estimates are that deaths due to cardiovascular disease in
individuals younger than 25 y of age account for less than
1% of all cardiac mortality.36 Due to this low event rate,
population-based epidemiological studies have been
required to deﬁne the incidence of unexpected, sudden
death in pediatric patients. These studies have been rela-
tively consistent, with an event rate between 1.3 and 4
deaths per 100 000 patient years.49,989–991 A deﬁnite or
probable cardiac cause has been estimated in 70% of
young, unexpected sudden death victims.433 This compares
with the estimated SCD rate of 100 per 100 000 patient
years in adult patients.992 Given the low incidence of
events, no randomized clinical trials have been performed
to deﬁne either risk stratiﬁcation for SCD in the young or
the role of primary prevention therapies. Therefore, the
level of evidence for most recommendations in young
patients is class C.
Despite these limitations, several groups of young patients
have been identiﬁed who are at an increased risk of SCD
compared with the general population. These include
patients with congenital heart disease, coronary artery
anomalies, cardiomyopathies, and primary arrhythmic diag-
noses such as the LQTSs.993 The risk of SCD and signiﬁcance
of ventricular arrhythmias in these patients are discussed in
the individual sections in this report regarding these topics.
This section discusses ventricular arrhythmias in the general
pediatric population and its signiﬁcance as a risk factor for
SCD.
SCD in pediatric patients with WPW syndrome is uncom-
mon and occurs primarily in patients with prior syncope,
multiple accessory pathways, or short refractory periods.
Therefore, in selected patients, an EP study may be indi-
cated and ablation performed if the patient is symptomatic
or the refractory period of the accessory pathway is equal to
or less than 240 ms.279
Isolated PVCs are common in infants, with 15% of all new-
borns reported as having some ventricular ectopy during
24-h ambulatory ECG monitoring. The prevalence of ventri-
cular ectopy decreases to less than 5% in children but then
increases to 10% by 10 y of age and 25% during late adoles-
cence and early adulthood.994–996 For the vast majority of
young patients with ventricular ectopy, the primary objec-
tive is to exclude any associated functional or structural
heart disease, in which case PVCs may have prognostic sig-
niﬁcance.434,997 Simple ventricular ectopy in the absence
of heart disease has not been demonstrated to have
adverse prognostic signiﬁcance.
Sustained ventricular arrhythmias may also occur in
infants, most commonly, it is an accelerated idioventricular
rhythm. By deﬁnition, this is a ventricular rhythm no more
than 20% faster than the sinus rate and occurring in the
absence of other heart disease.998 This arrhythmia typically
resolves spontaneously during the ﬁrst months of life. This is
in contrast to the rare infant with incessant VT, which may
be due to discrete myocardial tumors or cardiomyopa-
thy.999,1000 VF and SCD have been reported in these
infants, most often following the administration of intrave-
nous digoxin or verapamil for a presumptive diagnosis of
SVT.1001,1002 These ventricular arrhythmias may respond to
antiarrhythmic treatment or be amenable to surgical resec-
tion. Sustained VT in infants may also be caused by hyperka-
lemia or associated with one of the LQTSs, particularly those
forms with AV block or digital syndactyly.790,1003,1004
There is considerable debate regarding the sudden infant
death syndrome (SIDS) and potential role of the LQTS in
causing some of these deaths.1005,1006 However, population-
based studies have demonstrated a 40% decline in the inci-
dence of SIDS associated with avoidance of sleeping in the
prone position, supporting apnea, or impaired respiratory
regulation as the primary cause of SIDS in most cases.1007
Deﬁnition of the cause(s) of SIDS remains an area of
ongoing investigation and includes autonomic dysfunction
and ventricular arrhythmias due to genetic causes.
Beyond the ﬁrst year of life, most children with complex
ectopy or hemodynamically tolerated VT appear to have a
good prognosis.233,1008 The cause of these arrhythmias
remains unknown, and they often spontaneously resolve.
Pharmacological suppression of these ventricular arrhyth-
mias is generally ineffective and may increase the risk of
an adverse outcome.
RVOTand LVOT tachycardia and LV septal tachycardia may
be diagnosed during childhood or adolescence. The criteria
for diagnoses of these speciﬁc arrhythmias are discussed in
Section 12. The general prognosis for these arrhythmias is
mostly benign, with treatment for symptomatic patients
with catheter ablation offering a high rate of cure. As with
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other pediatric arrhythmias, a primary objective is to
exclude any associated cardiovascular disease.
Catecholaminergic or exercise-induced polymorphic VT is
one exception to the benign prognosis for hemodynamically
tolerated VT in patients with an otherwise normal heart.
Although patients with this form of VT may not be overtly
symptomatic, they are at risk for SCD.105 Also, symptomatic
ventricular arrhythmias may be the initial presentation of
cardiomyopathy in young patients.834,1009
The role and beneﬁt of ICD implantation for the preven-
tion of SCD in young children with advanced ventricular dys-
function have not been deﬁned. In older children and
adolescents, prophylactic ICD implantation may be con-
sidered, based on data derived from adult randomized clini-
cal trials of similar patients.8,248
The treatment of potentially life-threatening ventricular
arrhythmias in children is disease speciﬁc (e.g., beta block-
ade for LQTSs, catheter or surgical ablation for focal VTs,
and heart transplantation for end-stage cardiomyopathies).
When indicated, ICDs with transvenous lead systems are
generally feasible in children older than 10 y.1 However,
there is concern regarding the longevity of intravascular
leads when potentially used for decades of life.1010 The
use of ICDs in younger children and those with complex con-
genital heart disease remains challenging and often requires
the use of epicardial or subcutaneous array systems. The
higher incidence of lead failure and ICD infection or
erosion in these patients mandates the judicious use of
these devices in young patients.1011
13.5. Patients with implantable
cardioverter-deﬁbrillators
Recommendations
Class I
(1) Patients with implanted ICDs should receive regular
follow-up and analysis of the device status. (Level of
Evidence: C)
(2) Implanted ICDs should be programmed to obtain optimal
sensitivity and speciﬁcity. (Level of Evidence: C)
(3) Measures should be undertaken to minimize the risk of
inappropriate ICD therapies. (Level of Evidence: C)
(4) Patients with implanted ICDs who present with incessant
VT should be hospitalized for management. (Level of
Evidence: C)
Class IIa
(1) Catheter ablation can be useful for patients with
implanted ICDs who experience incessant or frequently
recurring VT. (Level of Evidence: B)
(2) In patients experiencing inappropriate ICD therapy, EP
evaluation can be useful for diagnostic and therapeutic
purposes. (Level of Evidence: C)
The placement of an ICD does not, in itself, decrease the
incidence of arrhythmias, although the patient is protected
from the consequences of the arrhythmias.
13.5.1. Supraventricular tachyarrhythmias
SVT may trigger ICD action due to fulﬁlling programmed ven-
tricular or SVT detection criteria. The effect of atrial
tachyarrhythmia on ventricular rate response is crucial. As
long as the ventricular rate ﬁts within the tachycardia
detection window, meaningful programming of the detec-
tion algorithms may prevent device action for VT. If ventri-
cular rate falls within the VF detection window,
appropriate therapy should not be withheld (see Section
7.6 for further discussion). Sophisticated algorithms
enhance speciﬁcity of VT therapy and help to avoid VT
therapies based on rate criteria alone.1012–1014 Beta block-
ade is also a valuable therapy that will prevent many
unwanted device interventions due to supraventricular
arrhythmias. Additional investigations such as Holter record-
ings, patient-activated loop recorders, and EP studies might
be required to guide the management of these arrhythmias.
13.5.2. Supraventricular tachycardia in patients with
ventricular implantable cardioverter-deﬁbrillators
Episode analysis relies mainly on the information from the
ventricular lead of the ICD, although in some instances
atrial activity is also sensed (see later).1015 Careful analysis
of detected episodes, the effects of antitachycardia pacing
on the cycle length intervals, and the mode of termination
or acceleration are important for classiﬁcation of the
detected tachycardia. Enhanced discrimination algorithms
help to reduce inappropriate VT therapies based on the
rate criterion alone. AF is the most frequent culprit of
arrhythmia. Rapid ventricular rate during SVTs may
provoke ventricular antitachycardia pacing. Device action
may be proarrhythmic, as inappropriate antitachycardia
pacing may cause VT or VF.1016
13.5.3. Dual-chamber implantable
cardioverter-deﬁbrillators
Dual-chamber ICDs provide improved atrial diagnostic fea-
tures with recording of local atrial electrograms, regularity
of atrial signals, and cycle lengths. This may provide
additional features to avoid inappropriate VT/VF therapies,
but inappropriate ventricular tachyarrhythmia sensing still
occurs in 10% to 15% of cases.1017 Oversensing of far-ﬁeld
signals by the atrial electrodes(s) may prompt inappropriate
therapies for SVTs, such as antitachycardia pacing or auto-
matic cardioversion. In case of programmed internal atrial
cardioversion therapies, even low-energy shocks may be
painful and compromise quality of life.1018 High-rate atrial
antitachycardia pacing may induce (transient) AF. Efﬁcacy
of advanced atrial pacing or cardioversion therapies varies
greatly in function of episode duration, atrial cycle length,
and atrial tachycardia mechanism.1013,1019,1020 Acute
efﬁcacy of atrial antitachycardia pacing may be as high as
40%.1013
13.5.4. Arrhythmia storm in implantable
cardioverter-deﬁbrillator patients
The term arrhythmia storm refers to a situation when
numerous device discharges occur due to recurrent repeti-
tive arrhythmias. A vicious cycle between device action
and cardiac dysfunction may lead to further deterioration.
The management must address all aspects to correct the
situation (see Section 7.6 for further discussion).
13.6. Drug-induced arrhythmias
13.6.1. Introduction
Because the problem of drug-induced arrhythmias is sporadic,
randomized, double-blind clinical trials have, with very few
ACC/AHA/ESC Guidelines 805
Downloaded from https://academic.oup.com/europace/article-abstract/8/9/746/534498
by guest
on 02 April 2018
exceptions, not been performed. Speciﬁc syndromes of
drug-induced arrhythmias, with diverse mechanisms andman-
agement strategies, are described in the sections that follow.
Treatment guidelines focus on avoiding drug treatment in
high-risk patients, recognizing the syndromes of drug-induced
arrhythmia and withdrawal of the offending agent(s). The
efﬁcacy of speciﬁc therapies is often inferred from anecdotal
evidence or preclinical, mechanism-based studies.
High drug concentrations due to overdose or drug inter-
actions generally increase the risk of drug-induced arrhyth-
mias. The largest increases in concentrations occur when a
drug is eliminated by a single pathway and that pathway is sus-
ceptible to inhibition by the administration of a second drug.
Table 11 lists examples of drug interactions that may cause
arrhythmias through this mechanism. Interactions can also
reduce plasma concentrations of antiarrhythmic drugs and
thereby exacerbate the arrhythmia being treated. Additive
pharmacological effects may also result in arrhythmias.
13.6.2. Digitalis toxicity
Recommendations
Class I
An antidigitalis antibody is recommended for patients
who present with sustained ventricular arrhythmias,
advanced AV block, and/or asystole that are considered
due to digitalis toxicity. (Level of Evidence: A)
Class IIa
(1) Patients taking digitalis who present with mild cardiac
toxicity (e.g., isolated ectopic beats only) can be
managed effectively with recognition, continuous moni-
toring of cardiac rhythm, withdrawal of digitalis, restor-
ation of normal electrolyte levels (including serum
potassium greater than 4 mM/L), and oxygenation.
(Level of Evidence: C)
(2) Magnesium or pacing is reasonable for patients who take
digitalis and present with severe toxicity (sustained ven-
tricular arrhythmias, advanced AV block, and/or asys-
tole). (Level of Evidence: C)
Class IIb
Dialysis for the management of hyperkalemia may be
considered for patients who take digitalis and present
with severe toxicity (sustained ventricular arrhythmias;
advanced AV block, and/or asystole). (Level of Evidence: C)
Class III
Management by lidocaine or phenytoin is not recom-
mended for patients taking digitalis and who present with
severe toxicity (sustained ventricular arrhythmias,
advancedAVblock, and/or asystole). (Level of Evidence: C)
13.6.2.1. Clinical presentation. Certain arrhythmias are
typical: enhanced atrial, junctional, or ventricular automa-
ticity (with ectopic beats or tachycardia) often combined
with AV block. Overdose of digitalis causes severe hyperka-
lemia and cardiac standstill. The diagnosis is established
by the combination of characteristic rhythm disturbances,
ancillary symptoms (visual disturbances, nausea, changes
in mentation), and elevated serum concentrations. Contri-
buting factors may include hypothyroidism, hypokalemia,
or renal dysfunction.
13.6.2.2. Speciﬁc management. In mild cases, management
includes discontinuing the drug, monitoring rhythm and
maintaining normal serum potassium. Occasionally, tempor-
ary pacing may be needed. For more severe intoxication
(serum digoxin concentration greater than 4 to 5 ng/mL,
and with serious arrhythmias), the treatment of choice is
digoxin-speciﬁc Fab antibody.1022 In one series of 150
severely intoxicated patients, response was rapid (30 min
to 4 h), and 54% of patients presenting with a cardiac
arrest survived hospitalization. Side effects include worsen-
ing of the underlying disease (increased ventricular rate
during AF, exacerbation of HF) and hypokalemia. Digoxin
concentration monitoring is unreliable after antidigoxin
antibody. There is little role for previously used therapies
such as lidocaine or phenytoin.
13.6.3. Drug-induced long QT syndrome
Recommendations
Class I
In patients with drug-induced LQTS, removal of the
offending agent is indicated. (Level of Evidence: A)
Class IIa
(1) Management with intravenous magnesium sulfate is
reasonable for patients who take QT-prolonging drugs
and present with few episodes of torsades de pointes
in which the QT remains long. (Level of Evidence: B)
(2) Atrial or ventricular pacing or isoproterenol is reason-
able for patients taking QT-prolonging drugs who
present with recurrent torsades de pointes. (Level of
Evidence: B)
Class IIb
Potassium ion repletion to 4.5 to 5 mmol/L may be
reasonable for patients who take QT-prolonging drugs
and present with few episodes of torsades de pointes
in whom the QT remains long. (Level of Evidence: C)
13.6.3.1. Clinical features. Marked QT prolongation, often
accompanied by the morphologically distinctive poly-
morphic VT torsades de pointes, occurs in 1% to 10% of
patients receiving QT-prolonging antiarrhythmic drugs and
much more rarely in patients receiving ‘noncardiovascular’
drugs with QT-prolonging potential. While many drugs have
been associated with isolated cases of torsades de pointes,
Table 12 lists those generally recognized as having
QT-prolonging potential. An up-to-date list is maintained
at www.torsades.org and www.qtdrugs.org.
Most cases of drug-induced torsades de pointes display a
‘short-long-short’ series of cycle length changes prior to
initiation of tachycardia. QT intervals, uncorrected for
rate, are generally greater than 500 ms, prominent U
waves are common, and marked QTU prolongation may be
evident only on postpause beats. Major risk factors for
drug-induced torsades de pointes are listed in Table 13;
often more than one is present. Drugs can expose subclinical
congenital LQTS; in addition, some studies have implicated
commoner DNA variants (polymorphisms, with frequencies
ranging up to 15% of some populations).70,1023
Presentations of drug-induced QT prolongation include
incidental detection in an asymptomatic patient, palpita-
tions due to frequent extrasystoles and nonsustained ventri-
cular arrhythmias, syncope due to prolonged episodes of
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Table 11 Drug interactions causing arrhythmias
Drug Interacting drug Effect
Increased concentration of arrhythmogenic drug
Digoxin Some antibiotics By eliminating gut ﬂora that metabolize digoxin,
some antibiotics may increase digoxin
bioavailability. Note: some antibiotics also
interfere with P-glycoprotein (expressed in the
intestine and elsewhere), another effect that
can elevate digoxin concentration
Digoxin Amiodarone
Quinidine
Verapamil
Increased digoxin bioavailability, reduced biliary
and renal excretion due to P-glycoprotein
inhibition
Cyclosporine
Itraconazole
Erythromycin
Digoxin toxicity
Quinidine Ketoconazole Increased drug levels
Cisapride Itraconazole
Terfenadine, astemizole Erythromycina
Clarithromycin
Some calcium blockersa
Some HIV protease inhibitors
(especially ritanovir)
Beta blockers propafenone Quinidine (even ultra-low dose) Increased beta blockade
Fluoxetine Increased beta blockade
Flecainide Some tricyclic antidepressants Increased adverse effects
Decreased analgesia (due to failure of
biotransformation to the active
metabolite morphine)
Dofetilide Verapamil Increased plasma dofetilide concentration
due to inhibition of renal excretion
Cimetidine
Trimethoprim
Ketoconazole
Megestrol
Decreased concentration of antiarrhythmic drug
Digoxin Antacids Decreased digoxin effect due to
decreased absorption
Rifampin Increased P-glycoprotein activity
Quinidine, mexiletine Rifampin, barbiturates Induced drug metabolism
Synergistic pharmacological activity causing arrhythmias
QT-prolonging antiarrhythmics Diuretics Increased torsades de pointes risk
due to diuretic-induced hypokalemia
Beta blockers Amiodarone, clonidine, digoxin,
diltiazem, verapamil
Bradycardia when used in combination
Digoxin Amiodarone, beta blockers, clonidine,
diltiazem, verapamil
Verapamil Amiodarone, beta blockers, clonidine,
digoxin, diltiazem
Diltiazem Amiodarone, beta blockers, clonidine,
digoxin, verapamil
Clonidine Amiodarone, beta blockers, digoxin,
diltiazem, verapamil
Amiodarone Beta blockers, clonidine, digoxin,
diltiazem, verapamil
Sildenaﬁl Nitrates Increased and persistent vasodilation;
risk of myocardial ischemia
aThese may also accumulate to toxic levels with co-administration of inhibitor drugs like ketoconazole. Data are from Roden DM, Anderson ME.
Proarrhythmia. In: Kass RS, Clancey CE, eds. Handbook of Experimental Pharmacology: vol. 171. Basis and Treatment of Cardiac Arrhythmias. Boston:
Springer Verlag, 2006:288–304.1021
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torsades de pointes, or SCD. The extent to which SCD in
patients receiving QT-prolonging therapies represents tor-
sades de pointes is uncertain. The QT-prolonging agent
D-sotalol increased mortality in a large randomized clinical
trial (SWORD [Survival With Oral D-sotalol]), an effect that
may have been due to torsades de pointes.970 In the
Danish Investigators of Arrhythmia and Mortality on
Dofetilide (DIAMOND) trial, 3.3% of patients with severe HF
had torsades de pointes during the ﬁrst 72 h of dofetilide
therapy.1024 High concentrations of erythromycin achieved
by intravenous therapy have been associated with torsades
de pointes, and a review of SCD in a Medicaid database
implicated the combination of oral erythromycin and drugs
blocking its metabolism as increasing SCD.603
13.6.3.2. Management. Monitoring high-risk patients
during initiation of QT-prolonging antiarrhythmic drugs and
recognition of the syndrome when it occurs are the ﬁrst
steps. Maintaining serum potassium between 4.5 and 5
mEq/L shortens QT;1026,1027 no speciﬁc data are available
on the efﬁcacy of potassium repletion to prevent torsades
de pointes. Intravenous magnesium can suppress episodes
of torsades de pointes without necessarily shortening QT,
even when serum magnesium is normal.1028 Magnesium
toxicity (areﬂexia progressing to respiratory depression)
can occur when concentrations reach 6 to 8 mEq/L but is a
very small risk with the doses usually used in torsades de
pointes, 1 to 2 g intravenously. Temporary pacing is
highly effective in managing torsades de pointes that is
recurrent after potassium repletion and magnesium
supplementation. Isoproterenol can also be used to increase
heart rate and abolish postectopic pauses. Anecdotes have
reported that lidocaine,1029 verapamil,1030 and even
occasionally amiodarone1031 have been effective. However,
amiodarone may itself cause torsades de pointes, albeit
much less commonly than with other QT-prolonging
antiarrhythmics.1032
13.6.4. Sodium channel blocker-related toxicity
Recommendations
Class I
In patients with sodium channel blocker-related toxicity,
removal of the offending agent is indicated. (Level of
Evidence: A)
Class IIa
(1) Stopping the drug, reprogramming the pacemaker or
repositioning leads can be useful in patients taking
sodium channel blockers who present with elevated
deﬁbrillation thresholds or pacing requirement. (Level
of Evidence: C)
(2) In patients taking sodium channel blockers who present
with atrial ﬂutter with 1:1 AV conduction, withdrawal of
the offending agent is reasonable. If the drug needs to
be continued, additional A-V nodal blockade with diltia-
zem, verapamil, or beta blocker or atrial ﬂutter ablation
can be effective. (Level of Evidence: C)
Class IIb
Administration of a beta blocker and a sodium bolus may
be considered for patients taking sodium channel block-
ers if the tachycardia becomes more frequent or more
difﬁcult to cardiovert. (Level of Evidence: C)
13.6.4.1. Clinical features. Arrhythmias caused by sodium
channel-blocking drugs are included in Table 14.
Antiarrhythmic drugs are the most common precipitants,
although other agents, notably tricyclic antidepressants
and cocaine, may produce some of their toxicities
through these mechanisms. Sodium channel-blocking drugs
with slower rates of dissociation tend to generate these
adverse effects more commonly; these include agents such
as ﬂecainide, propafenone, and quinidine that (as a
consequence of the slow dissociation rate) tend to prolong
QRS durations even at normal heart rates and therapeutic
dosages.1033
In large clinical trials, sodium channel-blocking drugs have
increased mortality among patients convalescing from MI.
Table 13 Risk factors for drug-induced torsades de pointes
† Female gender
† Hypokalemia
† Bradycardia
† Recent conversion from atrial ﬁbrillation
† Congestive heart failure
† Digitalis therapy
† High drug concentrations (exception: quinidine), often due to
drug interactions
† Rapid rate of intravenous drug administration
† Baseline QT prolongation
† Ventricular arrhythmia
† Left ventricular hypertrophy
† Congenital long QT syndrome
† Certain DNA polymorphisms
† Severe hypomagnesemia
† Concomitant use of 2 or more drugs that prolong the
QT interval
† Combination of QT-prolonging drug with its metabolic inhibitor
Adapted with permission from Roden DM. Drug-induced prolongation of
the QT interval. N Engl J Med 2004;350:1013–22. Copyright& 2004
Massachusetts Medical Society.1025
DNA, deoxyribonucleic acid.
Table 12 Examples of drugs causing torsades de pointesa
Frequent (greater than 1%) (e.g., hospitalization for monitoring
recommended during drug initiation in some circumstances)
† Disopyramide
† Dofetilide
† Ibutilide
† Procainamide
† Quinidine
† Sotalol
† Ajmaline
Less frequent
† Amiodarone
† Arsenic trioxide
† Bepridil
† Cisapride
† Anti-infectives: clarithromycin, erythromycin, halofantrine,
pentamidine, sparﬂoxacin
† Antiemetics: domperidone, droperidol
† Antipsychotics: chlorpromazine, haloperidol, mesoridazine,
thioridazine, pimozide
† Opioid dependence agents: methadone
aSee www.torsades.org for up-to-date listing. Adapted with permission
from Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med
2004;350:1013–22. Copyright& 2004 Massachusetts Medical Society.1025
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This effect was best demonstrated in CAST,967 but similar
trends were also seen with earlier trials of mexiletine1034
and disopyramide.1035 Analysis of the CAST database has
indicated that patients at risk for recurrent myocardial
ischemia are especially susceptible to SCD during sodium
channel-blocking drugs.1036
In patients treated for sustained VT, these agents may
provoke more frequent, and often more difﬁcult to cardio-
vert, episodes of sustained VT. While the drugs generally
slow the rate of VT, occasionally the arrhythmia becomes
disorganized and may be resistant to cardioversion; deaths
have resulted. It seems likely that at least some of the
excess mortality in CAST and other trials reﬂect such provo-
cation or exacerbation of sustained ventricular arrhythmias.
Sodium channel-blocking drugs increase deﬁbrillation
energy requirement and pacing thresholds;1037,1038 as a
consequence, patients may require reprogramming or
revision of pacing or ICD systems or changes in their drug
regimens. Sodium channel blockers can ‘convert’ AF to
slow atrial ﬂutter, which can show 1:1 AV conduction with
wide-QRS complexes. This drug-induced arrhythmia can be
confused with VT.1039
Sodium channel blockers can occasionally precipitate the
typical Brugada syndrome ECG.1040 This has been reported
not only with antiarrhythmic drugs but also with tricyclic
antidepressants1041 and cocaine.1042 Whether this represents
exposure of individuals with clinically inapparent Brugada
syndrome (see Section 11.1.3) or one end of a broad spec-
trum of responses to sodium channel-blocking drugs is not
known. The extent to which latent Brugada syndrome may
have played a role in the CAST result is also unknown.
13.6.4.2. Management. Sodium channel-blocking drugs
should not be used in patients with MI or sustained VT due
to structural heart disease. The extent to which this prohibi-
tion on sodium channel blockers in patients with structural
heart disease extends to tricyclic antidepressants that also
block sodium channels is unknown.1043
The major indication for these drugs is atrial arrhythmias
in patients without structural heart disease; this excludes at
least those studied in CAST (recent or remote MI) and by
mechanistic considerations extends to those with other
forms of ventricular dysfunction. When used for AF, AV
nodal-blocking drugs should be coadministered to prevent
rapid ventricular rates should atrial ﬂutter occur; amiodar-
one may be an exception. Patients presenting with atrial
ﬂutter and rapid rates (and in whom VT is not a consider-
ation) should be treated by slowing of AV conduction with
drugs such as intravenous diltiazem. Ablation of the atrial
ﬂutter and continuation of the antiarrhythmic drug may be
an option for long-term therapy.1044
Animal and clinical anecdotes suggest that administration
of sodium, as sodium chloride or sodium bicarbonate, may
be effective in the reversing conduction slowing or frequent
or cardioversion-resistant VT.1045,1046 Beta blockers have
also been used successfully.1047
13.6.5. Tricyclic antidepressant overdose
13.6.5.1. Clinical features. Tricyclic antidepressants are
second only to analgesics as a cause of serious overdose
toxicity. Typical cardiac manifestations include sinus
tachycardia, PR and QRS prolongation, and occasionally a
Brugada syndrome-like ECG.1041 Hypotension, fever, and
coma are other common manifestations of serious toxicity.
Torsades de pointes have been associated with tricyclic
antidepressant use, but this seems to be very rare.
13.6.5.2. Management. QRS duration can be shortened in
experimental animals and in humans by administration of
NaHCO3 or NaCl boluses.
1048 Antiarrhythmic drugs, including
beta blockers, are generally avoided. Supportive measures,
such as pressors, activated charcoal, and extracorporeal
circulation, may be required.
13.6.6. Sudden cardiac death and psychiatric or
neurological disease
The incidence of SCD is increased in patients with seizure
disorders1049 and schizophrenia. It is uncertain whether
this reﬂects speciﬁc abnormalities, such as autonomic dys-
function or an unusually high prevalence of cardiovascular
disease, or the therapies used to treat the disease.1049–1052
Drug interactions may also contribute.1053 Antipsychotic
agents well known to produce marked QT prolongation and
torsades de pointes include thioridazine and haloperidol.
Another group of generally newer antipsychotic drugs also
prolong the QT interval, but fewer cases of torsades de
Table 14 Syndromes of drug-induced arrhythmia and their management
Drugs Clinical settings Managementa
Digitalis Mild cardiac toxicity (isolated arrhythmias only)
Severe toxicity: sustained ventricular arrhythmias;
advanced AV block; asystole
Anti-digitalis antibody
Pacing
Dialysis for hyperkalemia
QT-prolonging drugs Torsades de pointes: few episodes, QT remains long IV magnesium sulfate (MgSO4)
Replete potassium (Kþ) to 4.5 to 5 mEq/L
Recurrent torsades de pointes Ventricular pacing
Isoproterenol
Sodium channel blockers Elevated deﬁbrillation or pacing requirement Stop drug; reposition leads
Atrial ﬂutter with 1:1 AV conduction Diltiazem, verapamil, beta blocker (IV)
Ventricular tachycardia (more frequent;
difﬁcult to cardiovert)
Beta blocker; sodium
Brugada syndrome Stop drug; treat arrhythmia
AV, atrioventricular; IV, intravenous.
aAlways includes recognition, continuous monitoring of cardiac rhythm, withdrawal of offending agents, restoration of normal electrolytes (including serum
potassium to greater than 4 mEq/L), and oxygenation. The order shown is not meant to represent the preferred sequence when more than one treatment is listed.
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pointes have been reported. It is not known whether this
reﬂects intrinsic differences between drugs producing
marked QT prolongation versus those producing lesser
degrees of QT prolongation or differences in patient
exposures to newer versus older drugs.238,1054
13.6.7. Other drug-induced toxicity
Recommendations
Class I
(1) High intermittent doses and cumulative doses exceeding
the recommended levels should be avoided in patients
receiving anthracyclines such as doxorubicin. (Level of
Evidence: B)
(2) All patients receiving 5-ﬂuorouracil therapy should
receive close supervision and immediate discontinuation
of the infusion if symptoms or signs of myocardial
ischemia occur. Further treatment with 5-ﬂuorouracil
must be avoided in these individuals. (Level of
Evidence: C)
(3) Patients with known cardiac disease should have a full
cardiac assessment including echocardiography, which
should be undertaken prior to use of anthracyclines
such as doxorubicin, and regular long-term follow-up
should be considered. (Level of Evidence: C)
Anthracycline cardiotoxicity is dose dependent, with inter-
mittent high doses and higher cumulative doses increasing
the risk of cardiomyopathy and lethal arrhythmias.1055,1056
Risk factors include younger age, female gender, and use of
trastuzimab.1055,1057–1059 This form of cardiomyopathy can
occur acutely soon after treatment, within a few months of
treatment (the so-called subacute form), or many years
later.1056,1060–1066 There is an increase in ventricular ectopy
in patients receiving doxorubicin during the acute infusion
period, but this is very rarely of any signiﬁcance.1067,1068
Some studies have suggested reduced HRV, abnormalities in
area ratios on SAECG, and increased QTc may be indicators
of impending cardiomyopathy and electrical instability, but
these have yet to be substantiated.1066,1069,1070 Long-term
intermittent cardiac assessment of patients is therefore
necessary and cardiac decompensation should be treated
conventionally. There is, however, little evidence of reversi-
bility in the anthracycline-induced myopathic process.
5-Fluorouracil causes lethal and potentially fatal arrhyth-
mias irrespective of underlying coronary disease during the
acute infusion period, the vast majority occurring during the
ﬁrst administration.1071 Cardiac monitoring during the infusion
period, especially the ﬁrst, is recommended for all patients
receiving 5-ﬂuorouracil therapy. Symptoms, with or without
corresponding ECG changes compatible with cardiac ischemia,
should lead to an immediate discontinuation of the infusion.
Ischemia should be treated conservatively or conventionally
with anticoagulants, nitrates, and calcium channel and beta
blockade as required.1071 Although this cardiotoxicity is revers-
ible, 5-ﬂuorouracil sensitizes individuals and should be avoided
in the future.1071 Cesium, well -recognized to produce torsades
de pointes in animal models, has also been used as ‘alternate
therapy’ for malignancy and when torsades de pointes has
been reported.1072
Toad venom, an ingredient of some traditional Chinese
medicines, produces clinical toxicity resembling that of
digoxin, and in animal models, digoxin-speciﬁc antibodies
are successful in reversing the toxicity.1073 Other herbal
products, including foxglove tea, have been reported to
produce similar effects.1074,1075
Cocaine has both slow offset sodium channel-blocking
properties and QT-prolonging (IKr-blocking) properties.
Arrhythmias associated with cocaine ingestion include wide-
complex tachycardias suggestive of sodium channel block
(and responding to sodium infusion) as well as torsades de
pointes. Cocaine also causes other cardiovascular compli-
cations that can lead to arrhythmias, notably myocarditis,
and coronary spasm.
Dietary supplements containing ephedra alkaloids (includ-
ing ‘ma huang’) are no longer marketed because they
appeared to have an infrequent association with serious car-
diovascular toxicity, including SCD.1076–1078 The mechanism is
unknown but may involve direct myocardial sympathomi-
metic stimulation, coronary spasm, and/or severe hyperten-
sion in susceptible individuals. Ephedrine, the active
component, is also detected in a number of street drugs.
Coronary spasm has been reported with multiple other medi-
cations and can present as VF: certain anticancer drugs
(5-ﬂuorouracil1079–1082), capecitabine,1083 triptans used in
the treatment of migraines,1084 recreational agents (e.g.,
ecstasy1085, cocaine), inadvertent vascular administration of
pressor catecholamines, and anaphylaxis due to any one of
a wide range of drugs (see Section 7.5 for further discussion).
Bradyarrhythmias are common (and desired) pharmaco-
logical effects of digoxin, verapamil, diltiazem, and beta
blockers. Severe bradyarrhythmias may occur with usual
doses in sensitized individuals, particularly those receiving
combinations, or in suicidal or accidental overdose.
Marked sinus bradycardia is also common with clonidine.
14. Conclusions
SCD continues to be a major cause of mortality in all devel-
oped countries. Using an evidence-based approach, this
document attempts to summarize the latest information
addressing the problem, with the goal of providing rec-
ommendations consistent with previous documents.
However, it is important to stress that the ﬁeld is evolving
and recommendations will certainly change as more is
learned about the problem. The lengthy list of references
serves as an indication of the large amount of research
addressing SCD already, and undoubtedly, the list will grow
in the future. Timely updates of this information will be criti-
cal as clinicians try to care for patients at risk of SCD.1021,1025
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